Design of Trypanosoma rangeli sialidase mutants with improved trans-sialidase activity

DEFF Research Database (Denmark)

Nyffenegger, Christian; Nordvang, Rune Thorbjørn; Jers, Carsten

2017-01-01

were analyzed via kinetics for their ability to carry out trans-sialidase reaction using CGMP and D-lactose as substrates. The sialidase variants with 15 and 16 mutations, respectively, exhibited significantly improved trans-sialidase activity for D-lactose sialylation. Our results corroborate......, that computational studies of trans-glycosylation can be a valuable input in the design of novel trans-glycosidases, but also highlight the importance of experimental validation in order to assess the performance. In conclusion, two of the seven mutants displayed a dramatic switch in specificity from hydrolysis...

Benzoic Acid Derivatives with Trypanocidal Activity: Enzymatic Analysis and Molecular Docking Studies toward Trans-Sialidase

Directory of Open Access Journals (Sweden)

Muhammad Kashif

2017-10-01

Full Text Available Chagas, or American trypanosomiasis, remains an important public health problem in developing countries. In the last decade, trans-sialidase has become a pharmacological target for new anti-Chagas drugs. In this work, the aims were to design and find a new series of benzoic acid derivatives as trans-sialidase (TS inhibitors and anti-trypanosomal agents. Three compounds (14, 18, and 19 sharing a para-aminobenzoic acid moiety showed more potent trypanocidal activity than the commercially available drugs nifurtimox and benznidazole in both strains: the lysis concentration of 50% of the population (LC50 was <0.15 µM on the NINOA strain, and LC50 < 0.22 µM on the INC-5 strain. Additionally, compound 18 showed a moderate inhibition (47% on the trans-sialidase enzyme and a binding model similar to DANA (pattern A.

Elevated expression of NEU1 sialidase in idiopathic pulmonary fibrosis provokes pulmonary collagen deposition, lymphocytosis, and fibrosis.

Science.gov (United States)

Luzina, Irina G; Lockatell, Virginia; Hyun, Sang W; Kopach, Pavel; Kang, Phillip H; Noor, Zahid; Liu, Anguo; Lillehoj, Erik P; Lee, Chunsik; Miranda-Ribera, Alba; Todd, Nevins W; Goldblum, Simeon E; Atamas, Sergei P

2016-05-15

Idiopathic pulmonary fibrosis (IPF) poses challenges to understanding its underlying cellular and molecular mechanisms and the development of better therapies. Previous studies suggest a pathophysiological role for neuraminidase 1 (NEU1), an enzyme that removes terminal sialic acid from glycoproteins. We observed increased NEU1 expression in epithelial and endothelial cells, as well as fibroblasts, in the lungs of patients with IPF compared with healthy control lungs. Recombinant adenovirus-mediated gene delivery of NEU1 to cultured primary human cells elicited profound changes in cellular phenotypes. Small airway epithelial cell migration was impaired in wounding assays, whereas, in pulmonary microvascular endothelial cells, NEU1 overexpression strongly impacted global gene expression, increased T cell adhesion to endothelial monolayers, and disrupted endothelial capillary-like tube formation. NEU1 overexpression in fibroblasts provoked increased levels of collagen types I and III, substantial changes in global gene expression, and accelerated degradation of matrix metalloproteinase-14. Intratracheal instillation of NEU1 encoding, but not control adenovirus, induced lymphocyte accumulation in bronchoalveolar lavage samples and lung tissues and elevations of pulmonary transforming growth factor-β and collagen. The lymphocytes were predominantly T cells, with CD8(+) cells exceeding CD4(+) cells by nearly twofold. These combined data indicate that elevated NEU1 expression alters functional activities of distinct lung cell types in vitro and recapitulates lymphocytic infiltration and collagen accumulation in vivo, consistent with mechanisms implicated in lung fibrosis.

Decreased sialidase activity in alveolar macrophages of guinea pigs exposed to coal mine dust.

Science.gov (United States)

Terzidis-Trabelsi, H; Lefèvre, J P; Bignon, J; Lambré, C R

1992-01-01

The origin of immune dysfunctions that are observed in pneumoconiotic miners still remains unknown. There is evidence that the carbohydrate moiety of membrane glycoconjugates is of primary importance in many functions of immunocompetent cells. The glycosylation, and especially the sialylation level of membrane components of various lymphocyte and macrophage subsets, vary depending on the state of cellular differentiation and activation. Sialidases, which may regulate the amount of sialic acids exposed on the cell membrane, can thus be considered as immunoregulatory enzymes. In this report, the sialidase activity has been measured in alveolar macrophages (AM) and in cell-free bronchoalveolar lavage fluid (BALF) from guinea pigs exposed for 4 months to coal mine dust at a concentration of 300 mg/m3. The samples were collected by bronchoalveolar lavage 2 months after cessation of exposure. The sialidase activity in the cell-free fluid and in the purified alveolar macrophages showed a 10-fold decrease (p less than 0.001). Kinetic parameters of the enzyme such as Km and optimum pH did not change. This changed activity was specific for sialidase, as two other lysosomal glycosidases, beta-galactosidase and N-acetylglucosaminidase, showed unchanged activities. These results suggest the possibility that, by inducing a decreased sialidase activity, exposure to coal mine dust may lead to a modified expression of AM membrane-associated sialic acids giving rise to altered immune functions (i. e., phagocytosis, antigen processing, response to cytokines, etc.). PMID:1396442

Endogenous glycosphingolipid acceptor specificity of sialosyltransferase systems in intact golgi membranes, synaptosomes, and synaptic plasma membranes from rat brain

International Nuclear Information System (INIS)

Durrie, R.; Saito, M.; Rosenberg, A.

1988-01-01

Preparations highly enriched in Golgi complex membranes, synaptosomes, and synaptic plasma membranes (SPM) by marker enzyme analysis and electron microscopic morphology were made from the brains of 28-day-old rats. These were incubated with cytidine 5'-monophosphate-N-acetyl[ 14 C]neuraminic acid (CMP-NeuAc) in a physiologic buffer, without detergents. Glycolipid sialosyltransferase activities (SATs) were measured by analyzing incorporation of radiolabeled NeuAc into endogenous membrane gangliosides. Golgi SAT was diversified in producing all the various molecular species of labeled gangliosides. Synaptosomal SAT exhibited a lower activity, but it was highly specific in its labeling pattern, with a marked preference for labeling NeuAcα2 → 8NeuAcα2 → 3Galβ1 → 4Glcβ1 → 1Cer (GD3 ganglioside). SPM prepared from the synaptosomes retained the GD3-related SAT (or SAT-2), and the total specific activity increased, which suggests that the location of the synaptosomal activity is in the SPM. These results indicate that SAT activity in Golgi membranes differs from that in synaptosomes with regard to endogenous acceptor substrate specificity and SAT activity of synaptosomes should be located in the synaptosomal plasma membrane. This SAT could function as an ectoenzyme in concert with ecto-sialidase to modulate the GD3 and other ganglioside population in situ at the SPM of the central nervous system

It All Starts with a Sandwich: Identification of Sialidases with Trans-Glycosylation Activity

DEFF Research Database (Denmark)

Nordvang, Rune Thorbjørn; Nyffenegger, Christian; Holck, Jesper

2016-01-01

structure of two amino acids proximal to the active site of the T. cruzi trans-sialidase infers trans-sialidase activity. On this basis, four enzymes with putative trans-sialidase activity were identified through an iterative alignment from 2909 native sialidases available in GenBank, which were cloned...... and expressed in Escherichia coli. Of these, one enzyme, SialH, derived from Haemophilus parasuis had an aromatic sandwich structure on the protein surface facing the end of the catalytic site (Phe168; Trp366), and was indeed found to exhibit trans-sialidase activity. SialH catalyzed production of the human...... provided data that help understand structure-function relations of trans-sialidases....

Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products.

Directory of Open Access Journals (Sweden)

Sandra L Diaz

Full Text Available Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc, but can metabolically incorporate it from dietary sources (particularly red meat and milk into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues. Metabolic incorporation of Neu5Gc from animal-derived cells and medium components also results in variable contamination of molecules and cells intended for human therapies. These Neu5Gc-incorporation phenomena are practically significant, because normal humans can have high levels of circulating anti-Neu5Gc antibodies. Thus, there is need for the sensitive and specific detection of Neu5Gc in human tissues and biotherapeutic products. Unlike monoclonal antibodies that recognize Neu5Gc only in the context of underlying structures, chicken immunoglobulin Y (IgY polyclonal antibodies can recognize Neu5Gc in broader contexts. However, prior preparations of such antibodies (including our own suffered from some non-specificity, as well as some cross-reactivity with the human sialic acid N-acetylneuraminic acid (Neu5Ac.We have developed a novel affinity method utilizing sequential columns of immobilized human and chimpanzee serum sialoglycoproteins, followed by specific elution from the latter column by free Neu5Gc. The resulting mono-specific antibody shows no staining in tissues or cells from mice with a human-like defect in Neu5Gc production. It allows sensitive and specific detection of Neu5Gc in all underlying glycan structural contexts studied, and is applicable to immunohistochemical, enzyme-linked immunosorbent assay (ELISA, Western blot and flow cytometry analyses. Non-immune chicken IgY is used as a reliable negative control. We show that these approaches allow sensitive detection of Neu5Gc in human tissue samples and in some biotherapeutic products, and finally show an example of how Neu5Gc might be eliminated from such products, by using a human cell

Characterization and immobilization of engineered sialidases from Trypanosoma rangeli for transsialylation

Directory of Open Access Journals (Sweden)

Birgitte Zeuner

2017-04-01

Full Text Available A sialidase (EC 3.2.1.18; GH 33 from non-pathogenic Trypanosoma rangeli has been engineered with the aim of improving its transsialylation activity. Recently, two engineered variants containing 15 and 16 amino acid substitutions, respectively, were found to exhibit significantly improved transsialylation activity: both had a 14 times higher ratio between transsialylation and hydrolysis products compared to the first reported mutant TrSA5mut. In the current work, these two variants, Tr15 and Tr16, were characterized in terms of pH optimum, thermal stability, effect of acceptor-to-donor ratio, and acceptor specificity for transsialylation using casein glycomacropeptide (CGMP as sialyl donor and lactose or other human milk oligosaccharide core structures as acceptors. Both sialidase variants exhibited pH optima around pH 4.8. Thermal stability of each enzyme was comparable to that of previously developed T. rangeli sialidase variants and higher than that of the native transsialidase from T. cruzi (TcTS. As for other engineered T. rangeli sialidase variants and TcTS, the acceptor specificity was broad: lactose, galactooligosaccharides (GOS, xylooligosaccharides (XOS, and human milk oligosaccharide structures lacto-N-tetraose (LNT, lacto-N-fucopentaose (LNFP V, and lacto-N-neofucopentaose V (LNnFP V were all sialylated by Tr15 and Tr16. An increase in acceptor-to-donor ratio from 2 to 10 had a positive effect on transsialylation. Both enzymes showed high preference for formation α(2,3-linkages at the non-reducing end of lactose in the transsialylation. Tr15 was the most efficient enzyme in terms of transsialylation reaction rates and yield of 3’-sialyllactose. Finally, Tr15 was immobilized covalently on glyoxyl-functionalized silica, leading to a 1.5-fold increase in biocatalytic productivity (mg 3’-sialyllactose per mg enzyme compared to free enzyme after 6 cycles of reuse. The use of glyoxyl-functionalized silica proved to be markedly better

Unraveling the differences of the hydrolytic activity of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli sialidase: a quantum mechanics-molecular mechanics modeling study.

Science.gov (United States)

Bueren-Calabuig, Juan A; Pierdominici-Sottile, Gustavo; Roitberg, Adrian E

2014-06-05

Chagas' disease, also known as American trypanosomiasis, is a lethal, chronic disease that currently affects more than 10 million people in Central and South America. The trans-sialidase from Trypanosoma cruzi (T. cruzi, TcTS) is a crucial enzyme for the survival of this parasite: sialic acids from the host are transferred to the cell surface glycoproteins of the trypanosome, thereby evading the host's immune system. On the other hand, the sialidase of T. rangeli (TrSA), which shares 70% sequence identity with TcTS, is a strict hydrolase and shows no trans-sialidase activity. Therefore, TcTS and TrSA represent an excellent framework to understand how different catalytic activities can be achieved with extremely similar structures. By means of combined quantum mechanics-molecular mechanics (QM/MM, SCC-DFTB/Amberff99SB) calculations and umbrella sampling simulations, we investigated the hydrolysis mechanisms of TcTS and TrSA and computed the free energy profiles of these reactions. The results, together with our previous computational investigations, are able to explain the catalytic mechanism of sialidases and describe how subtle differences in the active site make TrSA a strict hydrolase and TcTS a more efficient trans-sialidase.

New Insights into Molecular Organization of Human Neuraminidase-1: Transmembrane Topology and Dimerization Ability

Science.gov (United States)

Maurice, Pascal; Baud, Stéphanie; Bocharova, Olga V.; Bocharov, Eduard V.; Kuznetsov, Andrey S.; Kawecki, Charlotte; Bocquet, Olivier; Romier, Beatrice; Gorisse, Laetitia; Ghirardi, Maxime; Duca, Laurent; Blaise, Sébastien; Martiny, Laurent; Dauchez, Manuel; Efremov, Roman G.; Debelle, Laurent

2016-12-01

Neuraminidase 1 (NEU1) is a lysosomal sialidase catalyzing the removal of terminal sialic acids from sialyloconjugates. A plasma membrane-bound NEU1 modulating a plethora of receptors by desialylation, has been consistently documented from the last ten years. Despite a growing interest of the scientific community to NEU1, its membrane organization is not understood and current structural and biochemical data cannot account for such membrane localization. By combining molecular biology and biochemical analyses with structural biophysics and computational approaches, we identified here two regions in human NEU1 - segments 139-159 (TM1) and 316-333 (TM2) - as potential transmembrane (TM) domains. In membrane mimicking environments, the corresponding peptides form stable α-helices and TM2 is suited for self-association. This was confirmed with full-size NEU1 by co-immunoprecipitations from membrane preparations and split-ubiquitin yeast two hybrids. The TM2 region was shown to be critical for dimerization since introduction of point mutations within TM2 leads to disruption of NEU1 dimerization and decrease of sialidase activity in membrane. In conclusion, these results bring new insights in the molecular organization of membrane-bound NEU1 and demonstrate, for the first time, the presence of two potential TM domains that may anchor NEU1 in the membrane, control its dimerization and sialidase activity.

Enzyme catalysed production of sialylated human milk oligosaccharides and galactooligosaccharides by Trypanosoma cruzi trans-sialidase

DEFF Research Database (Denmark)

Holck, Jesper; Larsen, Dorte Møller; Michalak, Malwina

2014-01-01

Bifidobacterium strains in single culture fermentations. The trans-sialidase also catalysed the transfer of sialic acid from CGMP to galacto-oligosaccharides (GOS) and to the human milk oligosaccharide (HMO) backbone lacto-N-tetraose (LNT) to produce 3′-sialyl-GOS, including doubly sialylated GOS products, and 3...

Easy and Rapid Detection of Mumps Virus by Live Fluorescent Visualization of Virus-Infected Cells.

Directory of Open Access Journals (Sweden)

Tadanobu Takahashi

Full Text Available Mumps viruses show diverse cytopathic effects (CPEs of infected cells and viral plaque formation (no CPE or no plaque formation in some cases depending on the viral strain, highlighting the difficulty in mumps laboratory studies. In our previous study, a new sialidase substrate, 2-(benzothiazol-2-yl-4-bromophenyl 5-acetamido-3,5-dideoxy-α-D-glycero-D-galacto-2-nonulopyranosidonic acid (BTP3-Neu5Ac, was developed for visualization of sialidase activity. BTP3-Neu5Ac can easily and rapidly perform histochemical fluorescent visualization of influenza viruses and virus-infected cells without an antiviral antibody and cell fixation. In the present study, the potential utility of BTP3-Neu5Ac for rapid detection of mumps virus was demonstrated. BTP3-Neu5Ac could visualize dot-blotted mumps virus, virus-infected cells, and plaques (plaques should be called focuses due to staining of infected cells in this study, even if a CPE was not observed. Furthermore, virus cultivation was possible by direct pick-up from a fluorescent focus. In conventional methods, visible appearance of the CPE and focuses often requires more than 6 days after infection, but the new method with BTP3-Neu5Ac clearly visualized infected cells after 2 days and focuses after 4 days. The BTP3-Neu5Ac assay is a precise, easy, and rapid assay for confirmation and titration of mumps virus.

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.

Science.gov (United States)

Wiedermann, Ursula; Wiltschke, C; Jasinska, J; Kundi, M; Zurbriggen, R; Garner-Spitzer, E; Bartsch, R; Steger, G; Pehamberger, H; Scheiner, O; Zielinski, C C

2010-02-01

We have previously shown in mice that vaccination with three Her-2-peptides representing B-cell epitopes of the extracellular domain of Her-2/neu induces Her-2/neu-specific IgG antibodies with strong anti-tumor activity in vitro and in vivo. We have now finalized a phase I clinical trial with an anti-Her-2/neu vaccine-construct of immunopotentiating reconstituted influenza virosomes with the three peptides in patients with metastatic breast cancer (MBC). Ten MBC patients with low protein overexpression of Her-2/neu of MBC (+ or ++ upon immunohistochemistry, FISH negative) and positive hormone receptor status were enrolled in a single center phase I study. The virosomal formulated vaccine, consisting of 10 microg/peptide, was intramuscularly applied three times on days 1, 28, and 56. The primary endpoint of the study, which lasted 12 weeks, was safety, the secondary endpoint immunogenicity. Local erythema at the injection site was the only vaccine-related side effect occurring in four patients. In 8 of 10 patients an increase in peptide-specific antibody titer measured by ELISA was found. Importantly, the induced antibodies were also directed against the native Her-2/neu protein. Cellular immune responses, as measured by in vitro production of IL-2, IFN-c, and TNF-a of PBMCs showed a marked increase after vaccination in the majority of vaccinees. Notably, the number of CD4+CD25+Foxp3+T regulatory cells, which were significantly increased compared to healthy controls prior to vaccination, was markedly reduced following vaccination. In all, the immunological responses after vaccination indicated that the patients in stage IV of disease were immunocompetent and susceptible to vaccination. The Her-2/neu multipeptide vaccine was safe, well tolerated and effective in overcoming immunological tolerance to Her-2/neu. The induction of anti-Her-2-specific antibodies could result in clinical benefit comparable to passive anti-Her-2 antibody therapy.

Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells

Directory of Open Access Journals (Sweden)

Timo Faltus

2004-11-01

Full Text Available In eukaryotes, double-stranded (ds RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi. We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells. We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots. Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels. Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G0/G1 in the breast cancer cell lines SKBR-3 and BT-474, consistent with a powerful RNA silencing effect. siRNA treatment resulted in an antiproliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells. These data indicate that HER2/neu function is essential for the proliferation of HER2/neuoverexpressing breast cancer cells. Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as anti proliferative agents that display activity against neoplastic cells at very low doses.

Characterization and immobilization of engineered sialidases from Trypanosoma rangeli for transsialylation

DEFF Research Database (Denmark)

Zeuner, Birgitte; González-Delgado, Isabel; Holck, Jesper

2017-01-01

transsialylation activity: both had a 14 times higher ratio between transsialylation and hydrolysis products compared to the first reported mutant TrSA5mut. In the current work, these two variants, Tr15 and Tr16, were characterized in terms of pH optimum, thermal stability, effect of acceptor-to-donor ratio......, and acceptor specificity for transsialylation using casein glycomacropeptide (CGMP) as sialyl donor and lactose or other human milk oligosaccharide core structures as acceptors. Both sialidase variants exhibited pH optima around pH 4.8. Thermal stability of each enzyme was comparable to that of previously...... developed T. rangeli sialidase variants and higher than that of the native transsialidase from T. cruzi (TcTS). As for other engineered T. rangeli sialidase variants and TcTS, the acceptor specificity was broad: lactose, galactooligosaccharides (GOS), xylooligosaccharides (XOS), and human milk...

Enzymatic Decoration of Prebiotic Galacto-oligosaccharides (Vivinal® GOS) with Sialic Acid using Trypanosoma cruzi Trans-Sialidase and Two Bovine Sialoglycoconjugates as Donor Substrates

NARCIS (Netherlands)

Wilbrink, Maarten Hotse; Ten Kate, Geert Albert; Sanders, Peter; Gerwig, Gerrit J; van Leeuwen, Sander S; Sallomons, Erik; Klarenbeek, Bert; Hage, Johannes H; van Vuure, Carine A; Dijkhuizen, Lubbert; Kamerling, Johannis P

2015-01-01

Decoration of prebiotic galacto-oligosaccharides (GOS) with sialic acid yields mixtures of GOS and sialylated GOS (Sia-GOS), novel products that are expected to have both prebiotic and anti-adhesive functionalities. The recombinantly produced trans-sialidase enzyme from Trypanosoma cruzi (TcTS), an

Optimizing the biocatalytic productivity of an engineered sialidase from Trypanosoma rangeli for 3′-sialyllactose production

DEFF Research Database (Denmark)

Zeuner, Birgitte; Luo, Jianquan; Nyffenegger, Christian

2014-01-01

An engineered sialidase, Tr6, from Trypanosoma rangeli was used for biosynthetic production of 3′-sialyllactose, a human milk oligosaccharide case compound, from casein glycomacropeptide (CGMP) and lactose, components abundantly present in industrial dairy side streams. Four different enzyme re......-use methods were compared to optimize the biocatalytic productivity, i.e. 3′-sialyllactose formation per amount of Tr6 employed: (i) His-tag immobilization on magnetic Cu2+-iminodiacetic acid-functionalized nanoparticles (MNPs), (ii) membrane immobilization, (iii) calcium alginate encapsulation of cross......-linked Tr6, and (iv) Tr6 catalysis in a membrane reactor. Tr6 immobilized on MNPs gave a biocatalytic productivity of 84mg 3′-sialyllactose/mg Tr6 after seven consecutive reaction runs. Calcium-alginate and membrane immobilization were inefficient. Using free Tr6 in a 10kDa membrane reactor produced a 9...

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells

International Nuclear Information System (INIS)

Baumann, Jan; Wong, Jason; Sun, Yan; Conklin, Douglas S.

2016-01-01

HER2/neu-positive breast cancer cells have recently been shown to use a unique Warburg-like metabolism for survival and aggressive behavior. These cells exhibit increased fatty acid synthesis and storage compared to normal breast cells or other tumor cells. Disruption of this synthetic process results in apoptosis. Since the addition of physiological doses of exogenous palmitate induces cell death in HER2/neu-positive breast cancer cells, the pathway is likely operating at its limits in these cells. We have studied the response of HER2/neu-positive breast cancer cells to physiological concentrations of exogenous palmitate to identify lipotoxicity-associated consequences of this physiology. Since epidemiological data show that a diet rich in saturated fatty acids is negatively associated with the development of HER2/neu-positive cancer, this cellular physiology may be relevant to the etiology and treatment of the disease. We sought to identify signaling pathways that are regulated by physiological concentrations of exogenous palmitate specifically in HER2/neu-positive breast cancer cells and gain insights into the molecular mechanism and its relevance to disease prevention and treatment. Transcriptional profiling was performed to assess programs that are regulated in HER2-normal MCF7 and HER2/neu-positive SKBR3 breast cancer cells in response to exogenous palmitate. Computational analyses were used to define and predict functional relationships and identify networks that are differentially regulated in the two cell lines. These predictions were tested using reporter assays, fluorescence-based high content microscopy, flow cytometry and immunoblotting. Physiological effects were confirmed in HER2/neu-positive BT474 and HCC1569 breast cancer cell lines. Exogenous palmitate induces functionally distinct transcriptional programs in HER2/neu-positive breast cancer cells. In the lipogenic HER2/neu-positive SKBR3 cell line, palmitate induces a G2 phase cell cycle delay and

Tryptophan as a Molecular Shovel in the Glycosyl Transfer Activity of Trypanosoma cruzi Trans-sialidase

Science.gov (United States)

Mitchell, Felicity L.; Miles, Steven M.; Neres, João; Bichenkova, Elena V.; Bryce, Richard A.

2010-01-01

Abstract Molecular dynamics investigations into active site plasticity of Trypanosoma cruzi trans-sialidase, a protein implicated in Chagas disease, suggest that movement of the Trp312 loop plays an important role in the enzyme's sialic acid transfer mechanism. The observed Trp312 flexibility equates to a molecular shovel action, which leads to the expulsion of the donor aglycone leaving group from the catalytic site. These computational simulations provide detailed structural insights into sialyl transfer by the trans-sialidase and may aid the design of inhibitors effective against this neglected tropical disease. PMID:20441732

In vitro evaluation of a specific radiochemical compound based on 99mTc-labeled DARPinG3 for radionuclide imaging of tumors overexpressing Her-2/neu

Science.gov (United States)

Bragina, O.; Larkina, M.; Stasyuk, E.; Chernov, V.; Zelchan, R.; Medvedeva, A.; Sinilkin, I.; Yusubov, M.; Skuridin, V.; Deyev, S.; Buldakov, M.

2017-09-01

It is still necessary to search for new informative diagnostic methods to detect malignant tumors with overexpression of Her-2/neu, which are characterized by the aggressive course of the disease, rapid rate of tumor growth and low rates of relapse-free and overall survival. In recent years, the radioisotope techniques for detection of specific tumor targets have been developing actively. Purpose: to develop a chemically stable radiochemical compound for the targeted imaging of cells overexpressing Her-2/neu. Material and methods: The study was performed using 2 cell lines. The human breast adenocarcinoma HER2-overexpressing cell line BT-474 was chosen to detect specific binding. As a control, HER2-negative human breast adenocarcinoma MCF-7 was used. The human breast adenocarcinoma BT-474 and MCF-7 cell lines were seeded in chamber-slides at the density of 35,000 cells/ml in trypsin-EDTA (PanEco) medium and grown overnight at 37°C. After that both cell lines were washed with Phosphate buffered saline (PBS) and distributed into test tubes to 1 ml (5 millions cells in each). After adding 100 µl (70 MBq) studied complex of 99mTc-DPAH- DARPinG3 was incubated for 40 min at +4°C. Washing was performed three times with buffer PBS and 5% Bovine Serum Albumin (BSA). The characteristics of the binding specificity of the test set with the HER-2/neu receptor were determined by direct radiometric and planar scintigraphy. Nonparametric Mann-Whitney test was used to assess the differences in the quantitative characteristics between groups. Results: The output of the labeled complex was more than 91%, with a radiochemical purity of more than 94%. When carrying out a visual scintigraphic assessment much greater intensity accumulation of radiotracer was observed in the studied cell culture surface receptor overexpressing Her-2/neu. The results of direct radiometric also showed higher accumulation of the radiopharmaceutical in the adenocarcinoma cell line BT-474 human breast

NeuCode Proteomics Reveals Bap1 Regulation of Metabolism

Directory of Open Access Journals (Sweden)

Joshua M. Baughman

2016-07-01

Full Text Available We introduce neutron-encoded (NeuCode amino acid labeling of mice as a strategy for multiplexed proteomic analysis in vivo. Using NeuCode, we characterize an inducible knockout mouse model of Bap1, a tumor suppressor and deubiquitinase whose in vivo roles outside of cancer are not well established. NeuCode proteomics revealed altered metabolic pathways following Bap1 deletion, including profound elevation of cholesterol biosynthetic machinery coincident with reduced expression of gluconeogenic and lipid homeostasis proteins in liver. Bap1 loss increased pancreatitis biomarkers and reduced expression of mitochondrial proteins. These alterations accompany a metabolic remodeling with hypoglycemia, hypercholesterolemia, hepatic lipid loss, and acinar cell degeneration. Liver-specific Bap1 null mice present with fully penetrant perinatal lethality, severe hypoglycemia, and hepatic lipid deficiency. This work reveals Bap1 as a metabolic regulator in liver and pancreas, and it establishes NeuCode as a reliable proteomic method for deciphering in vivo biology.

Automated N-glycan profiling of a mutant Trypanosoma rangeli sialidase expressed in Pichia pastoris, using tandem mass spectrometry and bioinformatics

DEFF Research Database (Denmark)

Li, Haiying; Rasmussen, Morten I; Larsen, Martin R

2015-01-01

A mutant Trypanosoma rangeli sialidase, Tr7, expressed in Pichia pastoris, exhibits significant trans-sialidase activity, and has been used for analytical-scale production of sialylated human milk oligosaccharides. Mass spectrometry-based site-specific N-glycoprofiling of Tr7 showed that heteroge...

Influence of tunicamycin, sialidase, and cholera toxin on gangliosides and T-lymphocyte responses to interleukin 2

International Nuclear Information System (INIS)

Semmes, O.J.; Bailey, J.M.; Merritt, W.D.

1986-01-01

The authors have shown that gangliosides inhibit interleukin 2 (IL 2)-dependent proliferation of murine T cells. Tunicamycin (TM), sialidase, and cholera toxin-β subunit (β-CT) are known modulators of cell surface glycoconjugates. To test the possible role of endogenous gangliosides in T cell responses to IL-2, the effect of these agents on ganglioside expression and cell proliferation was studied. Gangliosides were labelled for 24 hrs with 3 H-glucosamine/galactose in the presence of IL-2 and purified sialidase, TM or β-CT. Gangliosides were isolated and the species separated by TLC. Alternatively, proliferation was assayed by 3 H-thymidine uptake after 48 hrs culture. TM treatment at a concentration (10 μg/ml) that completely inhibited proliferation resulted in a 86% reduction of incorporation of saccharide precursors into gangliosides compared to a 50% reduction into proteins. Sialidase treatment (0.1 IU/ml) resulted in a 70% inhibition of proliferation and 30% reduction of radiolabel into gangliosides, of which 3 species were specifically reduced. β-CT, which binds to GM 1 and to a lesser extent GD/sub 1a/, caused a 50% reduction in proliferation response at 35 units/ml. The results support the hypothesis that gangliosides are involved in IL-2-dependent proliferation

The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer

Directory of Open Access Journals (Sweden)

Penichet Manuel L

2011-11-01

Full Text Available Abstract Background HER2/neu is an oncogene that facilitates neoplastic transformation due to its ability to transduce growth signals in a ligand-independent manner, is over-expressed in 20-30% of human breast cancers correlating with aggressive disease and has been successfully targeted with trastuzumab (Herceptin®. Because trastuzumab alone achieves only a 15-30% response rate, it is now commonly combined with conventional chemotherapeutic drugs. While the combination of trastuzumab plus chemotherapy has greatly improved response rates and increased survival, these conventional chemotherapy drugs are frequently associated with gastrointestinal and cardiac toxicity, bone marrow and immune suppression. These drawbacks necessitate the development of new, less toxic drugs that can be combined with trastuzumab. Recently, we reported that orally administered alpha-tocopheryloxyacetic acid (α-TEA, a novel ether derivative of alpha-tocopherol, dramatically suppressed primary tumor growth and reduced the incidence of lung metastases both in a transplanted and a spontaneous mouse model of breast cancer without discernable toxicity. Methods In this study we examined the effect of α-TEA plus HER2/neu-specific antibody treatment on HER2/neu-expressing breast cancer cells in vitro and in a HER2/neu positive human xenograft tumor model in vivo. Results We show in vitro that α-TEA plus anti-HER2/neu antibody has an increased cytotoxic effect against murine mammary tumor cells and human breast cancer cells and that the anti-tumor effect of α-TEA is independent of HER2/neu status. More importantly, in a human breast cancer xenograft model, the combination of α-TEA plus trastuzumab resulted in faster tumor regression and more tumor-free animals than trastuzumab alone. Conclusion Due to the cancer cell selectivity of α-TEA, and because α-TEA kills both HER2/neu positive and HER2/neu negative breast cancer cells, it has the potential to be effective and

Rational Design of a New Trypanosoma rangeli Trans-Sialidase for Efficient Sialylation of Glycans

DEFF Research Database (Denmark)

Jers, Carsten; Michalak, Malwina; Larsen, Dorte Møller

2014-01-01

This paper reports rational engineering of Trypanosoma rangeli sialidase to develop an effective enzyme for a potentially important type of reactivity: production of sialylated prebiotic glycans. The Trypanosoma cruzi trans-sialidase and the homologous T. rangeli sialidase has previously been use...

A comparative study of N-glycolylneuraminic acid (Neu5Gc and cytotoxic T cell (CT carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle.

Directory of Open Access Journals (Sweden)

Paul T Martin

Full Text Available The expression of N-glycolylneuraminic acid (Neu5Gc and the cytotoxic T cell (CT carbohydrate can impact the severity of muscular dystrophy arising from the loss of dystrophin in mdx mice. Here, we describe the expression of these two glycans in skeletal muscles of dogs and humans with or without dystrophin-deficiency. Neu5Gc expression was highly reduced (>95% in muscle from normal golden retriever crosses (GR, n = 3 and from golden retriever with muscular dystrophy (GRMD, n = 5 dogs at multiple ages (3, 6 and 13 months when compared to mouse muscle, however, overall sialic acid expression in GR and GRMD muscles remained high at all ages. Neu5Gc was expressed on only a minority of GRMD satellite cells, CD8⁺ T lymphocytes and macrophages. Human muscle from normal (no evident disease, n = 3, Becker (BMD, n = 3 and Duchenne (DMD, n = 3 muscular dystrophy individuals had absent to very low Neu5Gc staining, but some punctate intracellular muscle staining was present in BMD and DMD muscles. The CT carbohydrate was localized to the neuromuscular junction in GR muscle, while GRMD muscles had increased expression on a subset of myofibers and macrophages. In humans, the CT carbohydrate was ectopically expressed on the sarcolemmal membrane of some BMD muscles, but not normal human or DMD muscles. These data are consistent with the notion that altered Neu5Gc and CT carbohydrate expression may modify disease severity resulting from dystrophin deficiency in dogs and humans.

Scintillator concept of NeuLAND at R3B

Energy Technology Data Exchange (ETDEWEB)

Aumann, Thomas; Ignatov, Alexander [Technische Universitaet Darmstadt (Germany); Boretzky, Konstanze; Heil, Michael; Simon, Haik [GSI Helmholtzzentrum fuer Schwerionenforschung, Darmstadt (Germany); Maroussov, Vassili [Institut fuer Kernphysik, Universitaet zu Koeln (Germany); GSI Helmholtzzentrum fuer Schwerionenforschung, Darmstadt (Germany); Zilges, Andreas [Institut fuer Kernphysik, Universitaet zu Koeln (Germany); Collaboration: R3B-Collaboration

2011-07-01

For the R3B experiment at FAIR a detection system for fast neutrons, NeuLAND (new Large Area Neutron Detector), is foreseen. Besides a time resolution of {sigma}{sub t}{approx_equal} 100 ps, spatial resolutions of {sigma}{sub x,y,z}{approx_equal} 1 cm, the detection efficiency of above 90% for neutrons of 0.2-1 GeV and a dedicated multi-neutron recognition capability are demanded. Using the FLUKA Monte Carlo code we studied a NeuLAND detector concept relying entirely on bars of a plastic scintillator (BC408). With a detector depth of 2 m the required efficiency is reached and the fraction of incident neutrons detected within resolution requirements varies from {proportional_to}70% to 80% in the desired energy range. Simulations have verified that the introduction of an inactive converter like iron deteriorates the timing performance. Due to the low density of the scintillator secondary protons typically cross several modules, thus allowing the tracking of secondaries. The status of the multi-hit recognition algorithm using the tracking information is presented along with the latest results for the scintillator prototypes for NeuLAND. Using the same framework a competing concept for NeuLAND based on MRPCs was studied as well and is contrasted to the scintillator concept.

NeuN/Rbfox3 nuclear and cytoplasmic isoforms differentially regulate alternative splicing and nonsense-mediated decay of Rbfox2.

Directory of Open Access Journals (Sweden)

B Kate Dredge

Full Text Available Anti-NeuN (Neuronal Nuclei is a monoclonal antibody used extensively to specifically detect post-mitotic neurons. Anti-NeuN reactivity is predominantly nuclear; by western it detects multiple bands ranging in molecular weight from 45 kDa to >75 kDa. Expression screening putatively identified R3hdm2 as NeuN; however immunoprecipitation and mass spectrometry of the two major NeuN species at 45-50 kDa identified both as the RNA binding protein Rbfox3 (a member of the Fox family of alternative splicing factors, confirming and extending the identification of the 45 kDa band as Rbfox3 by Kim et al. Mapping of the anti-NeuN reactive epitopes in both R3hdm2 and Rbfox3 reveals a common proline- and glutamine-rich domain that lies at the N-terminus of the Rbfox3 protein. Our data suggests that alternative splicing of the Rbfox3 pre-mRNA itself leads to the production of four protein isoforms that migrate in the 45-50 kDa range, and that one of these splicing choices regulates Rbfox3/NeuN sub-cellular steady-state distribution, through the addition or removal of a short C-terminal extension containing the second half of a bipartite hydrophobic proline-tyrosine nuclear localization signal. Rbfox3 regulates alternative splicing of the Rbfox2 pre-mRNA, producing a message encoding a dominant negative form of the Rbfox2 protein. We show here that nuclear Rbfox3 isoforms can also enhance the inclusion of cryptic exons in the Rbfox2 mRNA, resulting in nonsense-mediated decay of the message, thereby contributing to the negative regulation of Rbfox2 by Rbfox3 through a novel mechanism.

Mice doubly-deficient in lysosomal hexosaminidase A and neuraminidase 4 show epileptic crises and rapid neuronal loss.

Directory of Open Access Journals (Sweden)

Volkan Seyrantepe

2010-09-01

Full Text Available Tay-Sachs disease is a severe lysosomal disorder caused by mutations in the HexA gene coding for the α-subunit of lysosomal β-hexosaminidase A, which converts G(M2 to G(M3 ganglioside. Hexa(-/- mice, depleted of β-hexosaminidase A, remain asymptomatic to 1 year of age, because they catabolise G(M2 ganglioside via a lysosomal sialidase into glycolipid G(A2, which is further processed by β-hexosaminidase B to lactosyl-ceramide, thereby bypassing the β-hexosaminidase A defect. Since this bypass is not effective in humans, infantile Tay-Sachs disease is fatal in the first years of life. Previously, we identified a novel ganglioside metabolizing sialidase, Neu4, abundantly expressed in mouse brain neurons. Now we demonstrate that mice with targeted disruption of both Neu4 and Hexa genes (Neu4(-/-;Hexa(-/- show epileptic seizures with 40% penetrance correlating with polyspike discharges on the cortical electrodes of the electroencephalogram. Single knockout Hexa(-/- or Neu4(-/- siblings do not show such symptoms. Further, double-knockout but not single-knockout mice have multiple degenerating neurons in the cortex and hippocampus and multiple layers of cortical neurons accumulating G(M2 ganglioside. Together, our data suggest that the Neu4 block exacerbates the disease in Hexa(-/- mice, indicating that Neu4 is a modifier gene in the mouse model of Tay-Sachs disease, reducing the disease severity through the metabolic bypass. However, while disease severity in the double mutant is increased, it is not profound suggesting that Neu4 is not the only sialidase contributing to the metabolic bypass in Hexa(-/- mice.

Mutants of Micromonospora viridifaciens sialidase have highly variable activities on natural and non-natural substrates

DEFF Research Database (Denmark)

Jers, Carsten; Guo, Yao; Kepp, Kasper Planeta

2015-01-01

This study aimed to improve the hydrolase activity of the well-characterised bacterial sialidase from Micromonospora viridifaciens. The enzyme and its mutated versions were produced in Bacillus subtilis and secreted to the growth medium. Twenty amino acid positions in or near the active site were...

Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid.

Science.gov (United States)

Banda, Kalyan; Gregg, Christopher J; Chow, Renee; Varki, Nissi M; Varki, Ajit

2012-08-17

Although N-acetyl groups are common in nature, N-glycolyl groups are rare. Mammals express two major sialic acids, N-acetylneuraminic acid and N-glycolylneuraminic acid (Neu5Gc). Although humans cannot produce Neu5Gc, it is detected in the epithelial lining of hollow organs, endothelial lining of the vasculature, fetal tissues, and carcinomas. This unexpected expression is hypothesized to result via metabolic incorporation of Neu5Gc from mammalian foods. This accumulation has relevance for diseases associated with such nutrients, via interaction with Neu5Gc-specific antibodies. Little is known about how ingested sialic acids in general and Neu5Gc in particular are metabolized in the gastrointestinal tract. We studied the gastrointestinal and systemic fate of Neu5Gc-containing glycoproteins (Neu5Gc-glycoproteins) or free Neu5Gc in the Neu5Gc-free Cmah(-/-) mouse model. Ingested free Neu5Gc showed rapid absorption into the circulation and urinary excretion. In contrast, ingestion of Neu5Gc-glycoproteins led to Neu5Gc incorporation into the small intestinal wall, appearance in circulation at a steady-state level for several hours, and metabolic incorporation into multiple peripheral tissue glycoproteins and glycolipids, thus conclusively proving that Neu5Gc can be metabolically incorporated from food. Feeding Neu5Gc-glycoproteins but not free Neu5Gc mimics the human condition, causing tissue incorporation into human-like sites in Cmah(-/-) fetal and adult tissues, as well as developing tumors. Thus, glycoproteins containing glycosidically linked Neu5Gc are the likely dietary source for human tissue accumulation, and not the free monosaccharide. This human-like model can be used to elucidate specific mechanisms of Neu5Gc delivery from the gut to tissues, as well as general mechanisms of metabolism of ingested sialic acids.

Sialyltransferase activity probably counteracts that of sialidase as ...

African Journals Online (AJOL)

Sialyltransferase activity probably counteracts that of sialidase as one of the possible mechanisms of natural recovery or stabilization of erythrocyte mass in trypanosome-infected animals - A perspective.

THYDE-NEU: Nuclear reactor system analysis code

International Nuclear Information System (INIS)

Asahi, Yoshiro

2002-03-01

THYDE-NEU is applicable not only to transient analyses, but also to steady state analyses of nuclear reactor systems (NRSs). In a steady state analysis, the code generates a solution satisfying the transient equations without external disturbances. In a transient analysis, the code calculates temporal NRS behaviors in response to various external disturbances in such a way that mass and energy of the coolant as well as the number of neutrons conserve. The first half of the report is the description of the methods and models for use in the THYDE-NEU code, i.e., (1) the thermal-hydraulic network model, (2) the spatial kinetics model, (3) the heat sources in fuel, (4) the heat transfer correlations, (5) the mechanical behavior of clad and fuel, and (6) the steady state adjustment. The second half of the report is the users' mannual containing the items; (1) the program control, (2) the input requirements, (3) the execution of THYDE-NEU jobs, (4) the output specifications and (5) the sample calculation. (author)

Anti-influenza drugs: the development of sialidase inhibitors.

Science.gov (United States)

von Itzstein, Mark; Thomson, Robin

2009-01-01

Viruses, particularly those that are harmful to humans, are the 'silent terrorists' of the twenty-first century. Well over four million humans die per annum as a result of viral infections alone. The scourge of influenza virus has plagued mankind throughout the ages. The fact that new viral strains emerge on a regular basis, particularly out of Asia, establishes a continual socio-economic threat to mankind. The arrival of the highly pathogenic avian influenza H5N1 heightened the threat of a potential human pandemic to the point where many countries have put in place 'preparedness plans' to defend against such an outcome. The discovery of the first designer influenza virus sialidase inhibitor and anti-influenza drug Relenza, and subsequently Tamiflu, has now inspired a number of continuing efforts towards the discovery of next generation anti-influenza drugs. Such drugs may act as 'first-line-of-defence' against the spread of influenza infection and buy time for necessary vaccine development particularly in a human pandemic setting. Furthermore, the fact that influenza virus can develop resistance to therapeutics makes these continuing efforts extremely important. An overview of the role of the virus-associated glycoprotein sialidase (neuraminidase) and some of the most recent developments towards the discovery of anti-influenza drugs based on the inhibition of influenza virus sialidase is provided in this chapter.

Expression of Her-2/neu in extrahepatic cholangiocarcinoma

Directory of Open Access Journals (Sweden)

Shamekh R

2017-02-01

Full Text Available Rania Shamekh,1,* Marilin Rosa,2,* Zena Sayegh,2 Masoumeh Ghayouri,2 Richard Kim,3 Mokenge P Malafa,3 Domenico Coppola2 1Department of Pathology, University of South Florida, 2Department of Anatomic Pathology, 3Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA *These authors contributed equally to this work Background: Receptor tyrosine-protein kinase erbB-2, which is also frequently called human epidermal growth factor receptor-2 (Her-2 or Her-2/neu, has been found to be overexpressed in various human cancers.Hypothesis: The aim of this pilot study was to explore the frequency of Her-2/neu gene amplification and protein expression in extrahepatic cholangiocarcinoma (EHBC. We used the World Health Organization classification criteria for EHBC.Materials and methods: This was a retrospective study using 88 tissue samples, including 45 samples from non-neoplastic biliary tissue (NNB and 43 samples of extrahepatic cholangiocarcinoma (EHBC. A tissue microarray including NNB and EHBC was constructed and analyzed by immunohistochemistry (IHC and dual in situ hybridization for Her-2/neu protein expression and amplification, respectively. The Her-2/neu expression was scored following the guidelines used for the ToGA study.Results: All NNB samples and all but one EHBC samples showed no expression of Her-2/neu by IHC. The one EHBC case immunohistochemically positive for Her-2/neu had an IHC score of 3+. Her-2/neu gene amplification was present in two EHBC samples only and included the case found to be positive by IHC.Conclusion: Our findings are similar to those reported in the literature. Although Her-2/neu overexpression has been documented in many types of cancer, Her-2/neu protein overexpression tends to have no role in the development and/or progression of EHBC. Keywords: extrahepatic, cholangiocarcinoma, Her-2/neu, ToGA, immunohistochemistry

A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli

International Nuclear Information System (INIS)

Bull, J.J.; Vimr, E.R.; Molineux, I.J.

2010-01-01

Prior studies treating mice infected with Escherichia coli O18:K1:H7 observed that phages requiring the K1 capsule for infection (K1-dep) were superior to capsule-independent (K1-ind) phages. We show that three K1-ind phages all have low fitness when grown on cells in serum whereas fitnesses of four K1-dep phages were high. The difference is serum-specific, as fitnesses in broth overlapped. Sialidase activity was associated with all K1-dep virions tested but no K1-ind virions, a phenotype supported by sequence analyses. Adding endosialidase to cells infected with K1-ind phage increased fitness in serum by enhancing productive infection after adsorption. We propose that virion sialidase activity is the primary determinant of high fitness on cells grown in serum, and thus in a mammalian host. Although the benefit of sialidase is specific to K1-capsulated bacteria, this study may provide a scientific rationale for selecting phages for therapeutic use in many systemic infections.

Designing a HER2/neu promoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing

International Nuclear Information System (INIS)

Lanteri, Marion; Ollier, Laurence; Giordanengo, Valérie; Lefebvre, Jean-Claude

2005-01-01

Our goal was to specifically render tumor cells susceptible to natural cytolytic anti-αGal antibodies by using a murine α1,3galactosyltransferase (mαGalT) transgene driven by a designed form of HER2/neu promoter (pNeu), the transcription of which is frequently observed to be above basal in breast tumors. Indeed, the αGalT activity that promotes Galα1,3Galβ1,4GlcNAc-R (αGal) epitope expression has been mutationally disrupted during the course of evolution, starting from Old World primates, and this has led to the counter-production of large amounts of cytotoxic anti-αGal antibodies in recent primates, including man. Expression of the endogenous c-erbB-2 gene was investigated in various cell lines by northern blotting. A mαGalT cDNA was constructed into pcDNA3 vector downstream of the original CMV promoter (pCMV/mαGalT) and various forms of pNeu were prepared by PCR amplification and inserted in the pCMV/mαGalT construct upstream of the mαGalT cDNA, in the place of the CMV promoter. These constructs were transferred into HEK-293 control and breast tumor cell lines. Stably transfected cells were analyzed by northern blotting for their expression of αGalT and c-erbB-2, and by flow cytometry for their binding with fluorescein isothiocyanate-conjugated Griffonia simplicifolia/isolectin B4. We show that expression of the mαGalT was up- or down-modulated according to the level of endogenous pNeu activity and the particular form of constructed pNeu. Among several constructs, two particular forms of the promoter, pNeu250 containing the CCAAT box and the PEA3 motif adjacent to the TATAA box, and pNeu664, which has three additional PEA3 motifs upstream of the CCAAT box, were found to promote differential αGalT expression. Our results strengthen current concepts about the crucial role played by the proximal PEA3 motif of pNeu, and may represent a novel therapeutic approach for the development of targeted transgene expression

Sialidases affect the host cell adherence and epsilon toxin-induced cytotoxicity of Clostridium perfringens type D strain CN3718.

Directory of Open Access Journals (Sweden)

Jihong Li

2011-12-01

Full Text Available Clostridium perfringens type B or D isolates, which cause enterotoxemias or enteritis in livestock, produce epsilon toxin (ETX. ETX is exceptionally potent, earning it a listing as a CDC class B select toxin. Most C. perfringens strains also express up to three different sialidases, although the possible contributions of those enzymes to type B or D pathogenesis remain unclear. Type D isolate CN3718 was found to carry two genes (nanI and nanJ encoding secreted sialidases and one gene (nanH encoding a cytoplasmic sialidase. Construction in CN3718 of single nanI, nanJ and nanH null mutants, as well as a nanI/nanJ double null mutant and a triple sialidase null mutant, identified NanI as the major secreted sialidase of this strain. Pretreating MDCK cells with NanI sialidase, or with culture supernatants of BMC206 (an isogenic CN3718 etx null mutant that still produces sialidases enhanced the subsequent binding and cytotoxic effects of purified ETX. Complementation of BMC207 (an etx/nanH/nanI/nanJ null mutant showed this effect is mainly attributable to NanI production. Contact between BMC206 and certain mammalian cells (e.g., enterocyte-like Caco-2 cells resulted in more rapid sialidase production and this effect involved increased transcription of BMC206 nanI gene. BMC206 was shown to adhere to some (e.g. Caco-2 cells, but not all mammalian cells, and this effect was dependent upon sialidase, particularly NanI, expression. Finally, the sialidase activity of NanI (but not NanJ or NanH could be enhanced by trypsin. Collectively these in vitro findings suggest that, during type D disease originating in the intestines, trypsin may activate NanI, which (in turn could contribute to intestinal colonization by C. perfringens type D isolates and also increase ETX action.

Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool

Energy Technology Data Exchange (ETDEWEB)

Muchmore, E.A.; Milewski, M.; Varki, A.; Diaz, S. (San Diego Veterans Administration Medical Center, CA (USA))

1989-12-05

N-Glycolylneuraminic acid (Neu5Gc) is an oncofetal antigen in humans and is developmentally regulated in rodents. We have explored the biology of N-acetylneuraminic acid hydroxylase, the enzyme responsible for conversion of the parent sialic acid, N-acetylneuraminic acid (Neu5Ac) to Neu5Gc. We show that the major sialic acid in all compartments of murine myeloma cell lines is Neu5Gc. Pulse-chase analysis in these cells with the sialic acid precursor (6-3H)N-acetylmannosamine demonstrates that most of the newly synthesized Neu5Gc appears initially in the cytosolic low-molecular weight pool bound to CMP. The percentage of Neu5Gc on membrane-bound sialic acids closely parallels that in the CMP-bound pool at various times of chase, whereas that in the free sialic acid pool is very low initially, and rises only later during the chase. This implies that conversion from Neu5Ac to Neu5Gc occurs primarily while Neu5Ac is in its sugar nucleotide form. In support of this, the hydroxylase enzyme from a variety of tissues and cells converted CMP-Neu5Ac to CMP-Neu5Gc, but showed no activity towards free or alpha-glycosidically bound Neu5Ac. Furthermore, the majority of the enzyme activity is found in the cytosol. Studies with isolated intact Golgi vesicles indicate that CMP-Neu5Gc can be transported and utilized for transfer of Neu5Gc to glycoconjugates. The general properties of the enzyme have also been investigated. The Km for CMP-Neu5Ac is in the range of 0.6-2.5 microM. No activity can be detected against the beta-methylglycoside of Neu5Ac. On the other hand, inhibition studies suggest that the enzyme recognizes both the 5'-phosphate group and the pyrimidine base of the substrate. Taken together, the data allow us to propose pathways for the biosynthesis and reutilization of Neu5Gc.

In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging

International Nuclear Information System (INIS)

Daldrup-Link, Heike E.; Meier, Reinhardt; Metz, Stephan; Settles, Marcus; Rummeny, Ernst J.; Rudelius, Martina; Piontek, Guido; Schlegel, Juergen; Piert, Morand; Uherek, Christoph; Wels, Winfried

2005-01-01

The purpose of this study is to optimize labeling of the human natural killer (NK) cell line NK-92 with iron-oxide-based contrast agents and to monitor the in vivo distribution of genetically engineered NK-92 cells, which are directed against HER2/neu receptors, to HER2/neu positive mammary tumors with magnetic resonance (MR) imaging. Parental NK-92 cells and genetically modified HER2/neu specific NK-92-scFv(FRP5)-zeta cells, expressing a chimeric antigen receptor specific to the tumor-associated ErbB2 (HER2/neu) antigen, were labeled with ferumoxides and ferucarbotran using simple incubation, lipofection and electroporation techniques. Labeling efficiency was evaluated by MR imaging, Prussian blue stains and spectrometry. Subsequently, ferucarbotran-labeled NK-92-scFv(FRP5)-zeta (n=3) or parental NK-92 cells were intravenously injected into the tail vein of six mice with HER2/neu-positive NIH 3T3 mammary tumors, implanted in the mammary fat pad. The accumulation of the cells in the tumors was monitored by MR imaging before and 12 and 24 h after cell injection (p.i.). MR data were correlated with histopathology. Both the parental NK-92 and the genetically modified NK-92-scFv(FRP5)-zeta cells could be labeled with ferucarbotran and ferumoxides by lipofection and electroporation, but not by simple incubation. The intracellular cytoplasmatic iron-oxide uptake was significantly higher after labeling with ferucarbotran than ferumoxides (P 6 NK-92-scFv(FRP5)-zeta cells into tumor-bearing mice, MR showed a progressive signal decline in HER2/neu-positive mammary tumors at 12 and 24 h (p.i.). Conversely, injection of 5 x 10 6 parental NK-92 control cells, not directed against HER2/neu receptors, did not cause significant signal intensity changes of the tumors. Histopathology confirmed an accumulation of the former, but not the latter cells in tumor tissue. The human natural killer cell line NK-92 can be efficiently labeled with clinically applicable iron-oxide contrast

In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging

Energy Technology Data Exchange (ETDEWEB)

Daldrup-Link, Heike E. [UCSF Medical Center, Department of Radiology, San Francisco, CA (United States); Meier, Reinhardt; Metz, Stephan; Settles, Marcus; Rummeny, Ernst J. [Technical University Munich, Department of Radiology, Munich (Germany); Rudelius, Martina; Piontek, Guido; Schlegel, Juergen [Technical University Munich, Institute of Pathology, Division of Neuropathology, Munich (Germany); Piert, Morand [Technical University Munich, Department of Nuclear Medicine, Munich (Germany); Uherek, Christoph; Wels, Winfried [University of Frankfurt, Georg Speyer House, Frankfurt (Germany)

2005-01-01

The purpose of this study is to optimize labeling of the human natural killer (NK) cell line NK-92 with iron-oxide-based contrast agents and to monitor the in vivo distribution of genetically engineered NK-92 cells, which are directed against HER2/neu receptors, to HER2/neu positive mammary tumors with magnetic resonance (MR) imaging. Parental NK-92 cells and genetically modified HER2/neu specific NK-92-scFv(FRP5)-zeta cells, expressing a chimeric antigen receptor specific to the tumor-associated ErbB2 (HER2/neu) antigen, were labeled with ferumoxides and ferucarbotran using simple incubation, lipofection and electroporation techniques. Labeling efficiency was evaluated by MR imaging, Prussian blue stains and spectrometry. Subsequently, ferucarbotran-labeled NK-92-scFv(FRP5)-zeta (n=3) or parental NK-92 cells were intravenously injected into the tail vein of six mice with HER2/neu-positive NIH 3T3 mammary tumors, implanted in the mammary fat pad. The accumulation of the cells in the tumors was monitored by MR imaging before and 12 and 24 h after cell injection (p.i.). MR data were correlated with histopathology. Both the parental NK-92 and the genetically modified NK-92-scFv(FRP5)-zeta cells could be labeled with ferucarbotran and ferumoxides by lipofection and electroporation, but not by simple incubation. The intracellular cytoplasmatic iron-oxide uptake was significantly higher after labeling with ferucarbotran than ferumoxides (P<0.05). After intravenous injection of 5 x 10{sup 6} NK-92-scFv(FRP5)-zeta cells into tumor-bearing mice, MR showed a progressive signal decline in HER2/neu-positive mammary tumors at 12 and 24 h (p.i.). Conversely, injection of 5 x 10{sup 6} parental NK-92 control cells, not directed against HER2/neu receptors, did not cause significant signal intensity changes of the tumors. Histopathology confirmed an accumulation of the former, but not the latter cells in tumor tissue. The human natural killer cell line NK-92 can be efficiently

At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody.

Science.gov (United States)

Yu, Chuanfei; Gao, Kai; Zhu, Lei; Wang, Wenbo; Wang, Lan; Zhang, Feng; Liu, Chunyu; Li, Meng; Wormald, Mark R; Rudd, Pauline M; Wang, Junzhi

2016-01-29

Two non-human glycan epitopes, galactose-α-1,3-galactose (α-gal) and Neu5Gc-α-2-6-galactose (Neu5Gc) have been shown to be antigenic when attached to Fab oligosaccharides of monoclonal antibodies (mAbs) , while α-gal attached to Fc glycans was not. However, the antigenicity of Neu5Gc on the Fc glycans remains unclear in the context that most mAbs carry only Fc glycans. After studying two clinical mAbs carrying significant amounts of Fc Neu5Gc, we show that their binding activity with anti-Neu5Gc antibody resided in a small subset of mAbs carrying two or more Fc Neu5Gc, while mAbs harboring only one Neu5Gc showed no reactivity. Since most Neu5Gc epitopes were distributed singly on the Fc of mAbs, our results suggest that the potential antigenicity of Fc Neu5Gc is low. Our study could be referenced in the process design and optimization of mAb production in murine myeloma cells and in the quality control of mAbs for industries and regulatory authorities.

Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool.

Science.gov (United States)

Muchmore, E A; Milewski, M; Varki, A; Diaz, S

1989-12-05

N-Glycolylneuraminic acid (Neu5Gc) is an oncofetal antigen in humans and is developmentally regulated in rodents. We have explored the biology of N-acetylneuraminic acid hydroxylase, the enzyme responsible for conversion of the parent sialic acid, N-acetylneuraminic acid (Neu5Ac) to Neu5Gc. We show that the major sialic acid in all compartments of murine myeloma cell lines is Neu5Gc. Pulse-chase analysis in these cells with the sialic acid precursor [6-3H]N-acetylmannosamine demonstrates that most of the newly synthesized Neu5Gc appears initially in the cytosolic low-molecular weight pool bound to CMP. The percentage of Neu5Gc on membrane-bound sialic acids closely parallels that in the CMP-bound pool at various times of chase, whereas that in the free sialic acid pool is very low initially, and rises only later during the chase. This implies that conversion from Neu5Ac to Neu5Gc occurs primarily while Neu5Ac is in its sugar nucleotide form. In support of this, the hydroxylase enzyme from a variety of tissues and cells converted CMP-Neu5Ac to CMP-Neu5Gc, but showed no activity towards free or alpha-glycosidically bound Neu5Ac. Furthermore, the majority of the enzyme activity is found in the cytosol. Studies with isolated intact Golgi vesicles indicate that CMP-Neu5Gc can be transported and utilized for transfer of Neu5Gc to glycoconjugates. The general properties of the enzyme have also been investigated. The Km for CMP-Neu5Ac is in the range of 0.6-2.5 microM. No activity can be detected against the beta-methylglycoside of Neu5Ac. On the other hand, inhibition studies suggest that the enzyme recognizes both the 5'-phosphate group and the pyrimidine base of the substrate. Taken together, the data allow us to propose pathways for the biosynthesis and reutilization of Neu5Gc, with initial conversion from Neu5Ac occurring primarily at the level of the sugar nucleotide. Subsequent release and reutilization of Neu5Gc could then account for the higher steady-state level

HER 2/neu protein expression in colorectal cancer

International Nuclear Information System (INIS)

Schuell, B; Gruenberger, T; Scheithauer, W; Zielinski, Ch; Wrba, F

2006-01-01

Conflicting data exist about the prevalence of HER-2/neu overexpression in colorectal cancer ranging from 0 to 83 %. In our study we tried to clarify the extent of expression and its relationship to clinicopathological parameters. This study involved 77 specimens of malignant colorectal cancer lesions of surgically resected patients. HER-2/neu immunohistochemistry was performed using the Hercep-Test Kit. Out of 77 specimens, 56 were Her-2/neu negative (70%), 20 (26%) showed a barely immunostaining (1+), only 1 (1%) was moderately (2+) and 2 (3%) were strongly positive (3+). Her-2/neu staining (moderately and strongly positive) was only detected in primary tumours of patients with confirmed metastases. No relationship was found between membranous HER-2 expression and patients' gender or differentiation. The median survival time of patients with positive HER-2/neu immunostaining was 21 versus 39 months in patients without HER-2/neu expression (p = 0.088). The c-erbB protein expression was observed in colorectal cancer but rarely in the therapeutic range (2+ and 3+). There was no significant association with tumour grade, gender, localization of the primary tumour or survival. These data indicate that c-erbB-2 is unlikely to play a major role in the therapeutic management of colorectal cancer

The Aspergillus fumigatus Sialidase (Kdnase Contributes to Cell Wall Integrity and Virulence in Amphotericin B-Treated Mice

Directory of Open Access Journals (Sweden)

Jason R. Nesbitt

2018-01-01

Full Text Available Aspergillus fumigatus is a filamentous fungus that can cause a life-threatening invasive pulmonary aspergillosis (IPA in immunocompromised individuals. We previously characterized an exo-sialidase from A. fumigatus that prefers the sialic acid substrate, 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (Kdn; hence it is a Kdnase. Sialidases are known virulence factors in other pathogens; therefore, the goal of our study was to evaluate the importance of Kdnase in A. fumigatus. A kdnase knockout strain (Δkdnase was unable to grow on medium containing Kdn and displayed reduced growth and abnormal morphology. Δkdnase was more sensitive than wild type to hyperosmotic conditions and the antifungal agent, amphotericin B. In contrast, Δkdnase had increased resistance to nikkomycin, Congo Red and Calcofluor White indicating activation of compensatory cell wall chitin deposition. Increased cell wall thickness and chitin content in Δkdnase were confirmed by electron and immunofluorescence microscopy. In a neutropenic mouse model of invasive aspergillosis, the Δkdnase strain had attenuated virulence and a significantly lower lung fungal burden but only in animals that received liposomal amphotericin B after spore exposure. Macrophage numbers were almost twofold higher in lung sections from mice that received the Δkdnase strain, possibly related to higher survival of macrophages that internalized the Δkdnase conidia. Thus, A. fumigatus Kdnase is important for fungal cell wall integrity and virulence, and because Kdnase is not present in the host, it may represent a potential target for the development of novel antifungal agents.

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

International Nuclear Information System (INIS)

Paudyal, P.; Paudyal, B.; Hanaoka, Hirofumi

2010-01-01

Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with 64 Cu. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-immunoglobulin G (IgG). In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 Cu-DOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4±1.4% and 23.2±5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 Cu-DOTA-trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (author)

A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease.

Directory of Open Access Journals (Sweden)

Vered Padler-Karavani

Full Text Available N-glycolylneuraminic acid (Neu5Gc is an immunogenic sugar of dietary origin that metabolically incorporates into diverse native glycoconjugates in humans. Anti-Neu5Gc antibodies are detected in all human sera, though with variable levels and epitope-recognition profiles. These antibodies likely play a role in several inflammation-mediated pathologies including cardiovascular diseases and cancer. In cancer, they have dualistic and opposing roles, either stimulating or repressing disease, as a function of their dose, and some of these antibodies serve as carcinoma biomarkers. Thus, anti-Neu5Gc antibodies may signify risk of inflammation-mediated diseases, and changes in their levels could potentially be used to monitor disease progression and/or response to therapy. Currently, it is difficult to determine levels of anti-Neu5Gc antibodies in individual human samples because these antibodies recognize multiple Neu5Gc-epitopes. Here we describe a simple and specific method for detection and overall estimation of human anti-Neu5Gc antibodies. We exploit the difference between two mouse models that differ only by Neu5Gc-presence (wild-type or Neu5Gc-absence (Cmah(-/- knockout. We characterize mouse serum from both strains by HPLC, lectin and mass-spectrometry analysis and show the target Neu5Gc-epitopes. We then use Cmah(-/- knockout sera to inhibit all non-Neu5Gc-reactivity followed by binding to wild-type sera to detect overall anti-Neu5Gc response in a single assay. We applied this methodology to characterize and quantify anti-Neu5Gc IgG and IgA in sera of patients with Kawasaki disease (KD at various stages compared to controls. KD is an acute childhood febrile disease characterized by inflammation of coronary arteries that untreated may lead to coronary artery aneurysms with risk of thrombosis and myocardial infarction. This estimated response is comparable to the average of detailed anti-Neu5Gc IgG profile analyzed by a sialoglycan microarray

At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody

OpenAIRE

Yu, Chuanfei; Gao, Kai; Zhu, Lei; Wang, Wenbo; Wang, Lan; Zhang, Feng; Liu, Chunyu; Li, Meng; Wormald, Mark R.; Rudd, Pauline M.; Wang, Junzhi

2016-01-01

Two non-human glycan epitopes, galactose-Į-1,3-galactose (Į-gal) and Neu5Gc-Į-2-6-galactose (Neu5Gc) have been shown to be antigenic when attached to Fab oligosaccharides of monoclonal antibodies (mAbs) , while Į-gal attached to Fc glycans were not. However, the antigenicity of Neu5Gc on the Fc glycans remains unclear in the context that most mAbs carry only Fc glycans. After studying two clinical mAbs carrying significant amounts of Fc Neu5Gc, we show that their binding activity with anti-Ne...

Canine and feline parvoviruses preferentially recognize the non-human cell surface sialic acid N-glycolylneuraminic acid

Energy Technology Data Exchange (ETDEWEB)

Löfling, Jonas [Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, Center for Academic Research and Training in Anthropogeny, 9500 Gilman Drive, University of California, San Diego, La Jolla, CA 92093 (United States); Michael Lyi, Sangbom; Parrish, Colin R. [Baker Institute for Animal Health, Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853 (United States); Varki, Ajit, E-mail: a1varki@ucsd.edu [Departments of Medicine and Cellular and Molecular Medicine, Glycobiology Research and Training Center, Center for Academic Research and Training in Anthropogeny, 9500 Gilman Drive, University of California, San Diego, La Jolla, CA 92093 (United States)

2013-05-25

Feline panleukopenia virus (FPV) is a pathogen whose canine-adapted form (canine parvovirus (CPV)) emerged in 1978. These viruses infect by binding host transferrin receptor type-1 (TfR), but also hemagglutinate erythrocytes. We show that hemagglutination involves selective recognition of the non-human sialic acid N-glycolylneuraminic acid (Neu5Gc) but not N-acetylneuraminic acid (Neu5Ac), which differs by only one oxygen atom from Neu5Gc. Overexpression of α2-6 sialyltransferase did not change binding, indicating that both α2-3 and α2-6 linkages are recognized. However, Neu5Gc expression on target cells did not enhance CPV or FPV infection in vitro. Thus, the conserved Neu5Gc-binding preference of these viruses likely plays a role in the natural history of the virus in vivo. Further studies must clarify relationships between virus infection and host Neu5Gc expression. As a first step, we show that transcripts of CMAH (which generates Neu5Gc from Neu5Ac) are at very low levels in Western dog breed cells. - Highlights: ► Feline and canine parvoviruses recognize Neu5Gc but not Neu5Ac, which differ by one oxygen atom. ► The underlying linkage of these sialic acids does not affect recognition. ► Induced Neu5Gc expression on target cells that normally express Neu5Ac did not enhance infection. ► Thus, the conserved binding preference plays an important yet unknown role in in vivo infections. ► Population and breed variations in Neu5Gc expression occur, likely by regulating the gene CMAH.

Canine and feline parvoviruses preferentially recognize the non-human cell surface sialic acid N-glycolylneuraminic acid

International Nuclear Information System (INIS)

Löfling, Jonas; Michael Lyi, Sangbom; Parrish, Colin R.; Varki, Ajit

2013-01-01

Feline panleukopenia virus (FPV) is a pathogen whose canine-adapted form (canine parvovirus (CPV)) emerged in 1978. These viruses infect by binding host transferrin receptor type-1 (TfR), but also hemagglutinate erythrocytes. We show that hemagglutination involves selective recognition of the non-human sialic acid N-glycolylneuraminic acid (Neu5Gc) but not N-acetylneuraminic acid (Neu5Ac), which differs by only one oxygen atom from Neu5Gc. Overexpression of α2-6 sialyltransferase did not change binding, indicating that both α2-3 and α2-6 linkages are recognized. However, Neu5Gc expression on target cells did not enhance CPV or FPV infection in vitro. Thus, the conserved Neu5Gc-binding preference of these viruses likely plays a role in the natural history of the virus in vivo. Further studies must clarify relationships between virus infection and host Neu5Gc expression. As a first step, we show that transcripts of CMAH (which generates Neu5Gc from Neu5Ac) are at very low levels in Western dog breed cells. - Highlights: ► Feline and canine parvoviruses recognize Neu5Gc but not Neu5Ac, which differ by one oxygen atom. ► The underlying linkage of these sialic acids does not affect recognition. ► Induced Neu5Gc expression on target cells that normally express Neu5Ac did not enhance infection. ► Thus, the conserved binding preference plays an important yet unknown role in in vivo infections. ► Population and breed variations in Neu5Gc expression occur, likely by regulating the gene CMAH

Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles.

Science.gov (United States)

Bilyy, Rostyslav O; Shkandina, Tanya; Tomin, Andriy; Muñoz, Luis E; Franz, Sandra; Antonyuk, Volodymyr; Kit, Yuriy Ya; Zirngibl, Matthias; Fürnrohr, Barbara G; Janko, Christina; Lauber, Kirsten; Schiller, Martin; Schett, Georg; Stoika, Rostyslav S; Herrmann, Martin

2012-01-02

Inappropriate clearance of apoptotic remnants is considered to be the primary cause of systemic autoimmune diseases, like systemic lupus erythematosus. Here we demonstrate that apoptotic cells release distinct types of subcellular membranous particles (scMP) derived from the endoplasmic reticulum (ER) or the plasma membrane. Both types of scMP exhibit desialylated glycotopes resulting from surface exposure of immature ER-derived glycoproteins or from surface-borne sialidase activity, respectively. Sialidase activity is activated by caspase-dependent mechanisms during apoptosis. Cleavage of sialidase Neu1 by caspase 3 was shown to be directly involved in apoptosis-related increase of surface sialidase activity. ER-derived blebs possess immature mannosidic glycoepitopes and are prioritized by macrophages during clearance. Plasma membrane-derived blebs contain nuclear chromatin (DNA and histones) but not components of the nuclear envelope. Existence of two immunologically distinct types of apoptotic blebs may provide new insights into clearance-related diseases.

Bacterial vaginosis in pregnant adolescents: proinflammatory cytokine and bacterial sialidase profile. Cross-sectional study

Directory of Open Access Journals (Sweden)

Carolina Sanitá Tafner Ferreira

Full Text Available ABSTRACT CONTEXT AND OBJECTIVE: Bacterial vaginosis occurs frequently in pregnancy and increases susceptibility to sexually transmitted infections (STI. Considering that adolescents are disproportionally affected by STI, the aim of this study was to evaluate the cervicovaginal levels of interleukin (IL-1 beta, IL-6, IL-8 and bacterial sialidase in pregnant adolescents with bacterial vaginosis. DESIGN AND SETTING: Cross-sectional study at mother and child referral units in Belém, Pará, Brazil. METHODS: Vaginal samples from 168 pregnant adolescents enrolled were tested for trichomoniasis and candidiasis. Their vaginal microbiota was classified according to the Nugent criteria (1991 as normal, intermediate or bacterial vaginosis. Cervical infection due to Chlamydia trachomatisand Neisseria gonorrhoeae was also assessed. Cytokine and sialidase levels were measured, respectively, using enzyme-linked immunosorbent assays and MUAN conversion in cervicovaginal lavages. Forty-eight adolescents (28.6% were excluded because they tested positive for some of the infections investigated. The remaining 120 adolescents were grouped according to vaginal flora type: normal (n = 68 or bacterial vaginosis (n = 52. Their cytokine and sialidase levels were compared between the groups using the Mann-Whitney test (P < 0.05. RESULTS: The pregnant adolescents with bacterial vaginosis had higher levels of IL-1 beta, IL-6 and IL-8 (P < 0.05. Sialidase was solely detected in 35 adolescents (67.2% with bacterial vaginosis. CONCLUSIONS: Not only IL-1 beta and sialidase levels, but also IL-6 and IL-8 levels are higher in pregnant adolescents with bacterial vaginosis, thus indicating that this condition elicits a more pronounced inflammatory response in this population, which potentially increases vulnerability to STI acquisition.

Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines

Directory of Open Access Journals (Sweden)

Alonso Daniel F

2009-12-01

Full Text Available Abstract Background Carbohydrates embedded in the plasma membrane are one of the main actors involved in the communication of cells with the microenvironment. Neuraminic sialic acids are glycocalyx sugars that play important roles in the modulation of malignant cell behaviour. N-glycolylneuraminic acid (NeuGc is synthesized by the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH, an enzyme expressed in all mammals except humans. In mice, this sugar is synthesized in several somatic tissues. Methods We used the B16 melanoma and F3II mammary carcinoma mouse tumor cell lines. By CMAH directed RT-PCR and NeuGc detection with the specific anti-NeuGc-GM3 antibody 14F7 we evaluated enzyme and ganglioside expression in tumor cells, respectively. Expression of NeuGc-GM3 ganglioside was reached by in vitro incubation with NeuGc-rich bovine submaxillary mucin and evaluated by slot-blot and immunohistochemistry assays using the 14F7 antibody. Tumor cells treated with mucin or purified NeuGc were injected s.c. and i.v. in syngeneic mice to evaluate tumor and metastatic growth. Results In the present work we demonstrated the absence of expression of CMAH enzyme in B16 melanoma and F3II mammary carcinoma cells. In vitro incubation of these NeuGc-negative cells with NeuGc-rich mucin increased the presence of NeuGc in cell membranes for at least 48-72 h, as a component of the GM3 ganglioside. Preincubation with NeuGc-rich mucin reduced tumor latency and increased the metastatic potential of tumor cells in syngeneic animals. Similar results were obtained when cells were incubated with purified NeuGc alone. Conclusion Our results indicate that B16 and F3II mouse tumor cell lines do not express NeuGc in cell membranes but they are able to incorporate NeuGc from an exogenous source, contributing to the malignant phenotype of melanoma and mammary carcinoma cells.

Insights into the binding specificity of wild type and mutated wheat germ agglutinin towards Neu5Acα(2-3)Gal: a study by in silico mutations and molecular dynamics simulations.

Science.gov (United States)

Parasuraman, Ponnusamy; Murugan, Veeramani; Selvin, Jeyasigamani F A; Gromiha, M Michael; Fukui, Kazuhiko; Veluraja, Kasinadar

2014-08-01

Wheat germ agglutinin (WGA) is a plant lectin, which specifically recognizes the sugars NeuNAc and GlcNAc. Mutated WGA with enhanced binding specificity can be used as biomarkers for cancer. In silico mutations are performed at the active site of WGA to enhance the binding specificity towards sialylglycans, and molecular dynamics simulations of 20 ns are carried out for wild type and mutated WGAs (WGA1, WGA2, and WGA3) in complex with sialylgalactose to examine the change in binding specificity. MD simulations reveal the change in binding specificity of wild type and mutated WGAs towards sialylgalactose and bound conformational flexibility of sialylgalactose. The mutated polar amino acid residues Asn114 (S114N), Lys118 (G118K), and Arg118 (G118R) make direct and water mediated hydrogen bonds and hydrophobic interactions with sialylgalactose. An analysis of possible hydrogen bonds, hydrophobic interactions, total pair wise interaction energy between active site residues and sialylgalactose and MM-PBSA free energy calculation reveals the plausible binding modes and the role of water in stabilizing different binding modes. An interesting observation is that the binding specificity of mutated WGAs (cyborg lectin) towards sialylgalactose is found to be higher in double point mutation (WGA3). One of the substituted residues Arg118 plays a crucial role in sugar binding. Based on the interactions and energy calculations, it is concluded that the order of binding specificity of WGAs towards sialylgalactose is WGA3 > WGA1 > WGA2 > WGA. On comparing with the wild type, double point mutated WGA (WGA3) exhibits increased specificity towards sialylgalactose, and thus, it can be effectively used in targeted drug delivery and as biological cell marker in cancer therapeutics. Copyright © 2014 John Wiley & Sons, Ltd.

The development of a highly specific radiochemical compound based on labeled 99mtc recombinant molecules for targeted imaging of cells with the overexpression of Her-2 / neu

Directory of Open Access Journals (Sweden)

Olga D. Bragina

2017-01-01

Full Text Available Currently, there is a urgent need to search for new diagnostic methods that allow us to reveal malignant tumors with the overexpression of Her-2/neu with high accuracy. In recent years radioisotope methods have been actively developing to identify specific tumor targets, with antibodies being the “targeting” module.The purpose of the study. Creation of a chemically stable radiochemical compound for the imaging of cells with the overexpression of Her-2/neu.Materials and methods. The study was conducted using two human adenocarcinoma cell lines with expression (BT-474 and without expression (MCF-7 Her-2/neu. The specificity of the binding of the test complex with Her-2/neu receptor was determined by direct radiometric and planar scintigraphy. To evaluate the differences in quantitative characteristics between the groups a non-parametric Mann – Whitney test was used.Results. The yield of the labeled complex was more than 91% and the radiochemical frequency was more than 94%. When performing a visual scintigraphic evaluation, a much higher accumulation rate of the studied radiopharmaceutical preparation (RFP was observed in the culture of cells with overexpression of the surface Her-2/neu receptor. Direct radiometric results also demonstrated a higher accumulation of RFPs in the human BT-474 mammary adenocarcinoma cell line with Her-2/neu overexpression in comparison with the control group.Conclusion. Preclinical studies demonstrated high stability of the test compound, as well as its accumulation in the group of cells with Her-2/neu overexpression

NeuLAND prototype: response to fast neutrons

Energy Technology Data Exchange (ETDEWEB)

Jaehrling, Simon; Scheit, Heiko [Technische Universitaet Darmstadt (Germany); Aumann, Thomas [Technische Universitaet Darmstadt (Germany); GSI Helmholtzzentrum fuer Schwerionenforschung GmbH, Darmstadt (Germany); Boretzky, Konstanze; Heil, Michael; Kresan, Dmytro; Simon, Haik [GSI Helmholtzzentrum fuer Schwerionenforschung GmbH, Darmstadt (Germany); Gasparic, Igor [Technische Universitaet Darmstadt (Germany); Rudjer Boskovic Institute, Zagreb (Croatia); Collaboration: R3B-Collaboration

2014-07-01

Within the R3B collaboration (Reactions with Relativistic Radioactive Beams), a new neutron detector NeuLAND (New Large Area Neutron Detector) is being developed. It will be a fully active scintillation detector consisting of 3000 scintillator bars, arranged in 30 double layers. Within a double layer 50 bars are horizontal and 50 vertical orientated. The whole detector measures 2.5 x 2.5 x 3 m{sup 3}. A prototype with 150 NeuLAND bars was tested at GSI using quasi-mono-energetic neutrons with different energies from 200 to 1500 MeV stemming from quasi-free deuteron breakup reactions on a CH{sub 2} target. The experimental setup is described, and preliminary results for the time resolution and efficiency of the NeuLAND prototype detector are presented.

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity

International Nuclear Information System (INIS)

Dimitriadis, Alexios; Gontinou, Chrysanthi; Baxevanis, Constantin N; Mamalaki, Avgi

2009-01-01

Her2/neu is overexpressed in various human cancers of epithelial origin and is associated with increased metastatic potential and poor prognosis. Several attempts have been made using the extracellular domain of Her2/neu (ECD/Her2) as a prophylactic vaccine in mice with no success in tumor prevention. The extracellular domain of Her2/neu (ECD/Her2) was expressed in yeast P. pastoris, in a soluble highly mannosylated form. The immune response of the immunization with this recombinant ECD/Her2 was analyzed using immunoprecipitation and western blot analysis, proliferation and cytotoxicity assays as well as specific tumor growth assays. Mannosylated ECD/Her2 elicited a humoral response with HER2/neu specific antibodies in vaccinated mice, which were able to reduce the proliferation rate of cancer cells in vitro. Moreover, it elicited a cellular response with Her2/neu-specific CTL capable of lysing tumor cells, in vitro. When immunized Balb/c and HHD mice were challenged with Her2/neu-overexpressing cells, tumor growth was inhibited. Here we report on the efficacy of the extracellular domain of human Her2/neu produced in yeast P. pastoris, which confers mannosylation of the protein, to act as a potent anti-tumor vaccine against Her2/neu overexpressing tumors. Specific cellular and humoral responses were observed as well as efficacy

NeuLand submodules exposed to fast neutrons

Energy Technology Data Exchange (ETDEWEB)

Gasparic, Igor [Technische Univ. Darmstadt (Germany); Rudjer Boskovic Institute, Zagreb (Croatia); Aumann, Thomas [Technische Univ. Darmstadt (Germany); GSI Helmholtzzentrum fuer Schwerionenforschung GmbH, Darmstadt (Germany); Boretzky, Konstanze; Heil, Michael; Simon, Haik [GSI Helmholtzzentrum fuer Schwerionenforschung GmbH, Darmstadt (Germany); Jaehrling, Simon [Technische Univ. Darmstadt (Germany); Collaboration: R3B-Collaboration

2013-07-01

Within the R{sup 3}B collaboration (Reactions with Relativistic Radioactive Beams), a new neutron detector NeuLAND (New Large Area Neutron Detector) is being developed. The technical design was finalized in November 2011, a fully active scintillator concept was chosen. It will be a box-shaped 2.5 x 2.5 x 3 m{sup 3} detector consisting of 3000 scintillator bars arranged in 60 planes with mutually orthogonal orientation. An array of 150 NeuLAND bars was exposed to fast ''mono-energetic'' neutrons stemming from quasi-free deuteron breakup reactions on a CH{sub 2} target (250 to 1500 AMeV). The experiment carried out at GSI in Nov. 2012 aims for determination of both time resolution and efficiency of NeuLAND submodules. Preliminary results of the analysis are presented.

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.

Science.gov (United States)

Molina, Rafael; Augé, Jose M; Escudero, Jose M; Filella, Xavier; Zanon, Gabriel; Pahisa, Jaume; Farrus, Blanca; Muñoz, Montserrat; Velasco, Martin

2010-06-01

Tumor markers were studied in the sera of 883 untreated patients with primary breast cancer diagnosed between 1989 and 2007. Abnormal human epidermal growth factor receptor 2 (HER-2)/neu levels (>15 ng/mL) were found in 9.5%, carcinoembryonic antigen (CEA) in 15.9%, and cancer antigen (CA) 15.3 in 19.7% of the patients. One or more tumor markers were abnormal in 305 (34.5%) of the 883 studied patients. Significantly higher serum HER-2/neu levels were found in patients with tissue overexpression of this oncoprotein (p CEA, CA 15.3, and HER-2/neu (only in those patients with tissue overexpression) serum levels were related with tumor stage (tumor size and nodal involvement) and steroid receptors (higher values in estrogen receptor-negative (ER-) tumors). Univariate analysis showed that HER-2/neu serum levels were prognostic factors in disease-free survival (DFS) and overall survival (OS) only in patients with tissue overexpression. Multivariate analysis in 834 patients show that nodal involvement, tumor size, ER, CEA, and adjuvant treatment were independent prognostic factors in DFS and OS. When only patients with HER-2/neu overexpression in tissue were studied, tumor size, nodal involvement, and tumor markers (one or another positive) were independent prognostic factors for both DFS and OS. HER-2/neu serum levels were also an independent prognostic factor, with CEA, ER, and nodes in 106 patients treated with neoadjuvant treatment. In summary, serum HER-2/neu, CEA, and CA 15.3 are useful tools in the prognostic evaluation of patients with primary breast cancer.

Study of HER2/neu status in Qatari women with breast carcinoma

International Nuclear Information System (INIS)

Rasul, Kaki I.; Abdalla, Awidi S.; Mohammed, Kelta; Ahmad, Mubarak A.; Al-Homsi, Mohammed U.; Al-Hassan, Asma M.; Al-Alosi, Ahmad S.; Bener, A.

2003-01-01

The study is aimed at determining the prevalence of HER2/neu overexpression in Qatari women with breast cancer and to acess the survival in patients with HER2/neu positive tumors. This is a retropspective study of clinical data of 70 Qatari female patients diagonosed with breast cancer during the priod 1991through to 2001,at Hamad Medical Corporation, Doha, Qatar. We also performed a retrospective review of breast tissue for those patients using paraffin sections and applying immunohistochemistry staining -[Hercep test (DAKO Inc)] to determine the HER/neu status. Out of all the eighteen patients (26%) were HER2/neu positive(2+ and 3+) wih a mean age at diagonosis of 49.3 years, and 52 (74%) were negative (0and 1+)with mean age at diagonosis of 46.6 years.Of patients with positive HER2/neu, 5(28%) had a relapse of disease and 4 (22%) died of disease during followup. Of the patients with HER2/neu, negative test 9(17%) had a relapse of disease and10(19%) died of the disease . The median survival function at mean of covaritesfor HER2/neu positve patients was 26 months, and for HER2/neu negative patients was 28 months. The prevalence of HER2/neu and overexpression in Qatari female with breast cancer in study is 26%, but due to small sample size it may not reflect really the prevalence. Patients with HER/neu positive were older at diagonosis than ptients with HER2/neu negative also they had higher relapse rate and mortality. Median survival function was better for HER2/neu negative patients. (author)

Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Science.gov (United States)

Piperno, G M; López-Requena, A; Predonzani, A; Dorvignit, D; Labrada, M; Zentilin, L; Burrone, O R; Cesco-Gaspere, M

2015-12-01

The ganglioside GM3(Neu5Gc) has gained increasing attention as therapeutic target because of its selective expression in various human tumours, such as melanoma, breast and lung cancer. 14F7 is a mouse IgG1 with specific reactivity to GM3(Neu5Gc)-positive tumours. The therapeutic activity of 14F7 has also been demonstrated in vivo, through its repetitive passive administration in tumour-bearing animals. In this work we used an alternative strategy to deliver recombinant 14F7 in vivo and analysed the therapeutic efficacy of this approach. We engineered a recombinant adeno-associated vector to direct the expression of secretable recombinant 14F7 in BALB/c animals. A single administration of the rAAV induced efficient production and secretion of the antibody in the bloodstream, with an expression level reaching plateau at ∼3 weeks after injection and persisting for almost a year. Strikingly, upon challenge with GM3(Neu5Gc)-positive X63-AG8.653 myeloma cells, tumour development was significantly delayed in animals treated with rAAV-14F7 with respect to animals treated with a control rAAV codifying for an irrelevant antibody. Finally, no significant differences in survival proportion were detected in animals injected with rAAV-14F7 or treated by standard administration of repetitive doses of purified monoclonal antibody 14F7.

Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway

Directory of Open Access Journals (Sweden)

Chuan-Chen Lee

2012-01-01

Full Text Available Previously, we demonstrated that a submerged fermentation culture of Antrodia camphorata (AC promotes cell-cycle arrest and apoptosis in human estrogen receptor-positive/negative breast cancer cells. However, whether AC is effective against HER-2/neu-overexpressing breast cancers has not been thoroughly elucidated. In the present study, we showed that AC exhibited a significant cytotoxic effect against HER-2/neu-overexpressing MDA-MB-453 and BT-474 cells. Immunoblot analysis demonstrated that HER-2/neu and their tyrosine phosphorylation were inhibited by AC in a dose-dependent manner. An increase in intracellular reactive oxygen species (ROS was observed in AC-treated cells, whereas antioxidant N-acetylcysteine (NAC significantly prevented AC induced HER-2/neu depletion and cell death, which directly indicates that AC-induced HER-2/neu depletion and cell death was mediated by ROS generation. Also, AC significantly downregulated the expression of cyclin D1, cyclin E, and CDK4 followed by the suppression of PI3K/Akt, and their downstream effectors GSK-3β and β-catenin. Notably, AC-treatment induced apoptotic cell death, which was associated with sub-G1 accumulation, DNA fragmentation, mitochondrial dysfunction, cytochrome c release, caspase-3/-9 activation, PARP degradation, and Bcl-2/Bax dysregulation. Assays for colony formation also confirmed the growth-inhibitory effects of AC. This is the first report confirming the anticancer activity of this potentially beneficial mushroom against human HER-2/neu-overexpressing breast cancers.

Correlation and comparison of immunohistochemistry for HER2/neu, using the antibody SP3 and chromogenic in situ hybridization in breast carcinomas samples

Directory of Open Access Journals (Sweden)

Franciele F. Wolf

2015-12-01

Full Text Available ABSTRACT Introduction: Advances in the field of molecular biology have provided the differentiation of molecular subtypes of breast tumors, providing better prognosis and important tools for the treatment of patients with breast cancer. Among these subtypes, the changes in the human epidermal growth factor receptor 2 gene (HER2/neu, increase its copy number and generating HER2 protein amplification. Studies show that patients with breast cancer HER2/neu amplified tend to relapse earlier and have shorter survival time, the monoclonal antibody Trastuzumab is the therapy indicated. The eligibility of patients for therapy is initially made by the immunohistochemistry (IHC technique, which evaluates the expression level of the HER2 protein. After this evaluation, the cases with equivocal diagnosis (score 2+, are referred to a more accurate technique, the chromogenic in situ hybridization (CISH. Objective: To analyze the sensitivity and specificity of the antibody SP3, and determine their level of agreement with the CISH technique. Material and methods: Retrospective study in the database of the anatomy-pathology laboratory, in CISH tests reports for HER2/neu. Conclusion: The results revealed that clone SP3 showed 100% specificity and 92% sensitivity. IHC reveals variability in its results; however, it is known that the technique is an important tool in the daily routine of laboratories, contributing to the initial screening of patients with breast cancer, which later showed satisfactory results when compared with the CISH technique.

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

International Nuclear Information System (INIS)

Wang, Xiaoyan; Wang, Jian-Ping; Maughan, Maureen F; Lachman, Lawrence B

2005-01-01

Overexpression of the HER2/neu gene in breast cancer is associated with an increased incidence of metastatic disease and with a poor prognosis. Although passive immunotherapy with the humanized monoclonal antibody trastuzumab (Herceptin) has shown some effect, a vaccine capable of inducing T-cell and humoral immunity could be more effective. Virus-like replicon particles (VRP) of Venezuelan equine encephalitis virus containing the gene for HER2/neu (VRP-neu) were tested by an active immunotherapeutic approach in tumor prevention models and in a metastasis prevention model. VRP-neu prevented or significantly inhibited the growth of HER2/neu-expressing murine breast cancer cells injected either into mammary tissue or intravenously. Vaccination with VRP-neu completely prevented tumor formation in and death of MMTV-c-neu transgenic mice, and resulted in high levels of neu-specific CD8 + T lymphocytes and serum IgG. On the basis of these findings, clinical testing of this vaccine in patients with HER2/neu + breast cancer is warranted

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs.

Directory of Open Access Journals (Sweden)

Olivier Reynard

Full Text Available Polyclonal xenogenic IgGs, although having been used in the prevention and cure of severe infectious diseases, are highly immunogenic, which may restrict their usage in new applications such as Ebola hemorrhagic fever. IgG glycans display powerful xenogeneic antigens in humans, for example α1-3 Galactose and the glycolyl form of neuraminic acid Neu5Gc, and IgGs deprived of these key sugar epitopes may represent an advantage for passive immunotherapy. In this paper, we explored whether low immunogenicity IgGs had a protective effect on a guinea pig model of Ebola virus (EBOV infection. For this purpose, a double knock-out pig lacking α1-3 Galactose and Neu5Gc was immunized against virus-like particles displaying surface EBOV glycoprotein GP. Following purification from serum, hyper-immune polyclonal IgGs were obtained, exhibiting an anti-EBOV GP titer of 1:100,000 and a virus neutralizing titer of 1:100. Guinea pigs were injected intramuscularly with purified IgGs on day 0 and day 3 post-EBOV infection. Compared to control animals treated with IgGs from non-immunized double KO pigs, the anti-EBOV IgGs-treated animals exhibited a significantly prolonged survival and a decreased virus load in blood on day 3. The data obtained indicated that IgGs lacking α1-3 Galactose and Neu5Gc, two highly immunogenic epitopes in humans, have a protective effect upon EBOV infection.

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Science.gov (United States)

Reynard, Olivier; Jacquot, Frédéric; Evanno, Gwénaëlle; Mai, Hoa Le; Martinet, Bernard; Duvaux, Odile; Bach, Jean-Marie; Conchon, Sophie; Judor, Jean-Paul; Perota, Andrea; Lagutina, Irina; Duchi, Roberto; Lazzari, Giovanna; Le Berre, Ludmilla; Perreault, Hélène; Lheriteau, Elsa; Raoul, Hervé; Volchkov, Viktor; Galli, Cesare; Soulillou, Jean-Paul

2016-01-01

Polyclonal xenogenic IgGs, although having been used in the prevention and cure of severe infectious diseases, are highly immunogenic, which may restrict their usage in new applications such as Ebola hemorrhagic fever. IgG glycans display powerful xenogeneic antigens in humans, for example α1–3 Galactose and the glycolyl form of neuraminic acid Neu5Gc, and IgGs deprived of these key sugar epitopes may represent an advantage for passive immunotherapy. In this paper, we explored whether low immunogenicity IgGs had a protective effect on a guinea pig model of Ebola virus (EBOV) infection. For this purpose, a double knock-out pig lacking α1–3 Galactose and Neu5Gc was immunized against virus-like particles displaying surface EBOV glycoprotein GP. Following purification from serum, hyper-immune polyclonal IgGs were obtained, exhibiting an anti-EBOV GP titer of 1:100,000 and a virus neutralizing titer of 1:100. Guinea pigs were injected intramuscularly with purified IgGs on day 0 and day 3 post-EBOV infection. Compared to control animals treated with IgGs from non-immunized double KO pigs, the anti-EBOV IgGs-treated animals exhibited a significantly prolonged survival and a decreased virus load in blood on day 3. The data obtained indicated that IgGs lacking α1–3 Galactose and Neu5Gc, two highly immunogenic epitopes in humans, have a protective effect upon EBOV infection. PMID:27280712

Status of the neutron detector NeuLAND in 2014

Energy Technology Data Exchange (ETDEWEB)

Miki, Kenjiro; Caesar, Christoph; Scheit, Heiko [IKP, TU-Darmstadt, Darmstadt (Germany); Aumann, Thomas [IKP, TU-Darmstadt, Darmstadt (Germany); GSI, Darmstadt (Germany); Boretzky, Konstanze; Heil, Michael; Simon, Haik [GSI, Darmstadt (Germany); Gasparic, Igor [RBI, Zagreb (Croatia); Collaboration: R3B-Collaboration

2015-07-01

We report on the present status of the new neutron detector NeuLAND designed for the R3B facility at FAIR. The NeuLAND is a segmented large-volume plastic scintillation detector with a designed volume of 2.5(width) x 2.5(height) x 30 (depth) m{sup 3}, which will provide high efficiency, good timing resolution and high multi-neutron resolving power. Ten planes of scintillator walls, corresponding to the depth of 0.5 m, have been constructed and tested so far. The performance of this NeuLAND demonstrator was studied with fast neutrons from heavy-ion beams in GSI. The {sup 48}Ca, {sup 58}Ni and {sup 236,238}U beams with incident energies from 400 to 800 MeV/u were impinged on C, Pb, or U target, and neutrons produced around 0 degrees were detected by the NeuLAND. Neutron hit distributions were obtained for one and multiple neutron events, allowing us for detailed response studies. An excellent timing resolution of typically 150 psec (σ) was determined online. The presentation includes the detailed explanation of the experimental setups and obtained results. The outlook comprises further NeuLAND construction and data taking during the next year.

Cervicovaginal cytokines, sialidase activity and bacterial load in reproductive-aged women with intermediate vaginal flora.

Science.gov (United States)

Santos-Greatti, Mariana Morena de Vieira; da Silva, Márcia Guimarães; Ferreira, Carolina Sanitá Tafner; Marconi, Camila

2016-11-01

Studies have shown that not only bacterial vaginosis, but also intermediate vaginal flora has deleterious effects for women's reproductive health. However, literature still lacks information about microbiological and immunological aspects of intermediate flora. To characterize intermediate flora regarding levels of Interleukin (IL)-1beta, IL-6, IL-8, tumor necrosis factor-alpha, interleukin 1 receptor antagonist (IL-1ra), IL-10, sialidase; loads of Gardnerella vaginalis, total bacteria and to verify whether it is closer related to normal flora or bacterial vaginosis. This cross-sectional study enrolled 526 non-pregnant reproductive-aged women distributed in 3 groups according to pattern of vaginal flora using Nugent's system in normal, intermediate and bacterial vaginosis. Cervicovaginal levels of cytokines, sialidases, loads of G. vaginalis and total bacteria were assessed by ELISA, conversion of MUAN and quantitative real-time PCR, respectively. A principal component analysis(PCA) using all measured parameters was performed to compare the three different types of flora. Results showed that intermediate flora is associated with increased cervicovaginal IL-1beta in relation to normal flora(Pbacterial vaginosis, intermediate flora has higher IL-8 and IL-10 levels(Pbacterial vaginosis(Pbacterial differed among all groups(Pbacterial vaginosis. PCA showed that normal and intermediate flora were closely scattered, while bacterial vaginosis were grouped separately. Although intermediate flora shows some differences in cytokines, sialidases and bacterial loads in relation to normal flora and bacterial vaginosis, when taken together, general microbiological and immunological pattern pattern of intermediate flora resembles the normal flora. Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis.

Science.gov (United States)

Marconi, C; Donders, G G G; Bellen, G; Brown, D R; Parada, C M G L; Silva, M G

2013-04-01

To evaluate levels of proinflammatory cytokines and sialidase activity in aerobic vaginitis (AV) in relation to normal vaginal flora and bacterial vaginosis (BV). In this cross-sectional study, a total of 682 consecutive non-pregnant women attending the gynecology service were assessed and 408 women were included. Vaginal rinsing samples were collected from 223 women with microscopic finding of BV (n=98), aerobic vaginitis (n=25) and normal flora (n=100). Samples were tested for interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, and sialidase activity. Compared to women with normal flora, vaginal levels of IL-1β were highly increased in both BV and AV (pvaginal IL-6 was detected in AV (pvaginal flora types can be harmful to the maintenance of a healthy vaginal environment. Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

File list: ALL.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Cerebellum hg19 All antigens Neural Cerebellum SRX998295,SRX109682...3 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Cerebellum.bed ...

Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer

Directory of Open Access Journals (Sweden)

Ozgur Arikan

2015-12-01

Full Text Available Objective: We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression. Materials and Methods: Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2 and 40 healthy control group (Group 1 were included the study. Blood and urinary samples were collected from all patients and HER2/neu levels were measured by ELISA method. Blood and urinary HER2/neu levels and additionally, ratio of urinary HER2/neu levels to urinary creatinine levels were recorded. Demographic data and tumor characteristics were recorded. Results: Mean serum HER2/neu levels were similar between two groups and statistically significant difference wasn't observed. Urinary HER2/neu levels were significantly higher in group 2 than group 1. Ratio of urinary HER2/neu to urinary creatinine was significantly higher in group 2 than group 1, (p=0,021. Serum and urinary HER2/ neu levels were not associated with tumor stage, grade, recurrence and progression while ratio of urinary HER2/neu to urinary creatinin levels were significantly higher in high-grade tumors. HER2/neu, the sensitivity of the test was found to be 20.5%, and the specificity was 97.5%, also for the urinary HER2/neu/urinary creatinine ratio, the sensitivity and specificity of the test were found to be 31.8% and 87.5%, respectively. Conclusions: Urinary HER2/neu and ratio of urinary creatinine urine were significantly higher in patients with bladder cancer compared to healthy subjects. Large series and controlled studies are needed for use as a tumor marker.

Efficiency measurement of the NeuLAND detector

Energy Technology Data Exchange (ETDEWEB)

Toernqvist, Hans; Atar, Leyla; Aumann, Thomas; Holl, Matthias; Horvat, Andrea; Kahlbow, Julian; Miki, Kenjiro; Rossi, Dominic; Scheit, Heiko; Schindler, Fabia [Institut fuer Kernphysik, Technische Universitaet Darmstadt, Darmstadt (Germany); Boretzky, Konstanze; Caesar, Christoph; Simon, Haik [GSI Gesellschaft fuer Schwerionenforschung GmbH, Darmstadt (Germany); Gasparic, Igor [Ruder Boskovic Institute, Zagreb (Croatia); Collaboration: R3B-Collaboration

2016-07-01

NeuLAND is the next-generation high-energy and high-efficiency neutron detector currently under construction at GSI/FAIR by the R{sup 3}B collaboration. This detector will be used in a wide variety of experiments, ranging from nuclear-structure measurements of neutron-rich species to the investigation of the equation-of-state of asymmetric nuclear matter. The design goals of the full NeuLAND detector are a >95% detection efficiency for single neutrons, a time resolution of σ{sub t} ≤ 150 ps and a position resolution of σ{sub x,y,z} ≤ 1.5 cm, with a detection volume of 250 x 250 x 300 cm{sup 3}. While still under construction, a set of 4 of the 30 planned NeuLAND double-planes were used for a series of experiments at the SAMURAI setup at RIKEN. In particular, the time resolution and one-neutron efficiency were measured using neutrons from the {sup 7}Li(p,n){sup 7}Be reaction. The test setup at RIKEN are described, and the resolution and efficiency results are discussed.

Identification of oligo-N-glycolylneuraminic acid residues in mammal-derived glycoproteins by a newly developed immunochemical reagent and biochemical methods.

Science.gov (United States)

Sato, C; Kitajima, K; Inoue, S; Inoue, Y

1998-01-30

The occurrence of the alpha2-->8-linked oligomeric form of N-glycolylneuraminic acid (oligo-Neu5Gc) residues in mammalian glycoproteins was unequivocally demonstrated using a newly developed anti-oligo/poly-Neu5Gc monoclonal antibody as well as by chemical and biochemical methods. First, the antibody, designated mAb.2-4B, which specifically recognized oligo/poly-Neu5Gc with a degree of polymerization of >2, was developed by establishing a hybridoma cell line from P3U1 myeloma cells fused with splenocytes from an MRL autoimmune mouse immunized with dipalmitoylphosphatidylethanolamine-conjugated oligo/poly-Neu5Gc. Second, oligo-Neu5Gc was shown to occur in glycoproteins derived from pig spleen by Western blot analysis using mAb.2-4B, which was also confirmed by fluorometric high performance liquid chromatographic analysis of the product of periodate oxidation/reduction/acid hydrolysis of the purified glycopeptide fractions and by TLC and 600-MHz 1H NMR spectroscopic analysis of their mild acid hydrolysates. Finally, the ubiquitous occurrence of oligo-Neu5Gc chains as glycoproteinaceous components in Wistar rat tissue was immunochemically indicated. This is the first example demonstrating the diversity in oligo/poly-Sia structure in mammalian glycoproteins, where only poly-N-acetylneuraminic acid is known to occur. Such diversity in oligo/poly-Sia structure also implicates a diverged array of biological functions of this glycan unit in glycoproteins.

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments

International Nuclear Information System (INIS)

Tang Ying; Wang, Judy; Scollard, Deborah A.; Mondal, Hridya; Holloway, Claire; Kahn, Harriette J.; Reilly, Raymond M.

2005-01-01

Trastuzumab (Herceptin) Fab were prepared by digestion of intact IgG with immobilized papain, derivatized with diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with 111 In. The dissociation constant (K d ) for binding of Fab to HER2/neu-positive SK-BR-3 human breast cancer cells was two- to threefold higher than for intact IgG (14-36 vs. 8-14 nM). The binding affinity was not significantly decreased after DTPA derivatization (K d =47 nM). 111 In-trastuzumab Fab localized specifically in HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice with tumor uptake of 7.8±0.7% injected dose (ID)/g and tumor/blood ratio of 25.2±1.6 at 72 h postinjection compared with 2.7±0.7% ID/g and 7.0±0.9 for 111 In-HuM195 anti-CD33 Fab (significantly different, P 111 In-trastuzumab Fab as early as 24 h postinjection

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

International Nuclear Information System (INIS)

Meier, Reinhard; Piert, Morand; Piontek, Guido; Rudelius, Martina; Oostendorp, Robert A.; Senekowitsch-Schmidtke, Reingard; Henning, Tobias D.; Wels, Winfried S.; Uherek, Christoph; Rummeny, Ernst J.; Daldrup-Link, Heike E.

2008-01-01

Introduction: The objective of this study was to label the human natural killer (NK) cell line NK-92 with [ 18 F]fluoro-deoxy-glucose (FDG) for subsequent in vivo tracking to HER2/neu-positive tumors. Methods: NK-92 cells were genetically modified to NK-92-scFv(FRP5)-zeta cells, which express a chimeric antigen receptor that is specific to the tumor-associated ErbB2 (HER2/neu) antigen. NK-92 and NK-92-scFv(FRP5)-zeta cells were labeled with [ 18 F]FDG by simple incubation at different settings. Labeling efficiency was evaluated by a gamma counter. Subsequently, [ 18 F]FDG-labeled parental NK-92 or NK-92-scFv(FRP5)-zeta cells were intravenously injected into mice with implanted HER2/neu-positive NIH/3T3 tumors. Radioactivity in tumors was quantified by digital autoradiography and correlated with histopathology. Results: The NK-92 and NK-92-scFv(FRP5)-zeta cells could be efficiently labeled with [ 18 F]FDG by simple incubation. Optimal labeling efficiencies (80%) were achieved using an incubation period of 60 min and additional insulin (10 IU/ml). After injection of 5x10 6 [ 18 F]FDG-labeled NK-92-scFv(FRP5)-zeta cells into tumor-bearing mice, digital autoradiography showed an increased uptake of radioactivity in HER2/neu-positive tumors at 60 min postinjection. Conversely, injection of 5x10 6 NK-92 cells not directed against HER2/neu receptors did not result in increased uptake of radioactivity in the tumors. Histopathology confirmed an accumulation of the NK-92-scFv(FRP5)-zeta cells, but not the parental NK cells, in tumor tissues. Conclusion: The human NK cell line NK-92 can be directed against HER2/neu antigens by genetic modification. The genetically modified NK cells can be efficiently labeled with [ 18 F]FDG, and the accumulation of these labeled NK cells in HER2/neu-positive tumors can be monitored with autoradiography

Prenatal diagnosis of Neu-Laxova syndrome: a case report

Directory of Open Access Journals (Sweden)

Polat Ibrahim

2002-02-01

Full Text Available Abstract Background Neu-Laxova syndrome is a rare congenital abnormality involving multiple systems. We report a case of Neu-Laxova syndrome (NLS diagnosed prenatally by ultrasound examination. Case presentation A 29-year-old gravida 3, para 2 woman was first seen in our antenatal clinic at 38 weeks' pregnancy. Except for the consanguinity and two previous abnormal stillborn babies her medical history was unremarkable. On ultrasound examination microcephaly, flat forehead, micrognathia, intrauterine growth restriction, generalized edema of the skin, hypoplastic chest, excessive soft tissue deposition of hands and feet, joint contractures and a penis without scrotal sacs were detected. She delivered a 2000 g male fetus. He died five minutes after delivery. Postmortem examination confirmed the diagnosis of Neu-Laxova syndrome. Conclusion Because of the autosomal recessive inheritance of Neu-Laxova syndrome genetic counseling and early-serial ultrasound examination should be performed at risk families. Early diagnosis of the disease may offer termination of the pregnancy as an option.

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers

Directory of Open Access Journals (Sweden)

Ghislain Vanessa

2008-01-01

Full Text Available Abstract Background The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. Methods We determined the tumour mutation status of the entire tyrosine kinase (TK domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH. Results The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%. HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in exons 18–24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found in 10% and correlated with a high expression level by immunohistochemistry. Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes, but have been found in very rare cases by others. Conclusion Genomic alteration of the HER2-neu and EGFR genes is frequent (25% in ovarian cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in that subset of patients.

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using {sup 111}In-trastuzumab (Herceptin) Fab fragments

Energy Technology Data Exchange (ETDEWEB)

Tang Ying [Division of Nuclear Medicine, University Health Network, Toronto, Ontario, M5G 2C4 (Canada); Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, M5S 2S2 (Canada); Wang, Judy [Division of Nuclear Medicine, University Health Network, Toronto, Ontario, M5G 2C4 (Canada); Scollard, Deborah A. [Division of Nuclear Medicine, University Health Network, Toronto, Ontario, M5G 2C4 (Canada); Mondal, Hridya [Division of Nuclear Medicine, University Health Network, Toronto, Ontario, M5G 2C4 (Canada); Holloway, Claire [Sunnybrook and Women' s College Health Sciences Center, Toronto, Ontario, M4N 3M5 (Canada); Kahn, Harriette J. [Sunnybrook and Women' s College Health Sciences Center, Toronto, Ontario, M4N 3M5 (Canada); Reilly, Raymond M. [Division of Nuclear Medicine, University Health Network, Toronto, Ontario, M5G 2C4 (Canada) and Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, M5S 2S2 (Canada) and Department of Medical Imaging, University of Toronto, Toronto, Ontario, M5S 3E2 (Canada)]. E-mail: raymond.reilly@utoronto.ca

2005-01-01

Trastuzumab (Herceptin) Fab were prepared by digestion of intact IgG with immobilized papain, derivatized with diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with {sup 111}In. The dissociation constant (K{sub d}) for binding of Fab to HER2/neu-positive SK-BR-3 human breast cancer cells was two- to threefold higher than for intact IgG (14-36 vs. 8-14 nM). The binding affinity was not significantly decreased after DTPA derivatization (K{sub d}=47 nM). {sup 111}In-trastuzumab Fab localized specifically in HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice with tumor uptake of 7.8{+-}0.7% injected dose (ID)/g and tumor/blood ratio of 25.2{+-}1.6 at 72 h postinjection compared with 2.7{+-}0.7% ID/g and 7.0{+-}0.9 for {sup 111}In-HuM195 anti-CD33 Fab (significantly different, P<.001). Small (3-5 mm in diameter) BT-474 tumors were imaged with {sup 111}In-trastuzumab Fab as early as 24 h postinjection.

Expression of HER2/Neu in B-Cell Acute Lymphoblastic Leukemia.

Science.gov (United States)

Rodriguez-Rodriguez, Sergio; Pomerantz, Alan; Demichelis-Gomez, Roberta; Barrera-Lumbreras, Georgina; Barrales-Benitez, Olga; Aguayo-Gonzalez, Alvaro

2016-01-01

The expression of HER2/neu in B-cell acute lymphoblastic leukemia has been reported in previous studies. The objective of this research was to study the expression of HER2/neu on the blasts of patients with acute leukemia from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. From June 2015 to February 2016, a HER2/neu monoclonal antibody was added to the panel of antibodies that we routinely use in patients with acute leukemia. An expression of ≥ 30% was considered positive. We studied 33 patients: 19 had de novo leukemia (57.6%), three (9.1%) were in relapse, and in 11 (33.3%) their status could not be specified. Seventeen patients (51.5%) were classified as B-cell acute lymphoblastic leukemia with a median expression of HER2/neu of 0.3% (range 0-90.2). Three patients with B-cell acute lymphoblastic leukemia were positive for HER2/neu: 89.4%, 90.9%, and 62.4%. The first and third patient had de novo B-cell acute lymphoblastic leukemia. The second patient was in second relapse after allogeneic stem cell transplant. All three patients were categorized as high-risk at the time of diagnosis. In the studied Mexican population, we found a positive expression of HER2/neu in 17% of the B-cell acute lymphoblastic leukemia patients, similar to previous studies in which the expression was found in 15-50%.

Safety, immunogenicity, and early evidence of antitumor response with the use of the vaccine formulation NeuGcGM3 / VSSPs in patients with advanced melanoma

International Nuclear Information System (INIS)

Osorio Rodríguez, Marta de la Caridad

2014-01-01

Introduction. Melanoma is now considered an epidemic around the world. Its high lethality, constitutes a serious problem despite the continuous pharmacological and technological advances. NeuGcGM3/VSSP is a vaccine formulation containing ganglioside NeuGcGM3 incorporated in the acting of Neisseria meningitidis. It may be a choice therapeutic given this ganglioside in primary melanoma expression and immunogenicity and safety demonstrated by this vaccine in advanced breast cancer. This study evaluated the safety, immunogenicity and the anti-tumor response in patients with advanced melanoma to manage it via IM or SC. Material and methods: The expression of ganglioside in primary melanomas and its metastases was identified by immunohistochemical methods with the AcM 14F7 (anti-NGCGM3). 2 clinical trials Phase Ib/IIa escalation of doses with NeuGcGM3 /VSSP were conducted in patients with melanoma Advanced IM and SC routes. Safety and anti-tumour response were evaluated with the CTC and RECIST criteria. The statistical analysis was performed with the SPSS statistical package. Results: NeuGcGM3 is expressed in primary tumors and the studied lymph nodes metastases. NeuGcGM3/VSSP was safely managed by the SC and IM, roads without limiting toxicity. Immunogenic with IgM and IgG isotype antibody response resulted in 75% patients. There was anti-tumoral response in 38.5% with increase in median SV mainly associated with anti-tumor response. The appearance of vitiligo and the response of antibodies against other not present in the vaccine formulation gangliosides may be considered a manifestation of immune restoration. Conclusions. NeuGcGM3/VSSP managed IM and SC in patients with advanced melanoma was safe, immunogenic and antitumor activity associated with overall survival advantage. (author)

File list: DNS.Neu.05.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Adult_brains hg19 DNase-seq Neural Adult brains SRX189408,SRX18941...3 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.05.AllAg.Adult_brains.bed ...

File list: DNS.Neu.10.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Adult_brains hg19 DNase-seq Neural Adult brains SRX189408,SRX18941...3 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.10.AllAg.Adult_brains.bed ...

File list: DNS.Neu.50.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Adult_brains hg19 DNase-seq Neural Adult brains SRX189408,SRX18941...3 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.50.AllAg.Adult_brains.bed ...

File list: DNS.Neu.20.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Adult_brains hg19 DNase-seq Neural Adult brains SRX189408,SRX18941...3 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.20.AllAg.Adult_brains.bed ...

File list: Oth.Neu.10.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Cortical_neuron mm9 TFs and others Neural Cortical neuron SRX80425...3,SRX1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Cortical_neuron.bed ...

File list: Oth.Neu.20.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Cortical_neuron mm9 TFs and others Neural Cortical neuron SRX67167...3,SRX1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Cortical_neuron.bed ...

File list: Oth.Neu.50.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Cortical_neuron mm9 TFs and others Neural Cortical neuron SRX67167...3,SRX1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Cortical_neuron.bed ...

Tracking of [{sup 18}F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Energy Technology Data Exchange (ETDEWEB)

Meier, Reinhard [Department of Radiology, University of California San Francisco (United States)], E-mail: reinhardt.meier@gmail.com; Piert, Morand [Department of Radiology, Division of Nuclear Medicine, University of Michigan (United States); Piontek, Guido; Rudelius, Martina [Institute of Pathology, Klinikum rechts der Isar, Technische Universitaet Muenchen (Germany); Oostendorp, Robert A. [3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen (Germany); Senekowitsch-Schmidtke, Reingard [Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen (Germany); Henning, Tobias D. [Department of Radiology, University of California San Francisco (United States); Wels, Winfried S.; Uherek, Christoph [Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, Frankfurt am Main (Germany); Rummeny, Ernst J. [Department of Radiology, Klinikum rechts der Isar, Technische Universitaet Muenchen (Germany); Daldrup-Link, Heike E. [Department of Radiology, University of California San Francisco (United States)

2008-07-15

Introduction: The objective of this study was to label the human natural killer (NK) cell line NK-92 with [{sup 18}F]fluoro-deoxy-glucose (FDG) for subsequent in vivo tracking to HER2/neu-positive tumors. Methods: NK-92 cells were genetically modified to NK-92-scFv(FRP5)-zeta cells, which express a chimeric antigen receptor that is specific to the tumor-associated ErbB2 (HER2/neu) antigen. NK-92 and NK-92-scFv(FRP5)-zeta cells were labeled with [{sup 18}F]FDG by simple incubation at different settings. Labeling efficiency was evaluated by a gamma counter. Subsequently, [{sup 18}F]FDG-labeled parental NK-92 or NK-92-scFv(FRP5)-zeta cells were intravenously injected into mice with implanted HER2/neu-positive NIH/3T3 tumors. Radioactivity in tumors was quantified by digital autoradiography and correlated with histopathology. Results: The NK-92 and NK-92-scFv(FRP5)-zeta cells could be efficiently labeled with [{sup 18}F]FDG by simple incubation. Optimal labeling efficiencies (80%) were achieved using an incubation period of 60 min and additional insulin (10 IU/ml). After injection of 5x10{sup 6} [{sup 18}F]FDG-labeled NK-92-scFv(FRP5)-zeta cells into tumor-bearing mice, digital autoradiography showed an increased uptake of radioactivity in HER2/neu-positive tumors at 60 min postinjection. Conversely, injection of 5x10{sup 6} NK-92 cells not directed against HER2/neu receptors did not result in increased uptake of radioactivity in the tumors. Histopathology confirmed an accumulation of the NK-92-scFv(FRP5)-zeta cells, but not the parental NK cells, in tumor tissues. Conclusion: The human NK cell line NK-92 can be directed against HER2/neu antigens by genetic modification. The genetically modified NK cells can be efficiently labeled with [{sup 18}F]FDG, and the accumulation of these labeled NK cells in HER2/neu-positive tumors can be monitored with autoradiography.

Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus.

Science.gov (United States)

Canafoglia, Laura; Robbiano, Angela; Pareyson, Davide; Panzica, Ferruccio; Nanetti, Lorenzo; Giovagnoli, Anna Rita; Venerando, Anna; Gellera, Cinzia; Franceschetti, Silvana; Zara, Federico

2014-06-03

To identify the genetic cause of a familial form of late-onset action myoclonus in 2 unrelated patients. Both probands had 2 siblings displaying a similar disorder. Extensive laboratory examinations, including biochemical assessment for urine sialic acid in the 2 probands, were negative. Exome sequencing was performed in the probands using an Illumina platform. Segregation analysis of putative mutations was performed in all family members by standard Sanger sequencing protocols. NEU1 mutations were detected in 3 siblings of each family with prominent cortical myoclonus presenting in the third decade of life and having a mild and slowly progressive course. They did not have macular cherry-red spot and their urinary sialic acid excretion was within normal values. Genetic analysis demonstrated a homozygous mutation in family 1 (c.200G>T, p.S67I) and 2 compound heterozygous mutations in family 2 (c.679G>A, p.G227R; c.913C>T, p.R305C). Our observation indicates that sialidosis should be suspected and the NEU1 gene analyzed in patients with isolated action myoclonus presenting in adulthood in the absence of other typical clinical and laboratory findings. © 2014 American Academy of Neurology.

File list: Unc.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Brain mm9 Unclassified Neural Brain SRX218191,SRX1125792,SRX112579...3,SRX1125795,SRX1125794,SRX218193,SRX218192,SRX017294,SRX218195,SRX218194,SRX1125797,SRX1125796 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Brain.bed ...

File list: Unc.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Brain mm9 Unclassified Neural Brain SRX218191,SRX1125792,SRX112579...3,SRX218193,SRX017294,SRX218195,SRX1125795,SRX1125794,SRX218192,SRX1125797,SRX1125796,SRX218194 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.10.AllAg.Brain.bed ...

Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.

Science.gov (United States)

Ge, Xiaowen; Wang, Haixing; Zeng, Haiying; Jin, Xuejuan; Sujie, Akesu; Xu, Chen; Liu, Yalan; Huang, Jie; Ji, Yuan; Tan, Yunshan; Liu, Tianshu; Hou, Yingyong; Qin, Jing; Sun, Yihong; Qin, Xinyu

2015-06-01

One paraffin block is routinely used for human epidermal growth factor receptor 2 (Her2/neu) immunohistochemistry (IHC) assessment. Here, we investigated if picking 2 paraffin blocks for Her2/neu evaluation on 1 slide is an economical, efficient, and practical method, which may reduce false negativity of Her2/neu IHC assessment due to intratumoral heterogeneity. A total of 251 gastric cancer (GC) patients were divided into a cohort using 1 tumor tissue paraffin block (single-block group, n = 132) and a cohort using dual tumor tissue paraffin blocks (dual-block group, n = 119) when evaluating Her2/neu expression status by IHC. In dual-block group, we combined the results from 2 different paraffin blocks and used the higher one as the final score. The number of IHC 1+, 2+, and 3+ specimens in the single-block group was 31 (23.5%), 40 (30.3%), and 19 (14.4%), respectively. The combined final IHC score in the dual-block group of 1+, 2+, and 3+ was 26 (21.8%), 34 (28.6%), and 23 (19.3%), respectively. Inconsistent Her2/neu expression between blocks was found in 36 (30.3%) cases in the dual-block group. The pooled data in the single-block group and the dual-block group indicated that, when using dual blocks, the Her2/neu-positive (3+) rate of GC was higher compared to that in the single-block group. Our results implied that using dual paraffin blocks to assess Her2/neu expression of GC may help identify more patients with Her2/neu-positive GC who could benefit from targeted therapy, by reducing false-negative rate of Her2 status assessment. This is an efficient, economical, and practical method for Her2/neu evaluation of GC. Copyright © 2015 Elsevier Inc. All rights reserved.

Colloquium paper: uniquely human evolution of sialic acid genetics and biology.

Science.gov (United States)

Varki, Ajit

2010-05-11

Darwinian evolution of humans from our common ancestors with nonhuman primates involved many gene-environment interactions at the population level, and the resulting human-specific genetic changes must contribute to the "Human Condition." Recent data indicate that the biology of sialic acids (which directly involves less than 60 genes) shows more than 10 uniquely human genetic changes in comparison with our closest evolutionary relatives. Known outcomes are tissue-specific changes in abundant cell-surface glycans, changes in specificity and/or expression of multiple proteins that recognize these glycans, and novel pathogen regimes. Specific events include Alu-mediated inactivation of the CMAH gene, resulting in loss of synthesis of the Sia N-glycolylneuraminic acid (Neu5Gc) and increase in expression of the precursor N-acetylneuraminic acid (Neu5Ac); increased expression of alpha2-6-linked Sias (likely because of changed expression of ST6GALI); and multiple changes in SIGLEC genes encoding Sia-recognizing Ig-like lectins (Siglecs). The last includes binding specificity changes (in Siglecs -5, -7, -9, -11, and -12); expression pattern changes (in Siglecs -1, -5, -6, and -11); gene conversion (SIGLEC11); and deletion or pseudogenization (SIGLEC13, SIGLEC14, and SIGLEC16). A nongenetic outcome of the CMAH mutation is human metabolic incorporation of foreign dietary Neu5Gc, in the face of circulating anti-Neu5Gc antibodies, generating a novel "xeno-auto-antigen" situation. Taken together, these data suggest that both the genes associated with Sia biology and the related impacts of the environment comprise a relative "hot spot" of genetic and physiological changes in human evolution, with implications for uniquely human features both in health and disease.

Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells

DEFF Research Database (Denmark)

Dahl, Malin; Bouchelouche, Pierre; Kramer-Marek, Gabriela

2011-01-01

Increasing evidence suggests that Human epidermal growth factor receptor 2 (HER2/neu) is involved in progression of prostate cancer. Recently, sarcosine was reported to be highly increased during prostate cancer progression, and exogenous sarcosine induces an invasive phenotype in benign prostate...... epithelial cells. The aim of this work was to investigate the effect of sarcosine on HER2/neu expression in prostate cancer cell lines LNCaP (androgen dependent), PC-3 and DU145 (both androgen independent). Relative amounts of HER2/neu and androgen receptor (AR) transcripts were determined using RT...... that sarcosine is involved in the regulation of the oncoprotein HER2/neu. Thus, sarcosine may induce prostate cancer progression by increased HER2/neu expression. However, detailed information on cellular mechanisms remains to be elucidated....

NeuN Expression Alterations in the Hippocampus Following Ecstasy Treatment

Directory of Open Access Journals (Sweden)

Ghasemi Moravej

2016-05-01

Full Text Available Background The administration of 3-4-methylenedioxymethamphetamine (MDMA leads to learning and memory impairment. Objectives Due to the effect of neurogenesis on memory and learning, in this study, we investigated the effects of MDMA on NeuN expression (a marker of neurogenesis in the hippocampus. Methods Adult male Wistar rats (weighing 200 - 250 g received a single intraperitoneal dose of 10 mg/kg of MDMA or were left undisrupted. The expression of NeuN was assessed using the immunohistochemistry method 7, 14, 28, and 60 days following MDMA administration. Results Our results showed that MDMA administration caused a decrease in NeuN expression in the experimental group compared with the control group. Conclusions These results suggest a negative correlation between MDMA administration and adult hippocampal neurogenesis.

A Comprehensive Evaluation Of HER-2/NEU In Human Breast Cancer By Immunohistochemistry And Fluorescence In Situ Hybridization

International Nuclear Information System (INIS)

Abdel Fattah, H.I.; Seif, A.A.; El Hadidi, E.S.; Mohamed, A.A.; El Shinawi, M.E.; Shabaan, M.A.M.

2012-01-01

Background: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER2/neu) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. The food drug administration (FDA) approved immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) for HER2/neu evaluation. IHC is the most widely applicable diagnostic modality in studying HER-2 status. FISH is used for HER2/neu assessment in cases with an equivocal IHC status (score 2+). Objectives: The aim of this study was to detect the amplification and/or expression of HER2/neu in breast cancer using FISH and IHC techniques and to evaluate these applied techniques for their potential and clinical application, with special consideration of equivocal cases by IHC (2+). Subjects and Methods: Assessment of HER2/neu gene expression was made by FISH analysis using the HER2/CEP dual color probe (Vysis) in paraffin-embedded tissue sections of 32 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (CBII monoclonal antibody), 4 were classified as IHC 0, 4 were classified as IHC 1 +, 22 were classified as the borderline group; IHC 2+, and 2 were classified as IHC 3+. ER, PR, CEA and CA15-3 were performed to all cases. Survival data was obtained from 25 patients only. Results: The cut-off suggested for HER2/neu amplification by FISH ratio was > 1.3. No statistical significance was found between HER2/neu -by either FISH or IHC- and the different prognostic parameters. The overall survival for the studied patients -in average 3 years- was 16/25 (64%). A significant statistical association was revealed between breast cancer patients’ survival outcome and HER2/neu amplification (p < 0.05) using chi square test. Conclusion: All breast cancer patients should be assessed for HER2/neu status. IHC is a well established method for assessing HER2/neu status in

Three mutations switch H7N9 influenza to human-type receptor specificity

Energy Technology Data Exchange (ETDEWEB)

de Vries, Robert P.; Peng, Wenjie; Grant, Oliver C.; Thompson, Andrew J.; Zhu, Xueyong; Bouwman, Kim M.; de la Pena, Alba T. Torrents; van Breemen, Marielle J.; Ambepitiya Wickramasinghe, Iresha N.; de Haan, Cornelis A. M.; Yu, Wenli; McBride, Ryan; Sanders, Rogier W.; Woods, Robert J.; Verheije, Monique H.; Wilson, Ian A.; Paulson, James C.; Fernandez-Sesma, Ana

2017-06-15

The avian H7N9 influenza outbreak in 2013 resulted from an unprecedented incidence of influenza transmission to humans from infected poultry. The majority of human H7N9 isolates contained a hemagglutinin (HA) mutation (Q226L) that has previously been associated with a switch in receptor specificity from avian-type (NeuAcα2-3Gal) to human-type (NeuAcα2-6Gal), as documented for the avian progenitors of the 1957 (H2N2) and 1968 (H3N2) human influenza pandemic viruses. While this raised concern that the H7N9 virus was adapting to humans, the mutation was not sufficient to switch the receptor specificity of H7N9, and has not resulted in sustained transmission in humans. To determine if the H7 HA was capable of acquiring human-type receptor specificity, we conducted mutation analyses. Remarkably, three amino acid mutations conferred a switch in specificity for human-type receptors that resembled the specificity of the 2009 human H1 pandemic virus, and promoted binding to human trachea epithelial cells.

Three mutations switch H7N9 influenza to human-type receptor specificity.

Directory of Open Access Journals (Sweden)

Robert P de Vries

2017-06-01

Full Text Available The avian H7N9 influenza outbreak in 2013 resulted from an unprecedented incidence of influenza transmission to humans from infected poultry. The majority of human H7N9 isolates contained a hemagglutinin (HA mutation (Q226L that has previously been associated with a switch in receptor specificity from avian-type (NeuAcα2-3Gal to human-type (NeuAcα2-6Gal, as documented for the avian progenitors of the 1957 (H2N2 and 1968 (H3N2 human influenza pandemic viruses. While this raised concern that the H7N9 virus was adapting to humans, the mutation was not sufficient to switch the receptor specificity of H7N9, and has not resulted in sustained transmission in humans. To determine if the H7 HA was capable of acquiring human-type receptor specificity, we conducted mutation analyses. Remarkably, three amino acid mutations conferred a switch in specificity for human-type receptors that resembled the specificity of the 2009 human H1 pandemic virus, and promoted binding to human trachea epithelial cells.

Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.

Science.gov (United States)

Rota, Paola; La Rocca, Paolo; Piccoli, Marco; Montefiori, Marco; Cirillo, Federica; Olsen, Lars; Orioli, Marica; Allevi, Pietro; Anastasia, Luigi

2018-02-06

Neuraminidase activity is essential for the infection and propagation of paramyxoviruses, including human parainfluenza viruses (hPIVs) and the Newcastle disease virus (NDV). Thus, many inhibitors have been developed based on the 2-deoxy-2,3-didehydro-d-N-acetylneuraminic acid inhibitor (DANA) backbone. Along this line, herein we report a series of neuraminidase inhibitors, having C4 (p-toluenesulfonamido and azido substituents) and C5 (N-perfluorinated chains) modifications to the DANA backbone, resulting in compounds with 5- to 15-fold greater potency than the currently most active compound, the N-trifluoroacetyl derivative of DANA (FANA), toward the NDV hemagglutinin-neuraminidase (NDV-HN). Remarkably, these inhibitors were found to be essentially inactive against the human sialidase NEU3, which is present on the outer layer of the cell membrane and is highly affected by the current NDV inhibitor FANA. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis

OpenAIRE

Marconi, C.; Donders, G.G.G.; Bellen, G.; Brown, D.R.; Parada, C.M.G.L.; Silva, M.G.

2013-01-01

Objective: To evaluate levels of proinflammatory cytokines and sialidase activity in aerobic vaginitis (AV) in relation to normal vaginal flora and bacterial vaginosis (BV). Study design: In this cross-sectional study, a total of 682 consecutive non-pregnant women attending the gynecology service were assessed and 408 women were included. Vaginal rinsing samples were collected from 223 women with microscopic finding of BV (n = 98), aerobic vaginitis (n = 25) and normal flora (n = 100). Sample...

Immunohistochemical detection of Her-2/neu overexpression in ...

African Journals Online (AJOL)

Materials and Methods: Immunohistochemical staining for Her-2/neu was performed on 10% formalin-fixed, paraffinembedded primary carcinoma of the breast from 83 patients, between 2003 and 2007 using anti-Her-2/neu rabbit polyclonal antibody (DakoCytomation, CA, USA) and reactivity detected by an avidin-biotin ...

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

International Nuclear Information System (INIS)

Eralp, Yesim; Wang, Xiaoyan; Wang, Jian-Ping; Maughan, Maureen F; Polo, John M; Lachman, Lawrence B

2004-01-01

The purpose of the present study was to determine whether cytotoxic chemotherapeutic agents administered prior to immunotherapy with gene vaccines could augment the efficacy of the vaccines. Mice were injected in the mammary fat pad with an aggressive breast tumor cell line that expresses HER2/neu. The mice were treated 3 days later with a noncurative dose of either doxorubicin or paclitaxel, and the following day with a gene vaccine to HER2/neu. Two more doses of vaccine were given 14 days apart. Two types of gene vaccines were tested: a plasmid vaccine encoding a self-replicating RNA (replicon) of Sindbis virus (SINCP), in which the viral structural proteins were replaced by the gene for neu; and a viral replicon particle derived from an attenuated strain of Venezuelan equine encephalitis virus, containing a replicon RNA in which the Venezuelan equine encephalitis virus structural proteins were replaced by the gene for neu. Neither vaccination alone nor chemotherapy alone significantly reduced the growth of the mammary carcinoma. In contrast, chemotherapy followed by vaccination reduced tumor growth by a small, but significant amount. Antigen-specific CD8 + T lymphocytes were induced by the combined treatment, indicating that the control of tumor growth was most probably due to an immunological mechanism. The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu. The combination of chemotherapeutic agents plus vaccine immunotherapy may induce a tumor-specific immune response that could be beneficial for the adjuvant treatment of patients with minimal residual disease. The regimen warrants further evaluation in a clinical setting

Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH.

Science.gov (United States)

Leong, Anthony S-Y; Formby, Mark; Haffajee, Zenobia; Clarke, Megan; Morey, Adrienne

2006-12-01

The conventional method of scoring Her2/neu immunostaining is recognized to result in a high false-positive rate among 2+ cases when compared with results obtained with fluorescence in situ hybridization (FISH); however, costs and convenience dictates that immunohistochemistry remains the screening test for Her2/neu status in patients with breast cancer. We describe refined criteria for scoring of Her2/neu on the basis of anatomic localization rather than the subjective assessment of intensity. The presence of a circumferential tram track pattern that results from the staining of apposing cell membranes in >25% of the tumor cells was necessary for a 3+ score (Her2/neu overexpressed) and the presence of the tram track pattern in CISH testing in selected cases from the other categories validated the revised scoring method. These criteria reduced the numbers of equivocal staining cases that required FISH testing.

Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT

Directory of Open Access Journals (Sweden)

Wu Anna M

2009-12-01

Full Text Available Abstract Background Antibody Directed Enzyme Prodrug Therapy (ADEPT can be used to generate cytotoxic agents at the tumor site. To date non-human enzymes have mainly been utilized in ADEPT. However, these non-human enzymes are immunogenic limiting the number of times that ADEPT can be administered. To overcome the problem of immunogenicity, a fully human enzyme, capable of converting a non-toxic prodrug to cytotoxic drug was developed and joined to a human tumor specific scFv yielding a fully human targeting agent. Methods A double mutant of human purine nucleoside phosphorylase (hDM was developed which unlike the human enzyme can cleave adenosine-based prodrugs. For tumor-specific targeting, hDM was fused to the human anti-HER2/neu single chain Fv (scFv, C6 MH3B1. Enzymatic activity of hDM with its natural substrates and prodrugs was determined using spectrophotomeric approaches. A cell proliferation assay was used to assess the cytotoxicity generated following conversion of prodrug to drug as a result of enzymatic activity of hDM. Affinity of the targeting scFv, C6 MH3B1 fused to hDM to Her2/neu was confirmed using affinity chromatography, surface plasmon resonance, and flow-cytometry. Results In vitro hDM-C6 MH3B1 binds specifically to HER2/neu expressing tumor cells and localizes hDM to tumor cells, where the enzymatic activity of hDM-C6 MH3B1, but not the wild type enzyme, results in phosphorolysis of the prodrug, 2-fluoro-2'-deoxyadenosine to the cytotoxic drug 2-fluoroadenine (F-Ade causing inhibition of tumor cell proliferation. Significantly, the toxic small drug diffuses through the cell membrane of HER2/neu expressing cells as well as cells that lack the expression of HER2/neu, causing a bystander effect. F-Ade is toxic to cells irrespective of their growth rate; therefore, both the slowly dividing tumor cells and the non-dividing neighboring stromal cells that support tumor growth should be killed. Analysis of potential novel MHCII

Age related association of her-2/neu with prognostic markers in female breast carcinoma

International Nuclear Information System (INIS)

Sharif, M.A.; Mamoon, N.; Mushtaq, S.; Khadim, M.T.

2010-01-01

To determine age-related association of Her-2/neu expression with histological and immunohistochemical prognostic markers in female breast carcinoma. Study Design: Cross sectional, observational study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from January 2004 to December 2007. Methodology: Patients of primary operable female breast carcinoma were categorised as 50 years (post-menopausal) age groups. Histological type, tumour size, tumour grade and lymph node status were determined while estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu expression were evaluated immunohistochemically. Association of Her-2/neu with histological and immunohistochemical prognostic markers was determined in pre-menopausal, peri-menopausal and post- menopausal age groups using the x2 test for uni- and multivariate analysis. Results: Out of the 722 patients, 230 (31.9%) were in pre-menopuasal, 221 (30.6%) in peri-menopausal and 271 (37.5%) in post-menopausal age group. Infiltrating ductal carcinoma was the pre-dominant subtype in all the age groups. Mean tumour size was 4.3 +- 2.3 cm (range 0.4-17 cm) and lymph node metastasis was seen in 310 (70.8%) cases. Her-2/neu showed association with ER in the all the age groups while PR only showed association in the peri-menopausal and postmenopausal women. Her-2/neu showed no association with tumour size, tumor grade and lymph node metastases in pre-menopausal and peri-menopausal women while it showed positive association with tumour size and lymph node metastasis in the post-menopausal women (p < 0.05). Conclusion: Majority (62%) patients were under 50 years as against the Western epidemiology. Association of Her-2/neu with ER, PR, tumour size and lymph node metastasis was age related as pre-menopausal, peri-menopausal and postmenopausal had variable expression of these prognostic markers with therapeutic and prognostic implications. (author)

Immunohistochemical expression of HER-2/neu in patients with lung carcinoma and its prognostic significance

International Nuclear Information System (INIS)

Petrusevska, G.; Banev, S.; Ilievska-Poposka, B.; Smickova, S.; Spirovski, Z.

2004-01-01

Background. The HER-2 protein or p185her2 is a membrane receptor with tyrosine kinase activity encoded by HER-2/neu gene. Overexpression of HER-2/neu has been observed in many human cancers, including lung cancer. In the study, the expression of HER-2 protein is determined in the spectrum of lung cancer (adenocarcinoma, squamous cell carcinoma and small cell carcinoma). Patients and methods. The study population consisted of two groups: 19 patients that had undergone surgical treatment and 10 patients that had undergone fiber-optic bronchoscopy and biopsy for primary diagnosis only. Tissue specimens were neutral formaldehyde-fixed and paraffin-embedded. Standard histochemical and immunohistochemical staining were used for diagnosis. Expression of HER-2/neu protein was determined by immunohistochemical staining with Hercep Test (DAKO). The results were graded 0-1 as negative and 2-3 as positive. Results. Overall incidence of HER-2/neu overexpression was 34.4% (10 of 29). Higher incidence was found in the patients with adenocarcinoma 45.4% (5 of 11). In squamous cell carcinoma and small cell carcinoma, the overexpression incidence was 30.7% (4 of 13) and 20% (1 of 5), respectively. No statistically significant difference was seen given the age and gender. HER-2/neu overexpression was more pronounced in the patients with advanced tumour: all patients with squamous cell carcinoma and HER-2/neu overexpression had stage IIIB and stage IV disease, while 80 % of adenocarcinoma patients with HER-2/neu overexpression had stage IIIA and IIIB disease. Conclusions. These results are satisfactory and encourage us to continue this work in the follow-up study to evaluate HER-2/neu role as predictive and prognostic factor for the patients with lung cancer. (author)

Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay.

Science.gov (United States)

Goud, Kalal Iravathy; Dayakar, Seetha; Vijayalaxmi, Kolanupaka; Babu, Saidam Jangu; Reddy, P Vijay Anand

2012-03-01

Fluorescence in situ hybridization (FISH) is increasingly being recognized as the most accurate and predictive test for HER 2/neu gene amplification and response to therapy in breast cancer. In the present study we investigated HER-2/neu gene amplification by FISH in breast carcinoma tissue specimens and compared the results with that of immunohistochemical (IHC) analysis. A total of 90 breast carcinoma tissue samples were used for immunohistochemical (IHC) and FISH analysis. IHC was performed by using mouse monoclonal antibody to the intracellular domain of HER-2/neu protein. Each slide was scored in a blinded fashion by two pathologists according to the manufacturer's recommended criteria. FISH analysis was performed on paraffin embedded breast tumour tissue sections. The polysomy for centromere 17 (Spec green signal) was read as green signals less than 4 as moderate polysomy, and more than 4 as highly polysomy. Thirty of the 90 patients had negative results by IHC and FISH. Of the 28 patients with the score of 2+ by IHC, 20 were FISH positive for HER-2/neu gene amplification, three were FISH negative and five patients showed equivocal (1.8-2.2) results by FISH. These five cases were retested for IHC and FISH on different paraffin embedded tissue blocks, and all five were found positive for HER-2/neu gene amplification. Twenty five patients with the score of 3+ by IHC were FISH positive for HER-2/neu gene amplification (>2.2). Seven cases with the score of 3+ by IHC were FISH negative for HER-2/neu gene amplification (>2.2), and showed polysomy of chromosome number 17 high polysomy > 4. Our results indicated that HER-2/neu status by FISH should be performed in all cases of breast tumour with a 2+ score by IHC. Cases demonstrating a 3+ score by IHC may be subjected to FISH to rule out polysomy of chromosome 17 which could be falsely interpreted as HER-2/neu overexpression by IHC analysis. There is also a need for establishing a clinically validated cut-off value

HER-2/neu and CD117 (c-kit overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC

Directory of Open Access Journals (Sweden)

Potti Anil

2005-06-01

Full Text Available Abstract Background The rate of detection of HER-2/neu and CD117 (c-kit overexpression in small cell lung cancer (SCLC has varied widely; between 5–35% and 21–70% respectively. Methods To evaluate the relationship between pesticide exposure and HER-2/neu and CD117 overexpression in extensive stage SCLC (ESSCLC, we identified patients with ESSCLC and assessed pesticide exposure using a predetermined questionnaire. An exposure index (hours/day × days/year × years ≥ 2400 hours was considered as 'exposed.' HER-2/neu overexpression was evaluated on archival tissue using the DAKO Hercep test, and CD117 testing was performed using immunohistochemistry (A4052 polyclonal antibody. Results 193 ESSCLC patients were identified. Pesticide exposure data could be obtained on 174 patients (84 females and 109 males with a mean age of 68.5 years. 53/174 (30.4% revealed HER-2/neu overexpression. 54/174 (31.03% specimens showed CD117 overexpression by IHC. On multivariate analysis, HER-2/neu overexpression was associated with diminished survival (p neu overexpression and 47/121 (38.8% patients without overexpression had exposure to pesticides (odds ratio: 5.38; p Conclusion Pesticide exposure affects HER-2/neu but not CD117 overexpression. Future studies are needed to determine specific pesticide(s/pesticide components that are responsible for HER-2/neu overexpression in ESSCLC, and to validate our findings in other solid tumors that overexpress HER-2/neu.

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas

Directory of Open Access Journals (Sweden)

Li Jing

2011-06-01

Full Text Available Abstract Background HER-2/neu and VEGF expression is correlated with disease behaviors in various cancers. However, evidence for their expression in colon cancer is rather contradictory both for the protein expression status and prognostic value. HER-2/neu is found to participate in VEGF regulation, and has known correlation with VEGF expression in some tumors. In this study, we investigated HER-2/neu and VEGF expression in Chinese colon patients and explored whether there was any correlation between their expression patterns. Methods HER-2/neu and VEGF were investigated immunohistochemically using tumor samples obtained from 317 colon cancer patients with all tumor stages. Correlation of the degree of staining with clinicopathological parameters and survival was investigated. Results Positive expression rates of HER-2/neu and VEGF in colon cancer were 15.5% and 55.5% respectively. HER-2/neu expression was significantly correlated with tumor size and distant metastases (P (P > 0.05. Expression of VEGF was significantly correlated with tumor size, tumor stage, lymph node metastases, and distant metastases (P (P = 0.146. No correlation between HER-2/neu and VEGF expression was detected (P = 0.151. Conclusions HER-2/neu and VEGF are not important prognostic markers of colon cancer. The present results do not support any association between HER2/neu and VEGF expression in this setting.

Neu/Now tuleb varsti

Index Scriptorium Estoniae

2011-01-01

Neu/Now festivalil saab 17.-20. novembril Tallinna vanalinnas näha 35 kunstiprojekti 17 riigist. Cian McKenna (Iirimaa) disainiprojektist "Digitaalne teraapia", Richard Schwarzi (Austria) visuaalse kunsti projektist "Pikslitest" ja Maartje Meijeri (Holland) muusikaprojektist "Kuidas kirjutada fuugat?", mida tõstsid esile festivali kunstilised juhid Anthony Dean ja Paula Crabtree

Characterization of the N-Acetyl-5-neuraminic Acid-binding Site of the Extracytoplasmic Solute Receptor (SiaP) of Nontypeable Haemophilus influenzae Strain 2019

Energy Technology Data Exchange (ETDEWEB)

Johnston, Jason W.; Coussens, Nathan P.; Allen, Simon; Houtman, Jon C.D.; Turner, Keith H.; Zaleski, Anthony; Ramaswamy, S.; Gibson, Bradford W.; Apicella, Michael A. (Iowa); (Buck Inst.)

2012-11-14

Nontypeable Haemophilus influenzae is an opportunistic human pathogen causing otitis media in children and chronic bronchitis and pneumonia in patients with chronic obstructive pulmonary disease. The outer membrane of nontypeable H. influenzae is dominated by lipooligosaccharides (LOS), many of which incorporate sialic acid as a terminal nonreducing sugar. Sialic acid has been demonstrated to be an important factor in the survival of the bacteria within the host environment. H. influenzae is incapable of synthesizing sialic acid and is dependent on scavenging free sialic acid from the host environment. To achieve this, H. influenzae utilizes a tripartite ATP-independent periplasmic transporter. In this study, we characterize the binding site of the extracytoplasmic solute receptor (SiaP) from nontypeable H. influenzae strain 2019. A crystal structure of N-acetyl-5-neuraminic acid (Neu5Ac)-bound SiaP was determined to 1.4 {angstrom} resolution. Thermodynamic characterization of Neu5Ac binding shows this interaction is enthalpically driven with a substantial unfavorable contribution from entropy. This is expected because the binding of SiaP to Neu5Ac is mediated by numerous hydrogen bonds and has several buried water molecules. Point mutations targeting specific amino acids were introduced in the putative binding site. Complementation with the mutated siaP constructs resulted either in full, partial, or no complementation, depending on the role of specific residues. Mass spectrometry analysis of the O-deacylated LOS of the R127K point mutation confirmed the observation of reduced incorporation of Neu5Ac into the LOS. The decreased ability of H. influenzae to import sialic acid had negative effects on resistance to complement-mediated killing and viability of biofilms in vitro, confirming the importance of sialic acid transport to the bacterium.

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Science.gov (United States)

Rodrigues, Loreta M; Chung, Yuen-Li; Al Saffar, Nada M S; Sharp, Swee Y; Jackson, Laura E; Banerji, Udai; Stubbs, Marion; Leach, Martin O; Griffiths, John R; Workman, Paul

2012-05-23

The importance of ERBB2/NEU/HER2 in the response of breast tumours to the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG; tanespimycin) has been demonstrated in the clinic. ERBB2 is an oncoprotein client that is highly dependent on HSP90. This and other oncogenic client proteins (e.g. B-RAF, C-RAF, ALK and CDK4) are depleted by 17-AAG in both animal tumours and patients. Here we investigate by Magnetic Resonance Spectroscopy (MRS) the metabolic response of 17-AAG in spontaneous, NEU/HER2 driven mammary tumours in transgenic MMTV-NEU-NT mice and in cells isolated and cultured from these tumours. Mammary tumours were monitored by 31P MRS in vivo and in tumour extracts, comparing control and 17-AAG treated mice. A cell line derived from NEU/HER2 mammary tumours was also cultured and the effect of 17-AAG was measured by 31P MRS in cell extracts. Molecular biomarkers were assessed by immunoblotting in extracts from cells and tumours. For comparison of tumour volume, metabolite concentrations and Western blot band intensities, two-tailed unpaired t-tests were used. The NEU/HER2 mammary tumours were very sensitive to 17-AAG and responded in a dose-dependent manner to 3 daily doses of 20, 40 and 80mg/kg of 17-AAG, all of which caused significant regression. At the higher doses, 31P MRS of tumour extracts showed significant decreases in phosphocholine (PC) and phosphoethanolamine (PE) whereas no significant changes were seen at the 20mg/kg dose. Extracts of isolated cells cultured from the mammary carcinomas showed a significant decrease in viable cell number and total PME after 17-AAG treatment. Western blots confirmed the expected action of 17-AAG in inducing HSP72 and significantly depleting HSP90 client proteins, including NEU/HER2 both in tumours and in isolated cells. The data demonstrate the high degree of sensitivity of this clinically relevant NEU/HER2-driven tumour model to HSP90 inhibition by 17-AAG, consistent with the

File list: Unc.Neu.10.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Hypothalamus mm9 Unclassified Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.10.AllAg.Hypothalamus.bed ...

File list: Unc.Neu.20.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Hypothalamus mm9 Unclassified Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Hypothalamus.bed ...

File list: Unc.Neu.05.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Hypothalamus mm9 Unclassified Neural Hypothalamus SRX956254,SRX956...253 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Hypothalamus.bed ...

File list: Unc.Neu.50.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Hypothalamus mm9 Unclassified Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Hypothalamus.bed ...

File list: ALL.Neu.10.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Hypothalamus mm9 All antigens Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Hypothalamus.bed ...

File list: ALL.Neu.50.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Cerebellum hg19 All antigens Neural Cerebellum SRX1096823,SRX99829...5 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Cerebellum.bed ...

File list: ALL.Neu.20.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Cerebellum hg19 All antigens Neural Cerebellum SRX1096823,SRX99829...5 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Cerebellum.bed ...

File list: ALL.Neu.05.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Hypothalamus mm9 All antigens Neural Hypothalamus SRX956254,SRX956...253 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Hypothalamus.bed ...

File list: ALL.Neu.50.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Hypothalamus mm9 All antigens Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Hypothalamus.bed ...

File list: ALL.Neu.20.AllAg.Hypothalamus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Hypothalamus mm9 All antigens Neural Hypothalamus SRX956253,SRX956...254 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Hypothalamus.bed ...

Biocatalytic production of 3′-sialyllactose by use of a modified sialidase with superior trans-sialidase activity

DEFF Research Database (Denmark)

Michalak, Malwina; Larsen, Dorte Møller; Jers, Carsten

2014-01-01

′-sialyllactose production by optimizing pH, temperature, acceptor, and donor concentrations using response surface designs. At the optimum reaction conditions, the Tr6 catalyzed the transfer of sialic acid from cGMP to lactose at high efficiency without substantial hydrolysis of the 3′-sialyllactose product......Casein glycomacropeptide (cGMP) and lactose, which are purified (or semi-purified) components obtained from side streams from dairy industry operations, were used as substrates for enzyme catalyzed production of 3′-sialyllactose, a model case compound for human milk oligosaccharides (HMOs...

File list: Unc.Neu.20.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Hippocampus hg19 Unclassified Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.20.AllAg.Hippocampus.bed ...

File list: Unc.Neu.50.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Hippocampus hg19 Unclassified Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.50.AllAg.Hippocampus.bed ...

File list: Unc.Neu.05.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Hippocampus hg19 Unclassified Neural Hippocampus SRX1177283,SRX117...7282,SRX1177284 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.05.AllAg.Hippocampus.bed ...

File list: Unc.Neu.10.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Hippocampus hg19 Unclassified Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.10.AllAg.Hippocampus.bed ...

Development of a simple and efficient method for assaying cytidine monophosphate sialic acid synthetase activity using an enzymatic reduced nicotinamide adenine dinucleotide/oxidized nicotinamide adenine dinucleotide converting system.

Science.gov (United States)

Fujita, Akiko; Sato, Chihiro; Münster-Kühnel, Anja-K; Gerardy-Schahn, Rita; Kitajima, Ken

2005-02-01

A new reliable method to assay the activity of cytidine monophosphate sialic acid (CMP-Sia) synthetase (CSS) has been developed. The activation of sialic acids (Sia) to CMP-Sia is a prerequisite for the de novo synthesis of sialoglycoconjugates. In vertebrates, CSS has been cloned from human, mouse, and rainbow trout, and the crystal structure has been resolved for the mouse enzyme. The mouse and rainbow trout enzyme have been compared with respect to substrate specificity, demonstrating that the mouse enzyme exhibits a pronounced specificity for N-acetylneuraminic acid (Neu5Ac), while the rainbow trout CSS is equally active with either of three Sia species, Neu5Ac, N-glycolylneuraminic acid (Neu5Gc), and deaminoneuraminic acid (KDN). However, molecular details that explain the pronounced substrate specificities are unknown. Understanding the catalytic mechanisms of these enzymes is of major importance, since CSSs play crucial roles in cellular sialylation patterns and thus are potential drug targets in a number of pathophysiological situations. The availability of the cDNAs and the obtained structural data enable rational approaches; however, these efforts are limited by the lack of a reliable high-throughput assay system. Here we describe a new assay system that allows product quantification in a reduced nicotinamide adenine dinucleotide (NADH)-dependent color reaction. The activation reaction catalyzed by CSS, CTP+Sia-->CMP-Sia+pyrophosphate, was evaluated by a consumption of Sia, which corresponds to that of NADH on the following two successive reactions: (i) Sia-->pyruvate+ManNAc (or Man), catalyzed by a sialic acid lyase (SAL), and (ii) pyruvate+NADH-->lactate+oxidized nicotinamide adenine dinucleotide (NAD+), catalyzed by a lactate dehydrogenase (LDH). Consumption of NADH can be photometrically monitored on a microtiter plate reader for a number of test samples at the same time. Furthermore, based on the quantification of CSS used in the SAL/LDH assay

File list: ALL.Neu.10.AllAg.Putamen [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Putamen hg19 All antigens Neural Putamen SRX998291,SRX1096826,SRX9...98289 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.10.AllAg.Putamen.bed ...

File list: ALL.Neu.20.AllAg.Putamen [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Putamen hg19 All antigens Neural Putamen SRX998291,SRX1096826,SRX9...98289 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Putamen.bed ...

File list: ALL.Neu.05.AllAg.Putamen [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Putamen hg19 All antigens Neural Putamen SRX998291,SRX1096826,SRX9...98289 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Putamen.bed ...

File list: ALL.Neu.50.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Hippocampus hg19 All antigens Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Hippocampus.bed ...

File list: ALL.Neu.05.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Hippocampus hg19 All antigens Neural Hippocampus SRX1177283,SRX117...7282,SRX1177284 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Hippocampus.bed ...

File list: ALL.Neu.20.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Hippocampus hg19 All antigens Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Hippocampus.bed ...

File list: ALL.Neu.10.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Hippocampus hg19 All antigens Neural Hippocampus SRX1177282,SRX117...7284,SRX1177283 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.10.AllAg.Hippocampus.bed ...

File list: DNS.Neu.20.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Cerebellum mm9 DNase-seq Neural Cerebellum SRX191026,SRX191022,SRX...685872,SRX685874 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.20.AllAg.Cerebellum.bed ...

File list: DNS.Neu.50.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Cerebellum mm9 DNase-seq Neural Cerebellum SRX191022,SRX191026,SRX685874,SRX685872 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Cerebellum.bed ...

File list: His.Neu.20.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available 300,SRX216301,SRX216299 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Hippocampus.bed ... ...His.Neu.20.AllAg.Hippocampus mm9 Histone Neural Hippocampus SRX1430120,SRX1430132,S

File list: His.Neu.05.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available 455,SRX248469,SRX216301 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Hippocampus.bed ... ...His.Neu.05.AllAg.Hippocampus mm9 Histone Neural Hippocampus SRX1430132,SRX1430128,S

File list: His.Neu.10.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available 302,SRX216299,SRX216301 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Hippocampus.bed ... ...His.Neu.10.AllAg.Hippocampus mm9 Histone Neural Hippocampus SRX1430128,SRX1430120,S

File list: His.Neu.50.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available 07,SRX1430117,SRX216299 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Hippocampus.bed ... ...His.Neu.50.AllAg.Hippocampus mm9 Histone Neural Hippocampus SRX1430120,SRX1430132,S

File list: DNS.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Cerebellum mm9 DNase-seq Neural Cerebellum SRX191026,SRX191022,SRX...685872,SRX685874,SRX685876 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.05.AllAg.Cerebellum.bed ...

File list: DNS.Neu.10.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Cerebellum mm9 DNase-seq Neural Cerebellum SRX191026,SRX191022,SRX...685872,SRX685874,SRX685876 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Cerebellum.bed ...

File list: ALL.Neu.05.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Hippocampus mm9 All antigens Neural Hippocampus SRX1057076,SRX1057...17455,SRX248469,SRX216301 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Hippocampus.bed ...

File list: ALL.Neu.20.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Hippocampus mm9 All antigens Neural Hippocampus SRX1430120,SRX1430...16300,SRX216301,SRX216299 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Hippocampus.bed ...

File list: ALL.Neu.50.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Hippocampus mm9 All antigens Neural Hippocampus SRX1430120,SRX1430...0107,SRX1430117,SRX216299 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Hippocampus.bed ...

File list: ALL.Neu.10.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Hippocampus mm9 All antigens Neural Hippocampus SRX1430128,SRX1430...16302,SRX216299,SRX216301 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Hippocampus.bed ...

Her-2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry.

Science.gov (United States)

Kapila, Kusum; Al-Awadhi, S; Francis, Im

2011-04-01

Breast cancers with Her-2 neu gene amplification are recognized as important markers for aggressive disease and targets which respond to therapy with trastuzumab. Her-2 neu testing on histological sections is routinely performed to select patients who may benefit from anti- Her-2 neu therapy. Few reports are available which document Her-2 neu status on fine needle aspirates (FNA). This pilot study is to document expression of Her-2 neu (Cerb-B2) on cytospin smears from FNA of patients with breast carcinoma. Twenty samples of FNA already collected for diagnostic purposes from patients with primary breast carcinoma were studied for demonstration of Her-2 neu expression by immunohistochemistry (IHC), Fluorescent in-situ hybridization (FISH) and chromogenic in-situ hybridization (CISH) on cytospin smears from FNA. Their expression was compared with tissue sections where possible. Good correlation was observed between Her-2 neu protein expression and gene amplification in cytospin smears. Three of five (60%) breast carcinomas cases with 2+ and 3+ staining on IHC showed gene amplification by FISH and CISH. Three of 7 (43%) and 5 of 7 (71%) cases negative/1+ staining on IHC did not show gene amplification by FISH and CISH respectively. Tissue sections from 10 cases with 2+ and 3+ staining for Her2neu by IHC showed gene amplification in 8 cases. Demonstration of Her-2 neu by IHC, FISH or CISH in FNA is possible and may play a role in the management of patients with advanced breast cancer or those cases where surgical resection is not advisable.

File list: ALL.Neu.10.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Neurons mm9 All antigens Neural Neurons SRX032488,SRX047694,SRX032...X047691,SRX032485,SRX799005 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Neurons.bed ...

File list: ALL.Neu.05.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Neurons mm9 All antigens Neural Neurons SRX085427,SRX085426,SRX798...X032486,SRX047691,SRX032485 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Neurons.bed ...

File list: ALL.Neu.50.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Neurons mm9 All antigens Neural Neurons SRX032491,SRX032492,SRX032...X085427,SRX798999,SRX032490 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Neurons.bed ...

File list: ALL.Neu.20.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Neurons mm9 All antigens Neural Neurons SRX032491,SRX032492,SRX085...X032487,SRX798987,SRX032490 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Neurons.bed ...

File list: Pol.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Brain mm9 RNA polymerase Neural Brain SRX236085,ERX132833,SRX01708...2,SRX680480,SRX020249 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Brain.bed ...

File list: Pol.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Brain mm9 RNA polymerase Neural Brain SRX236085,ERX132833,SRX01708...2,SRX680480,SRX020249 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Brain.bed ...

File list: Pol.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Brain mm9 RNA polymerase Neural Brain SRX236085,ERX132833,SRX01708...2,SRX680480,SRX020249 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Brain.bed ...

File list: Pol.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Brain mm9 RNA polymerase Neural Brain SRX236085,ERX132833,SRX01708...2,SRX680480,SRX020249 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Brain.bed ...

File list: ALL.Neu.50.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Forebrain mm9 All antigens Neural Forebrain SRX093315,SRX377672,SR...SRX377671,SRX377674,SRX669235 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Forebrain.bed ...

File list: ALL.Neu.20.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Forebrain mm9 All antigens Neural Forebrain SRX093315,SRX377672,SR...SRX377674,SRX317036,SRX377671 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Forebrain.bed ...

File list: ALL.Neu.10.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Forebrain mm9 All antigens Neural Forebrain SRX093315,SRX377672,SR...SRX377673,SRX377671,SRX317036 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Forebrain.bed ...

File list: ALL.Neu.05.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Forebrain mm9 All antigens Neural Forebrain SRX002660,SRX093315,SR...SRX377673,SRX669235,SRX377671 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Forebrain.bed ...

Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Science.gov (United States)

Coyne, C P; Jones, Toni; Bear, Ryan

2012-11-01

Immunochemotherapeutics, epirubicin-(C 3 - amide )-SS-[anti-HER2/ neu ] with an internal disulfide bond, and epirubicin-(C 3 - amide )-[anti-HER2/ neu ] were synthesized utilizing succinimidyl 2-[(4,4'-azipentanamido) ethyl]-1,3'-dithioproprionate or succinimidyl 4,4-azipentanoate respectively. Western blot analysis was used to determine the presence of any immunoglobulin fragmentation or IgG-IgG polymerization. Retained HER2/ neu binding characteristics of epirubicin-(C 3 - amide )-[anti-HER2/ neu ] and epirubicin-(C 3 - amide )-SS-[anti-HER2/ neu ] were validated by cell-ELISA using a mammary adenocarcinoma (SKBr-3) population that highly over-expresses trophic HER2/ neu receptor complexes. Cytotoxic anti-neoplastic potency of epirubicin-(C 3 - amide )-[anti-HER2/ neu ] and epirubicin-(C 3 - amide )-SS-[anti-HER2/ neu ] between epirubicin-equivalent concentrations of 10 -10 M and 10 -6 M was determined by measuring the vitality/proliferation of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3 cell type). Cytotoxic anti-neoplastic potency of benzimidazoles (albendazole, flubendazole, membendazole) and griseofulvin were assessed between 0-to-2 μg/ml and 0-to-100 μg/ml respectively while mebendazole and griseofulvin were analyzed at fixed concentrations of 0.35 μg/ml and 35 g/ml respectively in dual combination with gradient concentrations of epirubicin-(C 3 - amide )-[anti-HER2/ neu ] and epirubicin-(C 3 - amide )-SS-[anti-HER2/ neu ]. Cytotoxic anti-neoplastic potency for epirubicin-(C 3 - amide )-[anti-HER2/ neu ] and epirubicin-(C 3 - amide )-SS-[anti-HER2/ neu ] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) was nearly identical at epirubicin-equivalent concentrations of 10 -10 M and 10 -6 M. The benzimadazoles also possessed cytotoxic anti-neoplastic activity with flubendazole and albendazole being the most and least potent respectively. Similarly, griseofulvin had cytotoxic anti-neoplastic activity and was more potent than

File list: Oth.Neu.20.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Neurons mm9 TFs and others Neural Neurons SRX032491,SRX032492,SRX0...85427,SRX032489,SRX085426,SRX032490 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Neurons.bed ...

File list: Oth.Neu.05.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Neurons mm9 TFs and others Neural Neurons SRX085427,SRX085426,SRX0...32490,SRX032491,SRX032492,SRX032489 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Neurons.bed ...

File list: Oth.Neu.50.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Neurons mm9 TFs and others Neural Neurons SRX032491,SRX032492,SRX0...32489,SRX085426,SRX085427,SRX032490 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Neurons.bed ...

File list: Oth.Neu.10.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Neurons mm9 TFs and others Neural Neurons SRX085427,SRX032490,SRX0...32491,SRX032492,SRX085426,SRX032489 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Neurons.bed ...

File list: His.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Brain mm9 Histone Neural Brain SRX680482,SRX017084,SRX680481,SRX21...9253,SRX680484,SRX680483,SRX680485 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Brain.bed ...

File list: His.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Brain mm9 Histone Neural Brain SRX680482,SRX219253,SRX680484,SRX68...0485,SRX680483,SRX017084,SRX680481 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Brain.bed ...

File list: His.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Brain mm9 Histone Neural Brain SRX680482,SRX219253,SRX680484,SRX68...0481,SRX680485,SRX017084,SRX680483 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Brain.bed ...

File list: His.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Brain mm9 Histone Neural Brain SRX680482,SRX680481,SRX219253,SRX68...0484,SRX680485,SRX017084,SRX680483 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Brain.bed ...

File list: Oth.Neu.20.Biotin.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.Biotin.AllCell mm9 TFs and others Biotin Neural SRX1057041,SRX1057049,SR...X1057045,SRX1057047,SRX1057043,SRX1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.Biotin.AllCell.bed ...

File list: Oth.Neu.50.Biotin.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.Biotin.AllCell mm9 TFs and others Biotin Neural SRX1057041,SRX1057049,SR...X1057045,SRX1057047,SRX1057043,SRX1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.Biotin.AllCell.bed ...

File list: Oth.Neu.05.Biotin.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.Biotin.AllCell mm9 TFs and others Biotin Neural SRX1057045,SRX1057047,SR...X1057049,SRX1057041,SRX1057051,SRX1057043 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.Biotin.AllCell.bed ...

File list: Pol.Neu.10.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Cerebellum mm9 RNA polymerase Neural Cerebellum SRX062952,SRX14381...7,SRX026426,SRX026423,SRX026425,SRX026424 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Cerebellum.bed ...

File list: His.Neu.50.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Cerebellum mm9 Histone Neural Cerebellum SRX545939,SRX026427,SRX06...X062950,SRX085441,SRX022869,SRX022868 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Cerebellum.bed ...

File list: His.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Cerebellum mm9 Histone Neural Cerebellum SRX062950,SRX085441,SRX02...X026432,SRX022868,SRX026431,SRX185811 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Cerebellum.bed ...

File list: His.Neu.10.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Cerebellum mm9 Histone Neural Cerebellum SRX085450,SRX062951,SRX02...X022868,SRX026431,SRX185811,SRX022869 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Cerebellum.bed ...

File list: Pol.Neu.50.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Cerebellum mm9 RNA polymerase Neural Cerebellum SRX062952,SRX14381...7,SRX026426,SRX026425,SRX026424,SRX026423 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Cerebellum.bed ...

File list: Pol.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Cerebellum mm9 RNA polymerase Neural Cerebellum SRX062952,SRX14381...7,SRX026424,SRX026426,SRX026423,SRX026425 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Cerebellum.bed ...

File list: Pol.Neu.20.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Cerebellum mm9 RNA polymerase Neural Cerebellum SRX062952,SRX14381...7,SRX026426,SRX026423,SRX026425,SRX026424 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Cerebellum.bed ...

File list: His.Neu.20.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Forebrain mm9 Histone Neural Forebrain SRX093315,SRX377672,SRX3776...70,SRX377678,SRX377676,SRX093314,SRX377674 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Forebrain.bed ...

File list: His.Neu.50.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Forebrain mm9 Histone Neural Forebrain SRX093315,SRX377672,SRX3776...70,SRX377678,SRX377676,SRX093314,SRX377674 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Forebrain.bed ...

File list: His.Neu.10.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Forebrain mm9 Histone Neural Forebrain SRX093315,SRX377672,SRX3776...70,SRX377678,SRX377676,SRX093314,SRX377674 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Forebrain.bed ...

File list: His.Neu.05.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Forebrain mm9 Histone Neural Forebrain SRX093315,SRX377678,SRX3776...72,SRX377670,SRX377676,SRX377674,SRX093314 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Forebrain.bed ...

Neu/Now testib talenti kontekstis / Mart Niineste

Index Scriptorium Estoniae

Niineste, Mart, 1983-

2011-01-01

17.-20. novembrini toimuvast rahvusvahelisest kunstifestivalist Neu/Now. Kahetasandilise festivali raames toimuvast online-festivalist ja live-festivalist. Festivali Eesti poolne kuraator Marje Lohuaru

Her-2 neu (Cerb-B2 expression in fine needle aspiration samples of breast carcinoma: A pilot study comparing FISH, CISH and immunocytochemistry

Directory of Open Access Journals (Sweden)

Kusum Kapila

2011-01-01

Full Text Available Background: Breast cancers with Her-2 neu gene amplification are recognized as important markers for aggressive disease and targets which respond to therapy with trastuzumab. Her-2 neu testing on histological sections is routinely performed to select patients who may benefit from anti- Her-2 neu therapy. Few reports are available which document Her-2 neu status on fine needle aspirates (FNA. Aim: This pilot study is to document expression of Her-2 neu (Cerb-B2 on cytospin smears from FNA of patients with breast carcinoma. Materials and Methods: Twenty samples of FNA already collected for diagnostic purposes from patients with primary breast carcinoma were studied for demonstration of Her-2 neu expression by immunohistochemistry (IHC, Fluorescent in-situ hybridization (FISH and chromogenic in-situ hybridization (CISH on cytospin smears from FNA. Their expression was compared with tissue sections where possible. Results: Good correlation was observed between Her-2 neu protein expression and gene amplification in cytospin smears. Three of five (60% breast carcinomas cases with 2+ and 3+ staining on IHC showed gene amplification by FISH and CISH. Three of 7 (43% and 5 of 7 (71% cases negative/1+ staining on IHC did not show gene amplification by FISH and CISH respectively. Tissue sections from 10 cases with 2+ and 3+ staining for Her2neu by IHC showed gene amplification in 8 cases. Conclusion: Demonstration of Her-2 neu by IHC, FISH or CISH in FNA is possible and may play a role in the management of patients with advanced breast cancer or those cases where surgical resection is not advisable.

File list: ALL.Neu.50.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Olf_neurosphere hg19 All antigens Neural Olf neurosphere SRX189414... http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Olf_neurosphere.bed ...

File list: ALL.Neu.05.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Olf_neurosphere hg19 All antigens Neural Olf neurosphere SRX189414... http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Olf_neurosphere.bed ...

File list: ALL.Neu.20.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Olf_neurosphere hg19 All antigens Neural Olf neurosphere SRX189414... http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Olf_neurosphere.bed ...

File list: ALL.Neu.10.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Olf_neurosphere hg19 All antigens Neural Olf neurosphere SRX189414... http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.10.AllAg.Olf_neurosphere.bed ...

HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens

DEFF Research Database (Denmark)

Lesnikova, Iana; Lidang, Marianne; Hamilton-Dutoit, Stephen

2009-01-01

intraepithelial neoplasia (CIN)1 (n = 262), CIN2 (n = 230), CIN3 (n = 186) and invasive carcinoma (n = 136), for HER2/neu protein expression by immunohistochemistry (IHC) and for HER2/neu gene amplification by chromogenic in situ hybridization (CISH). We found moderate or strong immunohistochemical positivity...... and invasive cervical carcinoma specimens. When present, Her-2/neu positivity is more commonly seen in higher grades of cervical dysplasia and in carcinoma. However, this large TMA study shows that HER2/neu oncoprotein expression and HER2/neu gene amplification overall are uncommon events in cervical neoplasia....... This provides compelling evidence that HER2/neu plays no major role in the development and progression of cervical neoplasia....

File list: Oth.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Brain mm9 TFs and others Neural Brain SRX661585,ERX450950,ERX33906...ERX1027837,ERX370082,ERX370085,ERX370083,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Brain.bed ...

File list: Oth.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Brain mm9 TFs and others Neural Brain SRX661585,SRX116258,SRX11625...,ERX370082,ERX370083,ERX370085,ERX370084,SRX150260 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Brain.bed ...

File list: Oth.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Brain mm9 TFs and others Neural Brain SRX661585,SRX116258,SRX01708...,SRX150260,ERX370082,ERX370083,ERX370085,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Brain.bed ...

File list: Oth.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Brain mm9 TFs and others Neural Brain SRX661585,SRX093164,SRX11625...,ERX339067,ERX370082,ERX370083,ERX370085,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Brain.bed ...

File list: Oth.Neu.50.Fosb.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.Fosb.AllCell mm9 TFs and others Fosb Neural SRX671671,SRX671678,SRX67167...5,SRX671682,SRX671658,SRX671654,SRX671667,SRX671662 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.Fosb.AllCell.bed ...

File list: Oth.Neu.20.Fosb.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.Fosb.AllCell mm9 TFs and others Fosb Neural SRX671675,SRX671671,SRX67167...8,SRX671682,SRX671658,SRX671654,SRX671667,SRX671662 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.Fosb.AllCell.bed ...

File list: Oth.Neu.10.Fosb.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.Fosb.AllCell mm9 TFs and others Fosb Neural SRX671671,SRX671678,SRX67167...5,SRX671662,SRX671654,SRX671658,SRX671682,SRX671667 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.Fosb.AllCell.bed ...

File list: Oth.Neu.05.Fosb.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.Fosb.AllCell mm9 TFs and others Fosb Neural SRX671675,SRX671671,SRX67166...7,SRX671682,SRX671678,SRX671658,SRX671662,SRX671654 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.Fosb.AllCell.bed ...

File list: ALL.Neu.20.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Cerebellum mm9 All antigens Neural Cerebellum SRX191026,SRX191022,...X150264,SRX150265,SRX019017,SRX022867,SRX022866,SRX150262,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Cerebellum.bed ...

File list: ALL.Neu.10.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Midbrain mm9 All antigens Neural Midbrain SRX002662,ERX102458,ERX1...02459,SRX332682,SRX317037,ERX102460,ERX102461,SRX332681 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Midbrain.bed ...

File list: ALL.Neu.05.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Midbrain mm9 All antigens Neural Midbrain SRX002662,SRX332682,ERX1...02458,ERX102459,SRX317037,ERX102460,ERX102461,SRX332681 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Midbrain.bed ...

File list: ALL.Neu.20.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Midbrain mm9 All antigens Neural Midbrain SRX332682,ERX102458,ERX1...02459,ERX102460,ERX102461,SRX317037,SRX002662,SRX332681 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Midbrain.bed ...

File list: ALL.Neu.50.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Midbrain mm9 All antigens Neural Midbrain ERX102458,ERX102459,ERX1...02460,ERX102461,SRX317037,SRX002662,SRX332682,SRX332681 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Midbrain.bed ...

File list: DNS.Neu.10.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Olf_neurosphere hg19 DNase-seq Neural Olf neurosphere SRX189414 ht...tp://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.10.AllAg.Olf_neurosphere.bed ...

File list: ALL.Neu.50.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Cortical_neuron mm9 All antigens Neural Cortical neuron SRX914998,...1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Cortical_neuron.bed ...

File list: ALL.Neu.20.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Cortical_neuron mm9 All antigens Neural Cortical neuron SRX914998,...1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Cortical_neuron.bed ...

File list: DNS.Neu.20.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Olf_neurosphere hg19 DNase-seq Neural Olf neurosphere SRX189414 ht...tp://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.20.AllAg.Olf_neurosphere.bed ...

File list: DNS.Neu.50.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Olf_neurosphere hg19 DNase-seq Neural Olf neurosphere SRX189414 ht...tp://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.50.AllAg.Olf_neurosphere.bed ...

File list: DNS.Neu.05.AllAg.Olf_neurosphere [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Olf_neurosphere hg19 DNase-seq Neural Olf neurosphere SRX189414 ht...tp://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.05.AllAg.Olf_neurosphere.bed ...

File list: ALL.Neu.10.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Cortical_neuron mm9 All antigens Neural Cortical neuron SRX217735,...1057051 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Cortical_neuron.bed ...

File list: ALL.Neu.05.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Cortical_neuron mm9 All antigens Neural Cortical neuron SRX217735,...1057043 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Cortical_neuron.bed ...

Immunohistochemical her-2/ neu expression with gene amplification by fluorescence in situ hybridization for assessment in breast carcinomas

International Nuclear Information System (INIS)

Moatter, T.; Zahida, Z.U.D.; Kayani, N.; Pervez, S.

2007-01-01

To compare gene amplification of HER-2/neu gene by fluorescence in situ hybridization (FISH) in moderate to strong immunohistochemically (IHS) positive HER-2/neu cases of invasive breast carcinomas. Forty one (41) diagnosed cases of invasive breast carcinomas were included in this study in which already determined immunohistochemical HER-2/neu expression was scored as either 2+ or 3+, based on the intensity of membranous staining. These cases were further evaluated for gene amplification by FISH. For gene amplification, a ratio of HER-2/CEP z 2 was accepted as positive gene amplification. Out of a total 41 cases, which were scored as 2+ and 3+ by IHC, 14 cases (34.1%, 95% confidence interval: 19% - 49.3% ) showed gene amplification by FISH. Proportion of FISH positivity in IHC 2+ cases alone was found to be 25% (95% confidence interval: 10.5% - 41%). In contrast, a majority of IHC 3+ cases (5 of 6) were positive by FISH studies. IHC is appropriate for initial HER-2/neu assessment and patients with tumors scored as 3+ may be treated alone based on this information provided strict quality control and 95% concordance with FISH assays; however, patients with tumors interpreted as 2+, would benefit from gene amplification by FISH studies for more accurate assessment to avoid inaccurate prognostication and treatment. (author)

File list: ALL.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Brain mm9 All antigens Neural Brain SRX661585,SRX218191,SRX188650,...,ERX513117,ERX370082,ERX370083,ERX370085,ERX370084,SRX150260,SRX150261 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Brain.bed ...

File list: ALL.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Brain mm9 All antigens Neural Brain SRX661585,SRX1125793,SRX112579...RX513117,ERX1027842,ERX1027837,ERX370082,ERX370085,ERX370083,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Brain.bed ...

File list: ALL.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Brain mm9 All antigens Neural Brain SRX661585,SRX188650,SRX191009,...,ERX339062,ERX339067,ERX513117,ERX370082,ERX370083,ERX370085,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Brain.bed ...

File list: ALL.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Brain mm9 All antigens Neural Brain SRX661585,SRX188650,SRX191009,...,SRX150260,SRX150261,ERX513117,ERX370082,ERX370083,ERX370085,ERX370084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Brain.bed ...

File list: ALL.Neu.10.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Cerebellum mm9 All antigens Neural Cerebellum SRX191026,SRX191022,...X669237,SRX669238,SRX685923,SRX685874,SRX685922,SRX150263,SRX150262,SRX685876 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Cerebellum.bed ...

File list: ALL.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Cerebellum mm9 All antigens Neural Cerebellum SRX191026,SRX062950,...X669237,SRX150265,SRX019017,SRX685922,SRX685924,SRX150262,SRX685876,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Cerebellum.bed ...

File list: ALL.Neu.50.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Fetal_brain hg19 All antigens Neural Fetal brain SRX142786,SRX2096...60880 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Fetal_brain.bed ...

File list: ALL.Neu.05.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Fetal_brain hg19 All antigens Neural Fetal brain SRX056802,SRX1427...60882 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Fetal_brain.bed ...

File list: ALL.Neu.20.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Fetal_brain hg19 All antigens Neural Fetal brain SRX142786,SRX2096...60882 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Fetal_brain.bed ...

File list: Oth.Neu.10.Epitope_tags.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.Epitope_tags.AllCell hg19 TFs and others Epitope tags Neural SRX367452,S...RX367451 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.10.Epitope_tags.AllCell.bed ...

File list: His.Neu.10.AllAg.White_Matter [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.White_Matter hg19 Histone Neural White Matter SRX998282,SRX1096828...,SRX998280,SRX1096827 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.10.AllAg.White_Matter.bed ...

File list: His.Neu.20.AllAg.White_Matter [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.White_Matter hg19 Histone Neural White Matter SRX998282,SRX1096828...,SRX998280,SRX1096827 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.20.AllAg.White_Matter.bed ...

File list: His.Neu.05.AllAg.White_Matter [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.White_Matter hg19 Histone Neural White Matter SRX998282,SRX998280,...SRX1096828,SRX1096827 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.05.AllAg.White_Matter.bed ...

File list: His.Neu.50.AllAg.White_Matter [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.White_Matter hg19 Histone Neural White Matter SRX998282,SRX1096828...,SRX998280,SRX1096827 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.50.AllAg.White_Matter.bed ...

File list: Oth.Neu.05.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Cortical_neuron mm9 TFs and others Neural Cortical neuron SRX67166...1,SRX1057043 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Cortical_neuron.bed ...

File list: His.Neu.05.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Thalamic_Nuclei hg19 Histone Neural Thalamic Nuclei SRX998288,SRX9...98287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.05.AllAg.Thalamic_Nuclei.bed ...

File list: ALL.Neu.10.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Thalamic_Nuclei hg19 All antigens Neural Thalamic Nuclei SRX998288...,SRX998287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.10.AllAg.Thalamic_Nuclei.bed ...

File list: ALL.Neu.50.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Adult_brains hg19 All antigens Neural Adult brains SRX643470,SRX11...189408,SRX189413 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Adult_brains.bed ...

File list: ALL.Neu.10.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Adult_brains hg19 All antigens Neural Adult brains SRX643470,SRX11...643463,SRX189413 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.10.AllAg.Adult_brains.bed ...

File list: ALL.Neu.20.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Adult_brains hg19 All antigens Neural Adult brains SRX643470,SRX11...189408,SRX189413 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Adult_brains.bed ...

File list: DNS.Neu.50.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Fetal_brain hg19 DNase-seq Neural Fetal brain SRX040380,SRX040395,...6,SRX121278 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.50.AllAg.Fetal_brain.bed ...

File list: DNS.Neu.20.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Fetal_brain hg19 DNase-seq Neural Fetal brain SRX040380,SRX040395,...6,SRX121278 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.20.AllAg.Fetal_brain.bed ...

File list: ALL.Neu.05.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Adult_brains hg19 All antigens Neural Adult brains SRX643470,SRX01...189408,SRX189413 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Adult_brains.bed ...

File list: DNS.Neu.10.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Fetal_brain hg19 DNase-seq Neural Fetal brain SRX040380,SRX040395,...6,SRX121278 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.10.AllAg.Fetal_brain.bed ...

File list: ALL.Neu.20.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Thalamic_Nuclei hg19 All antigens Neural Thalamic Nuclei SRX998288...,SRX998287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.20.AllAg.Thalamic_Nuclei.bed ...

File list: His.Neu.10.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Thalamic_Nuclei hg19 Histone Neural Thalamic Nuclei SRX998288,SRX9...98287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.10.AllAg.Thalamic_Nuclei.bed ...

File list: ALL.Neu.05.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Thalamic_Nuclei hg19 All antigens Neural Thalamic Nuclei SRX998288...,SRX998287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.05.AllAg.Thalamic_Nuclei.bed ...

File list: ALL.Neu.50.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Thalamic_Nuclei hg19 All antigens Neural Thalamic Nuclei SRX998288...,SRX998287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/ALL.Neu.50.AllAg.Thalamic_Nuclei.bed ...

File list: His.Neu.50.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Thalamic_Nuclei hg19 Histone Neural Thalamic Nuclei SRX998288,SRX9...98287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.50.AllAg.Thalamic_Nuclei.bed ...

File list: His.Neu.20.AllAg.Thalamic_Nuclei [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Thalamic_Nuclei hg19 Histone Neural Thalamic Nuclei SRX998288,SRX9...98287,SRX998286 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.20.AllAg.Thalamic_Nuclei.bed ...

Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.

Science.gov (United States)

Mason, Nicola J; Gnanandarajah, Josephine S; Engiles, Julie B; Gray, Falon; Laughlin, Danielle; Gaurnier-Hausser, Anita; Wallecha, Anu; Huebner, Margie; Paterson, Yvonne

2016-09-01

Recombinant Listeria vaccines induce tumor-specific T-cell responses that eliminate established tumors and prevent metastatic disease in murine cancer models. We used dogs with HER2/neu(+) appendicular osteosarcoma, a well-recognized spontaneous model for pediatric osteosarcoma, to determine whether a highly attenuated, recombinant Listeria monocytogenes expressing a chimeric human HER2/neu fusion protein (ADXS31-164) could safely induce HER2/neu-specific immunity and prevent metastatic disease. Eighteen dogs that underwent limb amputation or salvage surgery and adjuvant chemotherapy were enrolled in a phase I dose escalation clinical trial and received either 2 × 10(8), 5 × 10(8), 1 × 10(9), or 3.3 × 10(9) CFU of ADXS31-164 intravenously every 3 weeks for 3 administrations. Only low-grade, transient toxicities were observed. ADXS31-164 broke peripheral tolerance and induced antigen-specific IFNγ responses against the intracellular domain of HER2/neu in 15 of 18 dogs within 6 months of treatment. Furthermore, ADXS31-164 reduced the incidence of metastatic disease and significantly increased duration of survival time and 1-, 2-, and 3-year survival rates when compared with a historical control group with HER2/neu(+) appendicular osteosarcoma treated with amputation and chemotherapy alone. These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease can induce HER2/neu-specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings, therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu(+) cancers. Clin Cancer Res; 22(17); 4380-90. ©2016 AACR. ©2016 American Association for Cancer Research.

Synthesis and biological evaluation of several dephosphonated analogues of CMP-Neu5Ac as inhibitors of GM3-synthase.

Science.gov (United States)

Rota, Paola; Cirillo, Federica; Piccoli, Marco; Gregorio, Antonio; Tettamanti, Guido; Allevi, Pietro; Anastasia, Luigi

2015-10-05

Previous studies demonstrated that reducing the GM3 content in myoblasts increased the cell resistance to hypoxic stress, suggesting that a pharmacological inhibition of the GM3 synthesis could be instrumental for the development of new treatments for ischemic diseases. Herein, the synthesis of several dephosphonated CMP-Neu5Ac congeners and their anti-GM3-synthase activity is reported. Biological activity testes revealed that some inhibitors almost completely blocked the GM3-synthase activity in vitro and reduced the GM3 content in living embryonic kidney 293A cells, eventually activating the epidermal growth factor receptor (EGFR) signaling cascade. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

File list: Unc.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Brain mm9 Unclassified Neural Brain SRX1125793,SRX1125792,SRX21819...5,SRX218191,SRX218193,SRX218194,SRX017294,SRX1125795,SRX1125794,SRX1125796,SRX1125797,SRX218192 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Brain.bed ...

File list: Unc.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Brain mm9 Unclassified Neural Brain SRX218191,SRX1125793,SRX112579...2,SRX218193,SRX218192,SRX017294,SRX1125795,SRX1125794,SRX218195,SRX218194,SRX1125796,SRX1125797 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Brain.bed ...

File list: Oth.Neu.10.BMI1.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.BMI1.AllCell hg19 TFs and others BMI1 Neural SRX109477,SRX109480,SRX1094...82,SRX109479 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.10.BMI1.AllCell.bed ...

File list: Oth.Neu.05.BMI1.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.BMI1.AllCell hg19 TFs and others BMI1 Neural SRX109477,SRX109480,SRX1094...82,SRX109479 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.05.BMI1.AllCell.bed ...

File list: Oth.Neu.50.BMI1.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.BMI1.AllCell hg19 TFs and others BMI1 Neural SRX109477,SRX109480,SRX1094...82,SRX109479 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.50.BMI1.AllCell.bed ...

File list: Oth.Neu.20.BMI1.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.BMI1.AllCell hg19 TFs and others BMI1 Neural SRX109477,SRX109480,SRX1094...82,SRX109479 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.20.BMI1.AllCell.bed ...

File list: NoD.Neu.10.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Midbrain mm9 No description Neural Midbrain SRX002662,ERX102458,ER...X102459,ERX102460,ERX102461 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Midbrain.bed ...

File list: NoD.Neu.20.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Midbrain mm9 No description Neural Midbrain ERX102458,ERX102459,ER...X102460,ERX102461,SRX002662 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Midbrain.bed ...

File list: NoD.Neu.50.AllAg.Midbrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Midbrain mm9 No description Neural Midbrain ERX102458,ERX102459,ER...X102460,ERX102461,SRX002662 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.50.AllAg.Midbrain.bed ...

The role of natural selection in shaping genetic variation in a promising Chagas disease drug target: Trypanosoma cruzi trans-sialidase.

Science.gov (United States)

Gallant, Joseph P; Lima-Cordón, Raquel Asunción; Justi, Silvia A; Monroy, Maria Carlota; Viola, Toni; Stevens, Lori

2018-04-21

Rational drug design creates innovative therapeutics based on knowledge of the biological target to provide more effective and responsible therapeutics. Chagas disease, endemic throughout Latin America, is caused by Trypanosoma cruzi, a protozoan parasite. Current therapeutics are problematic with widespread calls for new approaches. Researchers are using rational drug design for Chagas disease and one target receiving considerable attention is the T. cruzi trans-sialidase protein (TcTS). In T. cruzi, trans-sialidase catalyzes the transfer of sialic acid from a mammalian host to coat the parasite surface membrane and avoid immuno-detection. However, the role of TcTS in pathology variance among and within genetic variants of the parasite is not well understood despite numerous studies. Previous studies reported the crystalline structure of TcTS and the TS protein structure in other trypanosomes where the enzyme is often inactive. However, no study has examined the role of natural selection in genetic variation in TcTS. To understand the role of natural selection in TcTS DNA sequence and protein variation, we examined a 471 bp portion of the TcTS gene from 48 T. cruzi samples isolated from insect vectors. Because there may be multiple parasite genotypes infecting one insect and there are multiple copies of TcTS per parasite genome, all 48 sequences had multiple polymorphic bases. To resolve these polymorphisms, we examined cloned sequences from two insect vectors. The data are analyzed to understand the role of natural selection in shaping genetic variation in TcTS and interpreted in light of the possible role of TcTS as a drug target. The analysis highlights negative or purifying selection on three amino acids previously shown to be important in TcTS transfer activity. One amino acid in particular, Tyr342, is a strong candidate for a drug target because it is under negative selection and amino acid substitutions inactivate TcTS transfer activity. Chagas disease

NeuRad detector prototype pulse shape study

Science.gov (United States)

Muzalevsky, I.; Chudoba, V.; Belogurov, S.; Kiselev, O.; Bezbakh, A.; Fomichev, A.; Krupko, S.; Slepnev, R.; Kostyleva, D.; Gorshkov, A.; Ovcharenko, E.; Schetinin, V.

2018-04-01

The EXPERT setup located at the Super-FRS facility, the part of the FAIR complex in Darmstadt, Germany, is intended for investigation of properties of light exotic nuclei. One of its modules, the high granularity neutron detector NeuRad assembled from a large number of the scintillating fiber is intended for registration of neutrons emitted by investigated nuclei in low-energy decays. Feasibility of the detector strongly depends on its timing properties defined by the spatial distribution of ionization, light propagation inside the fibers, light emission kinetics and transition time jitter in the multi-anode photomultiplier tube. The first attempt of understanding the pulse formation in the prototype of the NeuRad detector by comparing experimental results and Monte Carlo (MC) simulations is reported in this paper.

Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics.

Directory of Open Access Journals (Sweden)

Sunita Gulati

2015-12-01

Full Text Available Neisseria gonorrhoeae deploys a novel immune evasion strategy wherein the lacto-N-neotetraose (LNnT structure of lipooligosaccharide (LOS is capped by the bacterial sialyltransferase, using host cytidine-5'-monophosphate (CMP-activated forms of the nine-carbon nonulosonate (NulO sugar N-acetyl-neuraminic acid (Neu5Ac, a sialic acid (Sia abundant in humans. This allows evasion of complement-mediated killing by recruiting factor H (FH, an inhibitor of the alternative complement pathway, and by limiting classical pathway activation ("serum-resistance". We utilized CMP salts of six additional natural or synthetic NulOs, Neu5Gc, Neu5Gc8Me, Neu5Ac9Ac, Neu5Ac9Az, legionaminic acid (Leg5Ac7Ac and pseudaminic acid (Pse5Ac7Ac, to define structural requirements of Sia-mediated serum-resistance. While all NulOs except Pse5Ac7Ac were incorporated into the LNnT-LOS, only Neu5Gc incorporation yielded high-level serum-resistance and FH binding that was comparable to Neu5Ac, whereas Neu5Ac9Az and Leg5Ac7Ac incorporation left bacteria fully serum-sensitive and did not enhance FH binding. Neu5Ac9Ac and Neu5Gc8Me rendered bacteria resistant only to low serum concentrations. While serum-resistance mediated by Neu5Ac was associated with classical pathway inhibition (decreased IgG binding and C4 deposition, Leg5Ac7Ac and Neu5Ac9Az incorporation did not inhibit the classical pathway. Remarkably, CMP-Neu5Ac9Az and CMP-Leg5Ac7Ac each prevented serum-resistance despite a 100-fold molar excess of CMP-Neu5Ac in growth media. The concomitant presence of Leg5Ac7Ac and Neu5Ac on LOS resulted in uninhibited classical pathway activation. Surprisingly, despite near-maximal FH binding in this instance, the alternative pathway was not regulated and factor Bb remained associated with bacteria. Intravaginal administration of CMP-Leg5Ac7Ac to BALB/c mice infected with gonorrhea (including a multidrug-resistant isolate reduced clearance times and infection burden. Bacteria recovered

File list: ALL.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Induced_neural_progenitors mm9 All antigens Neural Induced neural progeni....biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: ALL.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Induced_neural_progenitors mm9 All antigens Neural Induced neural progeni....biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Induced_neural_progenitors.bed ...

N-Acetylneuraminic acid attenuates hypercoagulation on high fat diet-induced hyperlipidemic rats

Directory of Open Access Journals (Sweden)

Zhang Yida

2015-12-01

Full Text Available Background and objective: N-Acetylneuraminic acid (Neu5Ac, a type of sialic acid, has close links with cholesterol metabolism and is often used as a biomarker in evaluating the risk of cardiovascular diseases. However, most studies on the health implications of Neu5Ac have focused on its effects on the nervous system, while its effects on cardiovascular risk factors have largely been unreported. Thus, the effects of Neu5Ac on coagulation status in high fat diet (HFD-induced hyperlipidemic rats were evaluated in this study. Methods: Sprague Dawley male rats were divided into five different groups and fed with HFD alone, HFD low-dose Neu5Ac, HFD high-dose Neu5Ac, HFD simvastatin (10 mg/kg day, and normal pellet alone. Food was given ad libitum while body weight of rats was measured weekly. After 12 weeks of intervention, rats were sacrificed and serum and tissue samples were collected for biochemistry and gene expression analysis, respectively. Results: The results showed that Neu5Ac could improve lipid metabolism and hyperlipidemia-associated coagulation. Neu5Ac exerted comparable or sometimes better physiological effects than simvastatin, at biochemical and gene expression levels. Conclusions: The data indicated that Neu5Ac prevented HFD-induced hyperlipidemia and associated hypercoagulation in rats through regulation of lipid-related and coagulation-related genes and, by extension, induced metabolite and protein changes. The implications of the present findings are that Neu5Ac may be used to prevent coagulation-related cardiovascular events in hyperlipidemic conditions. These findings are worth studying further.

File list: InP.Neu.10.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Neurons mm9 Input control Neural Neurons SRX798995,SRX798994,SRX79...9006,SRX798993,SRX799007,SRX799005 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Neurons.bed ...

File list: InP.Neu.50.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Neurons mm9 Input control Neural Neurons SRX799007,SRX798994,SRX79...9006,SRX798993,SRX798995,SRX799005 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Neurons.bed ...

File list: InP.Neu.20.AllAg.Neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Neurons mm9 Input control Neural Neurons SRX799007,SRX798994,SRX79...9006,SRX799005,SRX798995,SRX798993 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Neurons.bed ...

File list: InP.Neu.20.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Forebrain mm9 Input control Neural Forebrain SRX377677,SRX377675,S...RX377679,SRX377673,SRX669236,SRX377671 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Forebrain.bed ...

File list: Pol.Neu.10.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Cortical_neuron mm9 RNA polymerase Neural Cortical neuron SRX21773...5,SRX759296,SRX217736,SRX759295,SRX759293,SRX759294 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Cortical_neuron.bed ...

File list: Pol.Neu.20.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Cortical_neuron mm9 RNA polymerase Neural Cortical neuron SRX75929...5,SRX759296,SRX217735,SRX759294,SRX759293,SRX217736 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Cortical_neuron.bed ...

File list: Pol.Neu.05.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Cortical_neuron mm9 RNA polymerase Neural Cortical neuron SRX21773...5,SRX217736,SRX759296,SRX759293,SRX759294,SRX759295 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Cortical_neuron.bed ...

File list: Pol.Neu.50.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Cortical_neuron mm9 RNA polymerase Neural Cortical neuron SRX75929...5,SRX759296,SRX759293,SRX759294,SRX217735,SRX217736 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Cortical_neuron.bed ...

File list: InP.Neu.10.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Forebrain mm9 Input control Neural Forebrain SRX377679,SRX669236,S...RX377677,SRX377675,SRX377673,SRX377671 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Forebrain.bed ...

File list: InP.Neu.50.AllAg.Forebrain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Forebrain mm9 Input control Neural Forebrain SRX377679,SRX377675,S...RX377677,SRX377673,SRX669236,SRX377671 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Forebrain.bed ...

File list: InP.Neu.05.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Hippocampus mm9 Input control Neural Hippocampus SRX769389,SRX2484...70,SRX216313,SRX517457,SRX248471,SRX517454 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Hippocampus.bed ...

File list: InP.Neu.10.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Hippocampus mm9 Input control Neural Hippocampus SRX248470,SRX7693...89,SRX216313,SRX517457,SRX517454,SRX248471 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Hippocampus.bed ...

File list: InP.Neu.20.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Hippocampus mm9 Input control Neural Hippocampus SRX248470,SRX7693...89,SRX517454,SRX517457,SRX216313,SRX248471 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Hippocampus.bed ...

File list: InP.Neu.50.AllAg.Hippocampus [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Hippocampus mm9 Input control Neural Hippocampus SRX248470,SRX7693...89,SRX517454,SRX517457,SRX216313,SRX248471 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Hippocampus.bed ...

File list: Unc.Neu.05.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Neural_progenitor_cells mm9 Unclassified Neural Neural progenitor ...cells http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Neural_progenitor_cells.bed ...

File list: Unc.Neu.20.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Neural_progenitor_cells mm9 Unclassified Neural Neural progenitor ...cells http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Neural_progenitor_cells.bed ...

File list: His.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 Histone Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: His.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 Histone Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Unc.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 Unclassified Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Unc.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 Unclassified Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Unc.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 Unclassified Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Unc.Neu.50.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Induced_neural_progenitors mm9 Unclassified Neural Induced neural ...progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Induced_neural_progenitors.bed ...

File list: Unc.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Induced_neural_progenitors mm9 Unclassified Neural Induced neural ...progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.10.AllAg.Induced_neural_progenitors.bed ...

File list: Unc.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Induced_neural_progenitors mm9 Unclassified Neural Induced neural ...progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: Unc.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Cerebellar_granule_neurons mm9 Unclassified Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: His.Neu.05.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Cerebellar_granule_neurons mm9 Histone Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Cerebellar_granule_neurons.bed ...

File list: His.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Cerebellar_granule_neurons mm9 Histone Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: His.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Cerebellar_granule_neurons mm9 Histone Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: Unc.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Cerebellar_granule_neurons mm9 Unclassified Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: Unc.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Cerebellar_granule_neurons mm9 Unclassified Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: His.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Cerebellar_granule_neurons mm9 Histone Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: Pol.Neu.50.RNA_Polymerase_III.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.RNA_Polymerase_III.AllCell mm9 RNA polymerase RNA Polymerase III Neural ...http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.RNA_Polymerase_III.AllCell.bed ...

File list: Unc.Neu.20.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Induced_neural_progenitors mm9 Unclassified Neural Induced neural progeni...tors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Induced_neural_progenitors.bed ...

File list: DNS.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 DNase-seq Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: DNS.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 DNase-seq Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Pol.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 RNA polymerase Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Pol.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 RNA polymerase Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: DNS.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 DNase-seq Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Pol.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 RNA polymerase Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: His.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 Histone Neural Nerve Sheath Neoplasms h...ttp://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: His.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 Histone Neural Nerve Sheath Neoplasms h...ttp://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: DNS.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 DNase-seq Neural Nerve Sheath Neoplasms... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Unc.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 Unclassified Neural Nerve Sheath Neopla...sms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: DNS.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 DNase-seq Neural Nerve Sheath Neoplasms... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Unc.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 Unclassified Neural Nerve Sheath Neopla...sms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: DNS.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 DNase-seq Neural Nerve Sheath Neoplasms... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: DNS.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 DNase-seq Neural Nerve Sheath Neoplasms... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: His.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 Histone Neural Nerve Sheath Neoplasms h...ttp://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Unc.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 Unclassified Neural Nerve Sheath Neopla...sms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Unc.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: His.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 Histone Neural Nerve Sheath Neoplasms h...ttp://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Pol.Neu.05.RNA_polymerase_III.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.RNA_polymerase_III.AllCell hg19 RNA polymerase RNA polymerase III Neural... http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.05.RNA_polymerase_III.AllCell.bed ...

File list: Pol.Neu.50.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Induced_neural_progenitors mm9 RNA polymerase Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Induced_neural_progenitors.bed ...

File list: Pol.Neu.20.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Induced_neural_progenitors mm9 RNA polymerase Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Induced_neural_progenitors.bed ...

File list: Pol.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Induced_neural_progenitors mm9 RNA polymerase Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: Pol.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Induced_neural_progenitors mm9 RNA polymerase Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Induced_neural_progenitors.bed ...

File list: Pol.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Cerebellar_granule_neurons mm9 RNA polymerase Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: Pol.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Cerebellar_granule_neurons mm9 RNA polymerase Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: Pol.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Cerebellar_granule_neurons mm9 RNA polymerase Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: NoD.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Brain mm9 No description Neural Brain ERX161927,ERX161926,ERX16192...274,SRX298040,ERX402277,ERX402292,ERX402281 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.05.AllAg.Brain.bed ...

File list: NoD.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Brain mm9 No description Neural Brain ERX161927,ERX161921,ERX16193...284,ERX402259,ERX402286,ERX402292,ERX402281 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Brain.bed ...

File list: NoD.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Brain mm9 No description Neural Brain ERX161927,ERX161921,SRX29803...270,ERX402277,ERX402286,ERX402292,ERX402281 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Brain.bed ...

File list: NoD.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Brain mm9 No description Neural Brain ERX161927,ERX161921,ERX16193...297,ERX402286,ERX402289,ERX402292,ERX402281 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.50.AllAg.Brain.bed ...

File list: DNS.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Induced_neural_progenitors mm9 DNase-seq Neural Induced neural progeni...tors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Induced_neural_progenitors.bed ...

File list: DNS.Neu.50.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Induced_neural_progenitors mm9 DNase-seq Neural Induced neural progeni...tors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Induced_neural_progenitors.bed ...

File list: Pol.Neu.10.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Neural_progenitor_cells mm9 RNA polymerase Neural Neural progenito...r cells http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Neural_progenitor_cells.bed ...

File list: Pol.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 RNA polymerase Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Pol.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 RNA polymerase Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Pol.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 RNA polymerase Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Pol.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 RNA polymerase Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: DNS.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Induced_neural_progenitors mm9 DNase-seq Neural Induced neural pro...genitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: Oth.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Cerebellar_granule_neurons mm9 TFs and others Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: Oth.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Cerebellar_granule_neurons mm9 TFs and others Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: Oth.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Cerebellar_granule_neurons mm9 TFs and others Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: Oth.Neu.05.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Cerebellar_granule_neurons mm9 TFs and others Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Cerebellar_granule_neurons.bed ...

Concordance Between FISH Analysis of Her-2/Neu Gene in Breast Duct Carcinoma and Corresponding Axillary Nodal Metastases: Egyptian National Cancer Institute Experience.

Science.gov (United States)

Badawy, Omnia M; Hassan, Hannan; ELBakey, Heba A; Mosaad, Maha

2018-05-10

Breast cancer is a major health problem in Egypt. Her-2/Neu gene is routinely assessed for all breast cancer patients primarily by immunohistochemistry. At National Cancer Institute (NCI), Cairo University, Flourescence In Situ hybridization (FISH) analysis of Her-2/Neu gene is carried out for Her-2/Neu score 2 and for some cases of score 3 (particularly those assessed outside NCI). The test is performed essentially on the primary tumor. However, some situations require testing on corresponding lymph node metastases. There is a debate about the concordance between Her-2/Neu status in the primary tumor and synchronous lymph node metastases in various studies. The aim of this study was to test for the concordance between Her-2/Neu status in the primary breast tumor and corresponding axillary nodal metastases. This is a retrospective study in which FISH analysis of Her-2/Neu was carried out simultaneously on archived material of 50 cases previously diagnosed as invasive duct carcinoma and the corresponding nodal metastases from the Pathology Department, NCI. There was complete concordance between Her-2 status in the primary tumor and the corresponding axillary lymph node metastatic deposits in which Her-2 was amplified in 44% of the studied cohort of Egyptian patients. Her-2/Neu gene assessed by FISH analysis on synchronous lymph node metastases is strongly correlated with the primary tumor. Hence, it is justified to carry out the Her-2/Neu test on synchronous lymph nodes to decide on whether to carry out anti-Her-2/Neu target therapy. Further studies on other metastatic sites is recommended.

Ascorbic acid prevents nonreceptor specific binding of [3H]-5-hydroxytryptamine to bovine cerebral cortex membranes

International Nuclear Information System (INIS)

Hamblin, M.W.; Adriaenssens, P.I.; Ariani, K.; Cawthon, R.M.; Stratford, C.A.; Tan, G.L.; Ciaranello, R.D.

1987-01-01

[ 3 H]-5-Hydroxytryptamine ([ 3 H]-5-HT) decomposes rapidly when exposed to air in solution at physiological pH if antioxidants are not present. The decomposition products appear to bind to two saturable sites on brain membranes (apparent Kd values = 1-2 and 100-1000 nM). This binding mimics ''specific'' ligand/receptor binding in that it is inhibited by 10 microM unlabeled 5-HT. This inhibition is not competitive, but rather is due to the prevention of [ 3 H]-5-HT breakdown by excess unlabeled 5-HT. Unlike genuine ligand/receptor binding, the binding of [ 3 H]-5-HT breakdown products is essentially irreversible and does not display a tissue distribution consistent with binding to authentic 5-HT receptors. [ 3 H]-5-HT decomposition can be eliminated by the inclusion of 0.05 to 5 mM ascorbic acid. At these concentrations ascorbic acid is not deleterious to reversible [ 3 H]-5-HT binding. When [ 3 H] 5-HT exposure to air occurs in the presence of brain membranes, the apparent antioxidant activity of brain membranes themselves affords protection against [ 3 H]-5-HT degradation equal to ascorbic acid. This protection is effective below final [ 3 H]-5-HT concentrations of 10 nM. Above 10 nM [ 3 H]-5-HT, addition of ascorbic acid or other antioxidants is necessary to avoid the occurrence of additional low affinity (apparent Kd = 15-2000 nM) binding sites that are specific but nonetheless irreversible. When care is taken to limit [ 3 H]-5-HT oxidation, the only reversible and saturable specific binding sites observed are of the 5-HT1 high affinity (Kd = 1-2 nM) type. Radioligand oxidation artifacts may be involved in previous reports of low affinity (Kd = 15-250 nM) [ 3 H]-5-HT binding sites in brain membrane preparations

File list: InP.Neu.20.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Brain mm9 Input control Neural Brain SRX236086,ERX132888,ERX132890...1027841,ERX1027839,ERX1027840,ERX513118,SRX150261,ERX513117 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Brain.bed ...

File list: InP.Neu.50.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Brain mm9 Input control Neural Brain SRX236086,ERX132888,ERX132890...ERX646161,ERX513118,ERX646137,ERX646145,ERX513117,SRX150261 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Brain.bed ...

File list: InP.Neu.05.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Brain mm9 Input control Neural Brain SRX236086,SRX116256,SRX116257...RX997759,SRX680477,ERX1027841,SRX150261,ERX513118,ERX513117 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Brain.bed ...

File list: InP.Neu.10.AllAg.Brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Brain mm9 Input control Neural Brain SRX236086,ERX279248,ERX279249...513118,ERX1027841,ERX1027839,ERX1027840,SRX150261,ERX513117 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Brain.bed ...

Optimized preparation and preliminary evaluation of [64Cu]-DOTA-trastuzumab for targeting ErbB2/Neu expression

International Nuclear Information System (INIS)

Behrooz Alirezapour; Mohammad Javad Rasaee

2013-01-01

Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing field of work in nuclear medicine research. Trastuzumab is a monoclonal antibody that binds with high affinity to HER2/neu, which is over expressed on breast and other tumors. Developing new tracers for the detection of this cancer is of great interest. In this study, trastuzumab was successively labeled with [ 64 Cu]CuCl 2 after conjugation with DOTA-NHS-ester. The conjugate was purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometric method. DOTA-trastuzumab was labeled with 64 Cu produced by 68 Zn(p,αn) 64 Cu nuclear reaction (30 MeV protons at 180 μA). Radiochemical purity, integrity of protein after radiolabeling and immunoreactivity of radiolabeled mAb trastuzumab with HER2/neu antigen and SkBr3 cell line were performed by RIA. In vitro stability of radiolabeled mAb in human serum was determined by thin layer chromatography. In vitro internalization studies were performed with the SkBr3 cell line and the tissue biodistribution of the 64 Cu-DOTA-trastuzumab was evaluated in wild-type rat (90 ± 5.5 μCi, 2, 6, 12, 24 h p.i.). The radioimmunoconjugate was prepared with a radiochemical purity of higher than 96 ± 0.5 % (ITLC) and specific activity as high as 5.3 μCi/μg. The average number of chelators per antibody for the conjugate used in this study was 5.8/1. The sample was showed to have similar patterns of migration in the gel electrophoresis. The 64 Cu-DOTA-trastuzumab showed high immunoreactivity towards HER2/neu antigen and SkBr3 cell line. In vitro stability of the labeled product was found to be more than 94 % in PBS and 82 ± 0.5 % in human serum over 48 h. In vitro internalization studies of the 64 Cu-DOTA-trastuzumab showed that up to 11.5 % of the radioimmunoconjugate internalized after 10 h. The accumulation of the radiolabeled mAb in liver, skin, intestine, lung

File list: His.Neu.20.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Induced_neural_progenitors mm9 Histone Neural Induced neural progeni...tors SRX667381,SRX668240 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Induced_neural_progenitors.bed ...

File list: His.Neu.50.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Induced_neural_progenitors mm9 Histone Neural Induced neural progeni...tors SRX667381,SRX668240 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Induced_neural_progenitors.bed ...

File list: InP.Neu.20.Input_control.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.Input_control.AllCell hg19 Input control Input control Neural SRX643470,...SRX026881 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/InP.Neu.20.Input_control.AllCell.bed ...

File list: Oth.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 TFs and others Neural Superior Cervical Ganglion... SRX435084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: ALL.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 All antigens Neural Superior Cervical Ganglion... SRX435084,SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: ALL.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 All antigens Neural Superior Cervical Ganglion... SRX435084,SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: ALL.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 All antigens Neural Superior Cervical Ganglion... SRX435084,SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: ALL.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 All antigens Neural Superior Cervical Ganglion... SRX435084,SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Oth.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 TFs and others Neural Superior Cervical Ganglion... SRX435084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Oth.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 TFs and others Neural Superior Cervical Ganglion... SRX435084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Oth.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 TFs and others Neural Superior Cervical Ganglion... SRX435084 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: ALL.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 All antigens Neural Nerve Sheath Neopla...sms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Oth.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 TFs and others Neural Nerve Sheath Neop...lasms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Oth.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 TFs and others Neural Nerve Sheath Neop...lasms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Oth.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 TFs and others Neural Nerve Sheath Neop...lasms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: ALL.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 All antigens Neural Nerve Sheath Neopla...sms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: Oth.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 TFs and others Neural Nerve Sheath Neop...lasms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: ALL.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 All antigens Neural Nerve Sheath Neopla...sms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: ALL.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 All antigens Neural Nerve Sheath Neopla...sms SRX337965 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: NoD.Neu.20.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Adult_brains hg19 No description Neural Adult brains ERX161917,SRX...019404 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.20.AllAg.Adult_brains.bed ...

File list: NoD.Neu.50.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Adult_brains hg19 No description Neural Adult brains ERX161917,SRX...019404 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.50.AllAg.Adult_brains.bed ...

File list: NoD.Neu.05.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Adult_brains hg19 No description Neural Adult brains SRX019404,ERX...161917 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.05.AllAg.Adult_brains.bed ...

File list: NoD.Neu.10.AllAg.Adult_brains [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Adult_brains hg19 No description Neural Adult brains ERX161917,SRX...019404 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.10.AllAg.Adult_brains.bed ...

File list: InP.Neu.10.Input_control.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.Input_control.AllCell hg19 Input control Input control Neural SRX643470,...RX1035591 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/InP.Neu.10.Input_control.AllCell.bed ...

File list: His.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Induced_neural_progenitors mm9 Histone Neural Induced neural proge...nitors SRX667381,SRX668240 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: His.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Induced_neural_progenitors mm9 Histone Neural Induced neural proge...nitors SRX667381,SRX668240 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Induced_neural_progenitors.bed ...

File list: InP.Neu.20.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Cerebellum mm9 Input control Neural Cerebellum SRX026435,SRX026436...38,SRX685924,SRX685922,SRX022872,SRX150265,SRX019017,SRX022867,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Cerebellum.bed ...

File list: InP.Neu.05.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Cerebellum mm9 Input control Neural Cerebellum SRX026438,SRX026435...53,SRX685923,SRX669238,SRX150265,SRX019017,SRX685922,SRX685924,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Cerebellum.bed ...

File list: InP.Neu.10.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Cerebellum mm9 Input control Neural Cerebellum SRX026438,SRX026435...17,SRX685924,SRX150265,SRX022872,SRX669238,SRX685923,SRX685922,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Cerebellum.bed ...

File list: InP.Neu.50.AllAg.Cerebellum [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Cerebellum mm9 Input control Neural Cerebellum SRX026435,SRX026436...24,SRX685923,SRX022872,SRX150265,SRX022867,SRX019017,SRX685922,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Cerebellum.bed ...

File list: Pol.Neu.20.RNA_Polymerase_II.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.RNA_Polymerase_II.AllCell mm9 RNA polymerase RNA Polymerase II Neural SR...,SRX685285,SRX217736 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Pol.Neu.20.RNA_Polymerase_II.AllCell.bed ...

File list: DNS.Neu.50.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Neural_progenitor_cells mm9 DNase-seq Neural Neural progenitor cel...ls SRX238870,SRX238868 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Neural_progenitor_cells.bed ...

File list: DNS.Neu.05.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.05.AllAg.Neural_progenitor_cells mm9 DNase-seq Neural Neural progenitor cel...ls SRX238870,SRX238868 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.05.AllAg.Neural_progenitor_cells.bed ...

File list: DNS.Neu.10.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Neural_progenitor_cells mm9 DNase-seq Neural Neural progenitor cel...ls SRX238868,SRX238870 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Neural_progenitor_cells.bed ...

File list: InP.Neu.05.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Cortical_neuron mm9 Input control Neural Cortical neuron SRX671676...74,SRX671672,SRX671651 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Cortical_neuron.bed ...

File list: InP.Neu.10.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Cortical_neuron mm9 Input control Neural Cortical neuron SRX671669...47,SRX671651,SRX671674 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Cortical_neuron.bed ...

File list: InP.Neu.20.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Cortical_neuron mm9 Input control Neural Cortical neuron SRX671659...76,SRX671651,SRX671655 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Cortical_neuron.bed ...

File list: InP.Neu.50.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Cortical_neuron mm9 Input control Neural Cortical neuron SRX804268...76,SRX671651,SRX671655 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Cortical_neuron.bed ...

File list: Oth.Neu.50.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Induced_neural_progenitors mm9 TFs and others Neural Induced neural... progenitors SRX323564,SRX323573 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.50.AllAg.Induced_neural_progenitors.bed ...

File list: Oth.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Induced_neural_progenitors mm9 TFs and others Neural Induced neural... progenitors SRX323573,SRX323564 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: Oth.Neu.20.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Induced_neural_progenitors mm9 TFs and others Neural Induced neural... progenitors SRX323564,SRX323573 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Induced_neural_progenitors.bed ...

File list: DNS.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Cerebellar_granule_neurons mm9 DNase-seq Neural Cerebellar granule neurons... SRX685885,SRX685882,SRX685880 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: ALL.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.50.AllAg.Cerebellar_granule_neurons mm9 All antigens Neural Cerebellar granule neurons... SRX685885,SRX685882,SRX685880 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: ALL.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.20.AllAg.Cerebellar_granule_neurons mm9 All antigens Neural Cerebellar granule neurons... SRX685885,SRX685882,SRX685880 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: DNS.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Cerebellar_granule_neurons mm9 DNase-seq Neural Cerebellar granule neurons... SRX685885,SRX685882,SRX685880 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: His.Neu.20.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Fetal_brain hg19 Histone Neural Fetal brain SRX860887,SRX860879,SR...X860886,SRX860883,SRX860881,SRX860885,SRX860884,SRX860880,SRX860888,SRX860882 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.20.AllAg.Fetal_brain.bed ...

File list: His.Neu.05.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Cortical_neuron mm9 Histone Neural Cortical neuron SRX671646,SRX10...759263,SRX759264,SRX759260,SRX759261,SRX759256,SRX759258,SRX759259,SRX759262,SRX759272 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Cortical_neuron.bed ...

File list: His.Neu.10.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Cortical_neuron mm9 Histone Neural Cortical neuron SRX1057033,SRX6...759261,SRX759255,SRX759258,SRX759262,SRX759257,SRX759259,SRX759272,SRX759267,SRX759264 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.10.AllAg.Cortical_neuron.bed ...

File list: His.Neu.50.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Cortical_neuron mm9 Histone Neural Cortical neuron SRX671649,SRX67...759268,SRX759267,SRX759263,SRX759264,SRX759273,SRX759262,SRX759259,SRX759261,SRX759272 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.50.AllAg.Cortical_neuron.bed ...

File list: His.Neu.20.AllAg.Cortical_neuron [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Cortical_neuron mm9 Histone Neural Cortical neuron SRX671649,SRX67...759260,SRX759258,SRX759267,SRX759262,SRX759259,SRX759261,SRX759263,SRX759264,SRX759272 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Cortical_neuron.bed ...

File list: His.Neu.05.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Fetal_brain hg19 Histone Neural Fetal brain SRX860887,SRX860886,SR...X860885,SRX860881,SRX860879,SRX860888,SRX860880,SRX860883,SRX860884,SRX860882 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.05.AllAg.Fetal_brain.bed ...

File list: His.Neu.10.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Fetal_brain hg19 Histone Neural Fetal brain SRX860887,SRX860886,SR...X860879,SRX860888,SRX860880,SRX860881,SRX860885,SRX860883,SRX860884,SRX860882 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.10.AllAg.Fetal_brain.bed ...

Cytolytic tests with hyperimmune patient sera is a good prognostic tool in racotumomab immunotherapy in advanced non-small cell lung cancer

Directory of Open Access Journals (Sweden)

Necdet Uskent

2017-10-01

Full Text Available Aberrant accumulation of a specific sialic acid has been shown to exist in many human malignant cell membranes termed as N-glycolyl neuraminic acid (NeuGc. This particular ganglioside do not normally exist in normal human cells, due to the lack of an enzyme (cytidine monophospho-N-acetyl-neuraminic acid which is responsible for the synthesis of N—glycolyl neurominic acid. The aberrant expression of NeuGcGM3 ganglioside in the cell surface of certain human tumors, made this molecule an attractive target for immunotherapy. By using 14 F7 monoclonal antibody directed to identify NeuGcGM3 in the tumor tissue, it is possible to select patients for anti-NeuGcGM3 immunotherapy. Racotumomab is an anti-idiotype vaccine, being a mirror image of NeuGcGm3 mimics this ganglioside and triggers an immune response. Antibodies reactive to NeuGcGM3 ganglioside in the vaccinated patient’s sera have cytotoxic anti-tumor properties which can be assessed in L1210 cell line, expressing this ganglioside.In this study, we monitored 12 patients with advanced non-small cell lung cancer (NSCLC who are on racotumomab vaccine maintenance following chemotherapy. Cytotoxic tests with vaccinated patients’ sera were performed using L1210 cell lines at the 3rd, 6th, 9th, and 12th months of vaccination and the results were compared with clinical outcomes. Serum antibodies to NeuGcGm3 ganglioside were also checked before initiation and thereafter with the same intervals. The aim of the study was to investigate the value of antibodies and cytotoxic test as biomarkers for treatment outcome. Our observation confirmed that consistently higher cytotoxicity rates in the cell culture correlated with better progression free survivals of the patients who are on racotumomab maintenance.

Biosynthesis of the polysialic acid capsule of Escherichia coli K1: factors influencing cessation of capsule expression at 150C

International Nuclear Information System (INIS)

Merker, R.I.

1987-01-01

Initial experiments were designed to determine if increases in unsaturated fatty acids (UFA) that usually occur in cells grown at 15 0 C were related to defects in membrane-associated sialyltransferase (ST) activity at 15 0 C. An E. coli K1 hybrid strain that did not increase UFA levels after growth at 15 0 C due to a mutant fabF gene was constructed. Isogenic strains with and without the fabF defect produced capsule at 33 0 C but not at 15 0 C. Membranous ST complexes isolated from both strains grown at 33 0 C transfered [ 14 C]-sialic acid (NeuNAC) from CMP-[ 14 C]-NeuNAc to endogeneous acceptors and to exogenous sialyl oligomers. Membranes from 15 0 C grown cells of the fabF + strain catalyzed incorporation of [ 14 C]NeuNAc from CMP-[ 14 C]-NeuNAc to exogenous sialyl oligomers, but required 2-4 h incubation at 33 0 C for endogenous incorporation. Membranes from the fabF mutant strain grown at 15 0 C did not incorporate [ 14 C]NeuNAc from CMP-[ 14 C]-NeuNAc under these conditions. We concluded that membrane-associated ST activity is not interrupted by low temperature increases in UFA content. Acapsular mutants derived from E. coli K1 that were defective in NeuNAc catabolism (NeuNAc aldolase) and activation or polymerization were used to examine the effects of growth at 15 0 C on NeuNAc synthesis and initiation of polysialic acid capsule synthesis. These strains accumulated high internal NeuNAc internal NeuNAc at 37 0 C, but NeuNAc was undetectable after growth at 15 0 C. Intracellular NeuNAc levels increased within 10 min. after shift from 15 0 C to 37 0 C even in the presence of rifampicin (100 g ml -1 ) or chloramphenicol (100 g ml -1 ). Extracts from these strains grown at 15 0 C and 37 0 C lacked NeuNAc synthase activity in 15 0 C assays, but were active in 37 0 C assays. We conclude that NeuNAc synthase is present but nonfunctional at 15 0 C

Neu-Laxova syndrome in an appropriate for gestational age newborn

Directory of Open Access Journals (Sweden)

Dilli Dilek

2008-01-01

Full Text Available Neu-Laxova syndrome is a rare lethal congenital disorder involving multiple systems. Intrauterine growth retardation, ichthyosis, microcephaly, abnormal facial findings, and limb contractures are its key features. We present a case of Neu-Laxova syndrome in a male appropriate for gestational age (AGA newborn with characteristic features including ichthyosis, microcephaly, severe ectropion, rudimentary ears, eclabion, limb contractures, and hypoplastic genitalia. The patient was born at 38 weeks of gestation to consanguinous Turkish parents. The mother was a 20-year-old primi gravida with lack of prenatal follow-up. Therefore, the case was diagnosed postnatally, and he died 5 days later. Because of the autosomal recessive inheritance of Neu-Laxova syndrome, in countries with high rates of consanguineous marriage, such as Turkey, physicians have to know this syndrome, and serial prenatal ultrasound examinations with genetic counseling should be performed on pregnant women at high risk. To the best of our knowledge, this is the first case described in an AGA newborn.

File list: Oth.Neu.20.Epitope_tags.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.Epitope_tags.AllCell mm9 TFs and others Epitope tags Neural SRX275807,SR...SRX691799,SRX691794,SRX759286,SRX691798,SRX691797,SRX275809,SRX275811,SRX691795,SRX022866 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.Epitope_tags.AllCell.bed ...

File list: Pol.Neu.20.RNA_polymerase_II.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.RNA_polymerase_II.AllCell hg19 RNA polymerase RNA polymerase II Neural S...6,SRX743838,SRX743832,SRX743834,SRX743840 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.20.RNA_polymerase_II.AllCell.bed ...

File list: Oth.Neu.05.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.05.AllAg.Neural_progenitor_cells mm9 TFs and others Neural Neural progenito...r cells SRX109472,SRX315274,SRX109471,SRX802060 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.05.AllAg.Neural_progenitor_cells.bed ...

File list: Oth.Neu.20.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Neural_progenitor_cells mm9 TFs and others Neural Neural progenito...r cells SRX109472,SRX315274,SRX802060,SRX109471 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/Oth.Neu.20.AllAg.Neural_progenitor_cells.bed ...

File list: His.Neu.20.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Neural_progenitor_cells mm9 Histone Neural Neural progenitor cells... SRX315278,SRX667383,SRX668241,SRX315277,SRX315276 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.20.AllAg.Neural_progenitor_cells.bed ...

File list: His.Neu.05.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.05.AllAg.Neural_progenitor_cells mm9 Histone Neural Neural progenitor cells... SRX315277,SRX667383,SRX668241,SRX315278,SRX315276 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/His.Neu.05.AllAg.Neural_progenitor_cells.bed ...

File list: InP.Neu.50.Input_control.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.Input_control.AllCell mm9 Input control Input control Neural SRX109476,S...X685922,SRX145797,SRX150263,SRX150261 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.Input_control.AllCell.bed ...

File list: Pol.Neu.50.RNA_polymerase_II.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.RNA_polymerase_II.AllCell hg19 RNA polymerase RNA polymerase II Neural S...6,SRX743834,SRX743838,SRX743840,SRX743832 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.50.RNA_polymerase_II.AllCell.bed ...

File list: Pol.Neu.05.RNA_polymerase_II.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.RNA_polymerase_II.AllCell hg19 RNA polymerase RNA polymerase II Neural S...1,SRX099887,SRX099886,SRX743834,SRX743832 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.05.RNA_polymerase_II.AllCell.bed ...

File list: InP.Neu.05.Input_control.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.Input_control.AllCell mm9 Input control Input control Neural SRX236086,S...X668239,ERX513118,SRX150263,ERX513117 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.Input_control.AllCell.bed ...

File list: InP.Neu.20.Input_control.AllCell [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.Input_control.AllCell mm9 Input control Input control Neural SRX109476,S...X513118,SRX150261,ERX513117,SRX150263 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.Input_control.AllCell.bed ...

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

Science.gov (United States)

Press, M F; Pike, M C; Chazin, V R; Hung, G; Udove, J A; Markowicz, M; Danyluk, J; Godolphin, W; Sliwkowski, M; Akita, R

1993-10-15

The HER-2/neu proto-oncogene (also known as c-erb B-2) is homologous with, but distinct from, the epidermal growth factor receptor. Amplification of this gene in node-positive breast cancers has been shown to correlate with both earlier relapse and shorter overall survival. In node-negative breast cancer patients, the subgroup for which accurate prognostic data could make a significant contribution to treatment decisions, the prognostic utility of HER-2/neu amplification and/or overexpression has been controversial. The purpose of this report is to address the issues surrounding this controversy and to evaluate the prognostic utility of overexpression in a carefully followed group of patients using appropriately characterized reagents and methods. In this report we present data from a study of HER-2/neu expression designed specifically to test whether or not overexpression is associated with an increased risk of recurrence in node-negative breast cancers. From a cohort of 704 women with node-negative breast cancer who experienced recurrent disease (relapsed cases) 105 were matched with 105 women with no recurrence (disease-free controls) after the equivalent follow-up period. Immunohistochemistry was used to assess HER-2/neu expression in archival tissue blocks from both relapsed cases and their matched disease-free controls. Importantly, a series of molecularly characterized breast cancer specimens were used to confirm that the antibody used was of sufficient sensitivity and specificity to identify those cancers overexpressing the HER-2/neu protein in this formalin-fixed, paraffin-embedded tissue cohort. In addition, a quantitative approach was developed to more accurately assess the amount of HER-2/neu protein identified by immunostaining tumor tissue. This was done using a purified HER-2/neu protein synthesized in a bacterial expression vector and protein lysates derived from a series of cell lines, engineered to express a defined range of HER-2/neu oncoprotein

File list: ALL.Neu.05.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.05.AllAg.Cerebellar_granule_neurons mm9 All antigens Neural Cerebellar granule neurons... SRX685885,SRX685878,SRX685882,SRX685877,SRX685880,SRX685883 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.05.AllAg.Cerebellar_granule_neurons.bed ...

File list: ALL.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available ALL.Neu.10.AllAg.Cerebellar_granule_neurons mm9 All antigens Neural Cerebellar granule neurons... SRX685882,SRX685880,SRX685883,SRX685885,SRX685877,SRX685878 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/ALL.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: DNS.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.10.AllAg.Cerebellar_granule_neurons mm9 DNase-seq Neural Cerebellar granule neurons... SRX685882,SRX685880,SRX685883,SRX685885,SRX685877,SRX685878 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/DNS.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

Asymptomatic Changes in Cardiac Function Can Occur in DCIS Patients Following Treatment with HER-2/neu Pulsed Dendritic Cell Vaccines

Science.gov (United States)

Bahl, Susan; Roses, Robert; Sharma, Anupama; Koldovsky, Ursula; Xu, Shuwen; Weinstein, Susan; Nisenbaum, Harvey; Fox, Kevin; Pasha, Theresa; Zhang, Paul; Araujo, Louis; Carver, Joseph; Czerniecki, Brian J

2009-01-01

Background Targeting HER-2/neu with Trastuzumab has been associated with development of cardiac toxicity. Methods Twenty-seven patients with ductal carcinoma in situ (DCIS) of the breast completed an IRB approved clinical trial of a HER-2/neu targeted dendritic cell based vaccine. Four weekly vaccinations were administered prior to surgical resection. All subjects underwent pre- and post-vaccine cardiac monitoring by MUGA/ECHO scanning allowing for a comparison of cardiac function. Results In 3 of 27 vaccinated patients (11%) transient asymptomatic decrements in ejection fraction of greater than 15% were noted after vaccination. Notably, evidence of circulating anti-HER-2/neu antibody was found prior to vaccination in all three patients, but cardiac toxicity was not noted until induction of cellular mediated immune responses. Conclusions This is the first description of HER-2/neu targeted vaccination associated with an incidence of cardiac changes, and the induction of cellular immune responses combined with antibody may contribute to changes in cardiac function. PMID:19800453

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

Science.gov (United States)

Blanco, Rancés; Domínguez, Elizabeth; Morales, Orlando; Blanco, Damián; Martínez, Darel; Rengifo, Charles E.; Viada, Carmen; Cedeño, Mercedes; Rengifo, Enrique; Carr, Adriana

2015-01-01

The prognostic role of N-glycolyl GM3 ganglioside (NeuGcGM3) expression in non-small cell lung carcinoma (NSCLC) still remains controversial. In this study, the NeuGcGM3 expression was reevaluated using an increased number of NSCLC cases and the 14F7 Mab (a highly specific IgG1 raised against NeuGcGM3). An immunohistochemical score integrating the percentage of 14F7-positive cells and the intensity of reaction was applied to reassess the relationship between NeuGcGM3 expression, some clinicopathological features, and the overall survival (OS) of NSCLC patients. The double and the triple expression of NeuGcGM3 with the epidermal growth factor receptor (EGFR) and/or its ligand, the epidermal growth factor (EGF), were also evaluated. NeuGcGM3 expression correlates with both S-Phase fraction (p = 0.006) and proliferation index (p = 0.000). Additionally, NeuGcGM3 expression was associated with a poor OS of patients in both univariate (p = 0.020) and multivariate (p = 0.010) analysis. Moreover, the double and/or the triple positivity of tumors to NeuGcGM3, EGFR, and/or EGF permitted us to identify phenotypes of NSCLC with a more aggressive biological behavior. Our results are in agreement with the negative prognostic significance of NeuGcGM3 expression in NSCLC patients. However, standardization of techniques to determine the expression of NeuGcGM3 in NSCLC as well as the implementation of a universal scoring system is recommended. PMID:26634172

Synthesis of specifically 2H-labeled reserpines, 3,4,5-trimethoxybenzoic acids, and syringic acid

International Nuclear Information System (INIS)

Roth, R.W.; Fischer, D.L.; Pachta, J.M.; Althaus, J.F.

1982-01-01

3,4,5-Trimethoxy- 2 H 9 -, 4-methoxy-3,5-dimethoxy- 2 H 6 , and 4-hydroxyl-3,5-dimethoxy- 2 H 6 -benzoic acids were prepared from n-propyl 3,4,5-trihydroxybenzoate (n-propyl gallate) by means of appropriate alkylation-hydrolysis sequences employing iodomethane- 2 H 3 or dimethyl- 2 H 6 -sulfate as the deuterium source. 4-Methoxy- 2 H 3 -3,5-dimethoxybenzoic acid was similarly prepared from ethyl 4-hydroxy-3,5-dimethoxybenzoate. The labeled trimethoxybenzoic acids were converted to the corresponding 2 H-labeled reserpines by condensation of the acid chlorides with methyl reserpate in pyridine according to the classical procedure. The labeled reserpine analog methyl 18-0-(4-hydroxy-3,5-dimethoxy- 2 H 6 )benzoyl reserpate was likewise prepared from 4-hydroxy-3,5-dimethoxy- 2 H 6 -benzoic acid via the intermediate methyl 18-0-(4-ethoxycarbonyloxy-3,5-dimethoxy- 2 H 6 -benzoyl)reserpate (syrosingopine- 2 H 6 ). The isotopic purity of each compound exceeded 99 atom percent 2 H. (author)

Improvement of trans-sialylation versus hydrolysis activity of an engineered sialidase from Trypanosoma rangeli by use of co-solvents

DEFF Research Database (Denmark)

Zeuner, Birgitte; Riisager, Anders; Mikkelsen, Jørn Dalgaard

2014-01-01

hexafluorophosphate), were examined as co-solvents for the improvement of the synthesis versus hydrolysis ratio in the trans-sialylation of lactose, catalysed by an engineered sialidase from Trypanosoma rangeli. The use of 25 % (v/v) t-butanol as co-solvent significantly increased 3'-sialyllactose production by 40...... % from 1.04 ± 0.09 to 1.47 ± 0.01 mM. The synthesis versus hydrolysis ratio increased correspondingly by 1.2-times. 1-2.5 % (v/v) EAN or [C2OHMIm][PF6] improved the synthesis versus hydrolysis ratio up to 2.5-times but simultaneously decreased the 3'-sialyllactose yield, probably due to enzyme...... inactivation caused by the ionic liquid. [MMIm][MeSO4] had a detrimental effect on the trans-sialylation yield and on the ratio between synthesis and hydrolysis....

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.

Science.gov (United States)

Madrid, Manuelito A; Lo, Raymundo W

2004-01-01

Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC). We assessed Her-2/neu alteration using CISH on formalin-fixed paraffin-embedded primary invasive ductal carcinoma tumors in which IHC (CB11 antibody) had previously been performed, and we compared the results with IHC. The 160 selected cases were equally stratified randomly into the four IHC categories (scores of 0, 1+, 2+, and 3+). We also compared age at diagnosis and tumor histologic grade with IHC and CISH Her-2/neu. We were able to perform and evaluate CISH successfully on all cases. The agreement between 3+ IHC and CISH-amplified cases as well as between all IHC and CISH Her-2/neu negative cases was 100%, and the concordance on all positive cases was 72.50%, with an overall agreement of 86.25%. All the discordant cases had 2+ IHC scores. Although we noted Her-2/neu positivity more in premenopausal women, the age at diagnosis was not significantly associated with IHC or CISH results. Similarly, although the small group of well-differentiated tumors was apparently Her-2/neu negative in both tests, no significant association was noted between any tumor histologic grade and either IHC or CISH results. CISH is easily integrated into routine testing in our laboratory. It is a necessary adjunct in determining the subset of non-amplified IHC-positive invasive tumors that will not benefit from trastuzumab therapy. Those cases with 2+ IHC results will be triaged and subjected to CISH. Her-2/neu testing should be done on all breast cancer cases regardless of age at presentation and tumor histologic grade.

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

International Nuclear Information System (INIS)

Madrid, Manuelito A; Lo, Raymundo W

2004-01-01

Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC). We assessed Her-2/neu alteration using CISH on formalin-fixed paraffin-embedded primary invasive ductal carcinoma tumors in which IHC (CB11 antibody) had previously been performed, and we compared the results with IHC. The 160 selected cases were equally stratified randomly into the four IHC categories (scores of 0, 1+, 2+, and 3+). We also compared age at diagnosis and tumor histologic grade with IHC and CISH Her-2/neu. We were able to perform and evaluate CISH successfully on all cases. The agreement between 3+ IHC and CISH-amplified cases as well as between all IHC and CISH Her-2/neu negative cases was 100%, and the concordance on all positive cases was 72.50%, with an overall agreement of 86.25%. All the discordant cases had 2+ IHC scores. Although we noted Her-2/neu positivity more in premenopausal women, the age at diagnosis was not significantly associated with IHC or CISH results. Similarly, although the small group of well-differentiated tumors was apparently Her-2/neu negative in both tests, no significant association was noted between any tumor histologic grade and either IHC or CISH results. CISH is easily integrated into routine testing in our laboratory. It is a necessary adjunct in determining the subset of non-amplified IHC-positive invasive tumors that will not benefit from trastuzumab therapy. Those cases with 2+ IHC results will be triaged and subjected to CISH. Her-2/neu testing should be done on all breast cancer cases regardless of age at presentation and tumor histologic grade

File list: NoD.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 No description Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: NoD.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 No description Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: NoD.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 No description Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: NoD.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 No description Neural Superior Cervical Ganglion... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: Unc.Neu.10.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.10.AllAg.Fetal_neural_progenitor_cells hg19 Unclassified Neural Fetal neural... progenitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.10.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: NoD.Neu.20.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Induced_neural_progenitors mm9 No description Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Induced_neural_progenitors.bed ...

File list: NoD.Neu.05.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Induced_neural_progenitors mm9 No description Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.05.AllAg.Induced_neural_progenitors.bed ...

File list: Unc.Neu.05.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.05.AllAg.Fetal_neural_progenitor_cells hg19 Unclassified Neural Fetal neural... progenitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.05.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: NoD.Neu.10.AllAg.Induced_neural_progenitors [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Induced_neural_progenitors mm9 No description Neural Induced neural... progenitors http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Induced_neural_progenitors.bed ...

File list: InP.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Cerebellar_granule_neurons mm9 Input control Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: InP.Neu.50.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Cerebellar_granule_neurons mm9 Input control Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Cerebellar_granule_neurons.bed ...

File list: NoD.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Cerebellar_granule_neurons mm9 No description Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: InP.Neu.05.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Cerebellar_granule_neurons mm9 Input control Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Cerebellar_granule_neurons.bed ...

File list: NoD.Neu.20.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Cerebellar_granule_neurons mm9 No description Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Cerebellar_granule_neurons.bed ...

File list: NoD.Neu.05.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Cerebellar_granule_neurons mm9 No description Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.05.AllAg.Cerebellar_granule_neurons.bed ...

File list: InP.Neu.10.AllAg.Cerebellar_granule_neurons [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Cerebellar_granule_neurons mm9 Input control Neural Cerebellar granule neurons... http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Cerebellar_granule_neurons.bed ...

File list: NoD.Neu.50.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Fetal_brain hg19 No description Neural Fetal brain SRX142786,SRX03...1421,SRX142793,SRX056802,SRX031451,SRX031404,SRX031387 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.50.AllAg.Fetal_brain.bed ...

File list: NoD.Neu.05.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Fetal_brain hg19 No description Neural Fetal brain SRX056802,SRX14...2786,SRX142793,SRX031387,SRX031451,SRX031404,SRX031421 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.05.AllAg.Fetal_brain.bed ...

File list: NoD.Neu.10.AllAg.Fetal_brain [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Fetal_brain hg19 No description Neural Fetal brain SRX142786,SRX05...6802,SRX031451,SRX031387,SRX142793,SRX031404,SRX031421 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/NoD.Neu.10.AllAg.Fetal_brain.bed ...

File list: Pol.Neu.05.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.05.AllAg.Fetal_neural_progenitor_cells hg19 RNA polymerase Neural Fetal neural progeni...tor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.05.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: DNS.Neu.20.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.20.AllAg.Fetal_neural_progenitor_cells hg19 DNase-seq Neural Fetal neural progeni...tor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.20.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: Unc.Neu.50.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Unc.Neu.50.AllAg.Fetal_neural_progenitor_cells hg19 Unclassified Neural Fetal neural progeni...tor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Unc.Neu.50.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: Pol.Neu.10.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.10.AllAg.Fetal_neural_progenitor_cells hg19 RNA polymerase Neural Fetal neural progeni...tor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.10.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: DNS.Neu.50.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available DNS.Neu.50.AllAg.Fetal_neural_progenitor_cells hg19 DNase-seq Neural Fetal neural progeni...tor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/DNS.Neu.50.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: InP.Neu.50.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Superior_Cervical_Ganglion mm9 Input control Neural Superior Cervical Ganglion... SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Superior_Cervical_Ganglion.bed ...

File list: InP.Neu.20.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Superior_Cervical_Ganglion mm9 Input control Neural Superior Cervical Ganglion... SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Superior_Cervical_Ganglion.bed ...

File list: InP.Neu.10.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Superior_Cervical_Ganglion mm9 Input control Neural Superior Cervical Ganglion... SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Superior_Cervical_Ganglion.bed ...

File list: InP.Neu.05.AllAg.Superior_Cervical_Ganglion [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Superior_Cervical_Ganglion mm9 Input control Neural Superior Cervical Ganglion... SRX435085 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Superior_Cervical_Ganglion.bed ...

File list: NoD.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 No description Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: InP.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 Input control Neural Nerve Sheath Neopl...asms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: NoD.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 No description Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: InP.Neu.05.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.05.AllAg.Nerve_Sheath_Neoplasms mm9 Input control Neural Nerve Sheath Neopl...asms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.05.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: InP.Neu.20.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.20.AllAg.Nerve_Sheath_Neoplasms mm9 Input control Neural Nerve Sheath Neopl...asms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.20.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: NoD.Neu.10.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.10.AllAg.Nerve_Sheath_Neoplasms mm9 No description Neural Nerve Sheath Neop...lasms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.10.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: InP.Neu.50.AllAg.Nerve_Sheath_Neoplasms [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available InP.Neu.50.AllAg.Nerve_Sheath_Neoplasms mm9 Input control Neural Nerve Sheath Neopl...asms http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/InP.Neu.50.AllAg.Nerve_Sheath_Neoplasms.bed ...

File list: His.Neu.10.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.10.AllAg.Fetal_neural_progenitor_cells hg19 Histone Neural Fetal neural pro...genitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.10.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: Pol.Neu.20.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.20.AllAg.Fetal_neural_progenitor_cells hg19 RNA polymerase Neural Fetal neural... progenitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.20.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: Pol.Neu.50.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Pol.Neu.50.AllAg.Fetal_neural_progenitor_cells hg19 RNA polymerase Neural Fetal neural... progenitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Pol.Neu.50.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: His.Neu.50.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.50.AllAg.Fetal_neural_progenitor_cells hg19 Histone Neural Fetal neural pro...genitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.50.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: His.Neu.20.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available His.Neu.20.AllAg.Fetal_neural_progenitor_cells hg19 Histone Neural Fetal neural pro...genitor cells http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/His.Neu.20.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: NoD.Neu.20.AllAg.Neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available NoD.Neu.20.AllAg.Neural_progenitor_cells mm9 No description Neural Neural progenito...SRX346675,SRX346817 http://dbarchive.biosciencedbc.jp/kyushu-u/mm9/assembled/NoD.Neu.20.AllAg.Neural_progenitor_cells.bed ...

File list: Oth.Neu.20.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.20.AllAg.Fetal_neural_progenitor_cells hg19 TFs and others Neural Fetal neural... progenitor cells SRX109477 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.20.AllAg.Fetal_neural_progenitor_cells.bed ...

File list: Oth.Neu.50.AllAg.Fetal_neural_progenitor_cells [Chip-atlas[Archive

Lifescience Database Archive (English)

Full Text Available Oth.Neu.50.AllAg.Fetal_neural_progenitor_cells hg19 TFs and others Neural Fetal neural... progenitor cells SRX109477 http://dbarchive.biosciencedbc.jp/kyushu-u/hg19/assembled/Oth.Neu.50.AllAg.Fetal_neural_progenitor_cells.bed ...

Ion-exchange equilibrium of N-acetyl-D-neuraminic acid on a strong anionic exchanger.

Science.gov (United States)

Wu, Jinglan; Ke, Xu; Zhang, Xudong; Zhuang, Wei; Zhou, Jingwei; Ying, Hanjie

2015-09-15

N-acetyl-D-neuraminic acid (Neu5Ac) is a high value-added product widely applied in the food industry. A suitable equilibrium model is required for purification of Neu5Ac based on ion-exchange chromatography. Hence, the equilibrium uptake of Neu5Ac on a strong anion exchanger, AD-1 was investigated experimentally and theoretically. The uptake of Neu5Ac by the hydroxyl form of the resin occurred primarily by a stoichiometric exchange of Neu5Ac(-) and OH(-). The experimental data showed that the selectivity coefficient for the exchange of Neu5Ac(-) with OH(-) was a non-constant quantity. Subsequently, the Saunders' model, which took into account the dissociation reactions of Neu5Ac and the condition of electroneutrality, was used to correlate the Neu5Ac sorption isotherms at various solution pHs and Neu5Ac concentrations. The model provided an excellent fit to the binary exchange data for Cl(-)/OH(-) and Neu5Ac(-)/OH(-), and an approximate prediction of equilibrium in the ternary system Cl(-)/Neu5Ac(-)/OH(-). This basic information combined with the general mass transfer model could lay the foundation for the prediction of dynamic behavior of fixed bed separation process afterwards. Copyright © 2015 Elsevier Ltd. All rights reserved.